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Abstract  
Bacillus thuringiensis produces a range of toxins that include both the insecticidal Cry 
toxins, non-insecticidal, non-haemolytic, and Parasporins. The latter exhibits cytocidal 
activity to some cancer cell lines. Parasporins 3 or Cry41Aa is cytocidal to human hepatic 
HepG2 cell lines. It contains the five conserved sequence blocks found in many 
insecticidal 3-domain Cry toxins and is also believed to possess the same 3-domain 
structure. In addition, it has an extra loop in its domain II as well as an additional ricin 
domain at its C-terminus. studies on insecticidal Cry toxins have implicated domain II 
loops in the specificity of a toxin to target a particular cell. In this study the specificity of 
Cry41Aa towards HepG2 cell lines was investigated. Bioinformatic tools were used to 
predict domain II loops of Cry41Aa. A number of mutants were created to investigate its 
specificity. Loop exchange mutants between loop 3 Cry41Aa and Cry loop 3 of 
insecticidal were created but did not result in a proteolytically stable protein. Domain II 
hybrids of Cry41Aa and insecticidal Cry toxins were created but these did not result in a 
proteolytic stable protein. Finally, residue substitutions with alanine in loop 1,3, and the 
extra loop resulted in stable activated toxins. loop 1 mutants retained toxicity. The extra 
loop mutant lost toxicity towards HepG2 cell lines. A number of Loop 3 mutants were 
made. Recombinant, Y514A and W511F retained toxicity towards HepG2 cells. 
Recombinant W511A and several recombinants at position 509 including F509A did not 
exert toxicity as confirmed by cell viability assays. Despite the lack of toxicity, membrane 
damage assays and western blots on HepG2 incubated with F509A revealed the likely 
presence of pores and phosphorylation of p38. Cell electrophysiology tools were applied 
to investigate the effect that nontoxic recombinant F509A on artificial and cell 
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membrane. Cry41Aa induced the formation of stable pores, cell membrane damage and 
subsequent cell death. F509A induced the formation of unstable pores and did not 
compromise the integrity of cell membrane. The study Findings indicated that Cry41Aa 
is likely to have a similar mode of action as insecticidal Cry toxins. 
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1.0 Introduction 
Cancer is a global disease that can strike anyone despite the age, race or gender. Current 
treatment includes the use of chemotherapy, radiation, and surgery, but each is limited 
in its ability to completely eradicate cancer of the body. Chemotherapy produces an 
initially good response; however persistent cycles and the non-specificity of drugs used 
result in chemo-resistance and peripheral toxicity. The application of radiotherapy to 
treat cancer has been limited by the unpredictable deleterious effect that it has on 
normal cells. The surgical removal of tumour cells can not completely remove metastatic 
cells which usually cause a relapse of the disease (Mathew and Verma, 2009). It becomes 
increasingly clear that in order to successfully treat cancer a specific targeted treatment 
with permanent effects and minimal damage to healthy cells is required.  
The term ‘magic bullet’ was first coined by Paul Ehrlich to describe toxic compounds that 
bind to cell receptors. He theorised that toxic compounds or drugs can interact with 
intended cell structures targeting and attacking pathogens but remaining harmless to 
healthy tissue.   Ehrlich’s research on treatment of infectious diseases with drugs derived 
from the German dye industry indicated that targeting receptors of pathogens absent 
in the host cells resulted severe effect in patients (Strebhardt and  
Ullrich, 2008).  Current cancer treatments include targeting of tumour associated 
antigens and carbohydrate antigens expressed by cancer cells by toxins derived from 
plants and bacteria. Commonly used bacterial toxins include Pseudomonas exotoxins, 
anthrax, and diphtheria toxin. These are incorporated to a selective ligand which results 
in chimeric immunotoxin proteins to target cancer cells. Immunotoxin proteins are not 
yet the ‘magic bullet’ as they have been found to target healthy cells that express target 
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receptors even at low levels making them nonspecific. They also induce an immune 
response in human and there is the need for immunosuppressant agents to reduce this 
response (Mathew and Verma, 2009).  
 
 Ohba et al. (2009) introduced Bt cancer killing parasporins as candidates in the race to 
finding the ‘magic bullet’ and the cure for cancer (Ohba et al., 2009). Parasporins were 
first highlighted by Mizuki and colleagues (Mizuki et al., 1999; Mizuki et al., 2000; Ohba 
et al., 2009; Kitada et al., 2005). Bt  is part of the Bacillaceae family  (Pigott and Ellar, 
2007). They are pathogenic bacteria known to produce toxin molecules that target 
specific host organisms.  
 
Mizuki et al. (1999) claimed that parasporal inclusions of parasporins are different to 
other Bt toxins in the way that these Bt toxins are non hemolytic, non-insecticidal and 
exhibit cytocidal activity on some cancer cells lines (Mizuki et al.,1999). There are 
presently six different parasporin groups, namely PS1, PS2, PS3, PS4, PS5, PS6 (Kitada et 
al., 2005;  Yamashita et al, 2009;  Mizuki et al., 1999;  Mizuki et al., 2000). 
 
 This study uses molecular biology techniques to clone, express, characterise and study 
the parasporin 3 (PS3) or Cry41Aa/Cry41Ab a Bt toxin found in Bt crystal inclusions which 
were reported to have cytocidal activity on some cancer cell lines (Yamashita et al., 
2005). In doing so this study investigated Yamashita et al. (2005) claim that Cry41Aa has 
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cytocidal activity on cancer cells with the aim to understand and locate regions 
responsible for Cry41Aa specificity towards certain cancer lines.   
 
1.1 The Bt Bacterium  
Bt is found almost everywhere and is capable of surviving in a number of different 
environments and habitats such as soil, dust of storage containers, and leaves. It has 55 
different flagellar serotypes and eight non flagellar biotypes (Schnepf et al., 1998). It is 
a gram-positive bacterium that belong to the Bacillus cereus group which includes 
Bacillus. cereus, Bacillus. anthracis, Bacillus. mycoides, Bacillus. pseudomycoides, and 
Bacillus. weihenstephanensi. (de Maagd et al., 2005;  Xu et al., 2014).  Bt is a spore 
forming entomopathogenic bacteria that produces toxic parasporal inclusions. It stands 
out from the other Bacillus species by its ability to produce these parasporal inclusions 
or crystals during sporulation (Xu et al., 2014;  Bravo et al., 2011). However, during the 
vegetative growth phase, some Bt strains excrete soluble non-crystal vegetative 
insecticidal proteins (Vip). Vip Bt producing group are relatively small compared to Bt 
that from parasporal inclusion (Bravo et al., 2007).  
 
The crystalline inclusion of Bt contains protein protoxins that are either Cry (for crystal) 
and also known as δ -endotoxin or Cyt (for cytotoxic) proteins (Nagamatsu et al., 2010; 
de Maagd et al., 2003; Crickmore et al., 1998). The term ‘Cry toxin’ is defined as a Bt 
derived toxin that can induce a toxic effect on a target organism. Any other protein(s) 
with noticeable sequence similarity is also termed a Cry toxin. The type and number of 
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the different protoxins in a given inclusion defines the toxicity profile of a Bt strain 
(Pigott and Ellar, 2007).  
 
The diversity of Bt toxins within a strain is possible due to the fact that most of the genes 
encoding them are found on plasmids as part of structures that include transposable 
elements. Plasmids hold about 10-20% of the genetic makeup of Bt genomes, where 
many toxic genes are expressed as part of an operon (Baum and Malvar, 2005). Bt carries 
out a number of different molecular mechanisms that allows expression of toxin during 
its stationary phase of growth (Schnepf et al., 1998, de Maagd et al., 2003). Schnepf et 
al. (1998) describe the toxin as folds of domains that have been recombined to give a 
novel toxin. The toxins exhibit similar mode of action as mammalian toxins giving weight 
to the theory that all Bt toxins originated from a common evolutionary ancestor. 
 
 The toxins are found within parasporal crystalline inclusions. There are no definitive 
answers as to why Bt would invest energy producing these inclusions, but there are a 
number of possible reasons. It is thought that in a nutrient limited environment, Bt 
ensures access to future nutrients by undergoing sporulation and producing crystal 
inclusion that would kill the host insect, providing plenty of nutrients.  it is thought that 
the size and insolubility of parasporal inclusions in neutral pH stops them being leached 
away from the soil (de Maagd et al., 2003) 
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There are four Vip families that are toxins secreted into the medium during the 
vegetative stage of a Bt life cycle (Crickmore et al., 2018). These were discovered when 
Bt and B. cereus cultures were screened and found to produce protein toxins that were 
not crystals.  Warren et al. (1998) describe Vip 1 and 2 as binary proteins (A+B types) 
that have toxicity towards coleopteran insects (Warren et al., 1998; de Maagd et al., 
2003). They both possess the N-terminal signal sequence for secretion and are needed 
together to be active against some coleopteran larvae inducing a binary effect. A 
possible mode of action is thought to involve Vip2 as the cytotoxic A domain and Vip 1 
as the receptor binding B domain.  Vip3 is known to target the insect order of  some 
lepidopterans whilst the targets of Vip 4 are still elusive (de Maagd et al., 2003). Vips are 
thought to cause cell death through different modes of action. Vip 1 is moved to the cell 
cytoplasm via Vip 2, there it enables ADP-ribosylation of actin. Vip 3 has been observed 
to cause pores in the planar lipid bilayers of target cells (de Maagd et al., 2003).  
 
1.2 Bt toxins  
The group encompasses the 3-domain Cry toxins, the binary toxins of Bacillus. 
sphaericus, and the ETX/MTX toxins. These share a certain degree of homology 
suggesting that they have a common evolutionary origin (de Maagd et al., 2003). The 
largest category in the group is the 3-domain toxins (Crickmore et al., 2018). Amino acid 
sequence homology has identified more than 300 Bt toxins holotypes which have been 
organised into 73 cry and 3 cyt families (Xu et al., 2014). cyt toxins share little sequence 
homology with cry toxins. The term ‘Cyt toxin’ is defined as ‘Bt derived toxin(s) that 
18 
 
exhibits hemolytic activity and other any protein(s) with obvious sequence similarity are 
termed as such (Schnepf et al., 1998).  
 
A nomenclature that classified Cry crystals based on their amino acid sequence 
homology and Bt host range was first proposed by Höfte and Whitely in 1989 (Höfte and 
Whiteley, 1989). It was later revised by Crickmore et al. (1998). The Bacillus thuringiensis 
Toxin Nomenclature Committee classifies Bt toxins on a four-rank system. Toxins are 
given a primary rank such as cry1, cry2, then a secondary rank such as cry1A, cry2A, then 
a tertiary rank such as cry1Aa, cry1Ab and quaternary rank such as cry1Aa1 or cry1Aa2. 
The classification indicates that identified Bt toxins sequences respectively share less 
than 45%, 78%, 95% and ≤100% pairwise identity (Crickmore et al., 1998; Crickmore et 
al., 2018).   
 
Cry toxins have shown toxicity to specific insect orders that include Lepidoptera 
(butterflies and moths), Diptera (flies and mosquitoes) and Coleoptera (beetles and 
weevils); with recent additions of insect orders that include  Hymenoptera, Orthoptera, 
Hemiptera, Isoptera, Mallophaga, Thisanoptera, as well as nematodes and mites (Xu et 
al., 2014; Nagamatsu et al., 2010; Pigott and Ellar, 2007). Cyt proteins are cytotoxic to 
vertebrate and invertebrate cells, as well as being haemolytic in vitro whilst exhibiting 
some insecticidal activity in vivo (Mizuki et al., 1999). Figure 1 lists Bt toxins according 
to their primary rank (Adang et al., 2014). 
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Figure 1 List of Bt Cry toxins based on their primary rank.  
The largest Cry toxins is the 3-domain family shown in blue. The Bin family shown in pink and the ETX/MTX2 family 
are shown in orange. Other colours indicate unrelated Cry toxins that have not been classified into current family 
groups. Parasporins are in red font. Taken from Adang et al. (2014). 
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The Cyt toxins are made by mosquitiocidal Bacillus. sphaericus strain and organised into 
four families (Crickmore et al., 2018;  de Maagd et al., 2003). In vitro studies have shown 
Cyt toxins to be cytotoxic to a number of different vertebrate cell lines that include 
erythrocytes (Bravo et al., 2007;  Soberón et al., 2013). In vivo studies showed that Cyt 
toxins are mostly toxic to dipteran insects whilst some exhibit toxicity to coleopteran 
species (Soberón et al., 2013).  Cyt toxins have a single domain made up of three-layer 
alpha-beta proteins with a distinctive fold. Studies have indicated that Cyt toxins play a 
role in the toxicity of Bt Cry toxins by exerting a synergistic effect to overcome Cry 
mosquitocidal resistance (Bravo et al., 2007; Crickmore et al., 1995; Soberón et al., 2013) 
 Cyt toxins are activated in the susceptible insect gut and result in a 25  KDa protease 
resistant core. Contrary to Cry toxins which are thought to interact or bind to midgut 
epithelium cell, Cyt are thought to act on the saturated membrane lipids. Two models 
have been proposed to explain their mode of action. A pore formation model where Cyt 
toxins bind to cell membranes and initiate the formation of cation-selective channels in 
membrane vesicles that subsequently results in colloid-osmotic lysis of the cell. In the 
detergent effect model, Cyt toxins are thought to aggregate non-specifically on the 
surface of the lipid bilayer that results in the disarrangement of cell membrane and 
eventual cell death. Structure of Cyt toxins has shown that they exhibit similar topology 
with a single domain made up of two outer layers of helix hairpins that coil around α-
sheets (Soberón et al., 2013).  
 
With the exception of parasporins, Cry proteins are not known to be harmful to 
vertebrate or  plants cells (Nagamatsu et al., 2010). For many decades, commercialised 
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pesticide Bt spore sprays have been used safely to control agricultural pests (de Maagd 
et al., 2003). Other species such as israelensis exhibit mosquitocidal activity and are used 
to control disease vectors such as mosquitoes and blackflies. In addition, research on 
Cry expressing transgenic plants has led to their commercialised use (de Maagd et al., 
2003). 
 
The other remaining subgroups within the Bt toxin group include the binary and MTX 
group which are mentioned briefly. The binary (Bin) toxins are found in crystals that 
contain two separate proteins known as Bin A and Bin B which are homologous to each 
other and both are required for the recombinant production of toxins in E. coli. They are 
similar to Cry toxins in that they require solubilisation and activation by protease in the 
insect midgut.  Binary toxins are toxic to western corn rootworm.  Cry34 and Cry35 are 
both required in order to cause a toxic effect on target cells and it’s requirement for two 
components, that has referred these toxins as binary insecticidal crystal proteins (de 
Maagd et al., 2003). Their molecular structure and mode of action is still unclear, but 
they are thought to cause pores in the target insect gut (Adang et al., 2014).  
 
The MTX Cry family are found in Bacillus. sphaericus strains and are toxic to some 
mosquito species, those made by Bt, demonstrate toxicity to some lepidopterna and 
coleoptern species (de Maagd et al., 2003) . There are 11 members of the MTX Cry family 
and they share homology to the cyt toxin of Pseudomonas aeruginosa, the epsilon toxin 
of Clostridium perfringens, alpha-toxin of Clostridium septicum and aerolysin of 
Aeromonas hydrophila (de Maagd et al., 2003).    
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The Mtx toxin group are also pore forming toxins and includes two toxins: Mtx2 and 
Mtx3. Both are related to each other and are distantly related to other Bt crystal 
proteins. Of the two, Mtx 2 demonstrates more amino acid diversity allowing it to 
change its toxicity between different mosquitos’ species (de Maagd et al, 2003) Figure 
2 summaries the protein toxins produced by Bt and illustrates their classification 
according to sequence homology between them. Figure 3 shows the insect orders 
susceptible to Bt δ endotoxins (Palma et al., 2014).   
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Figure 2 Classification of parasporin toxins produced by Bt 
Figure summarises the parasporin toxins produced by Bt. These are classified according to sequence homology to other protein toxins produced by Bt. The Cry proteins are comprised of 
phylogenetically different families: insecticidal 3-domain, other 3-domain Cry toxins, Bin, and ETX/MTX2.
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Figure 3 Diversity of hosts and Bt toxins organised based on target specificity  
Figure illustrates both Cry and Cyt Bt δ endotoxins and type of insect orders that they kill. The toxins are grouped 
according to target specificity. Taken from Palma et al. 2014.  
 
 
 
1.2.1 3-domain Cry toxins  
Cry toxins belonging to the three-domain Cry toxin family, demonstrate differences in their 
amino acid sequences but they all share a conserved three-domain structure. The 3-domain 
toxins are described as pore forming toxins that can kill insect orders Lepidoptera, 
Diptera, Coleoptera, Hymenopters, and some nematodes. The protoxins have a usual 
length of ˜ 130  KDa or the smaller size of  ˜ 70  KDa (de Maagd et al., 2003). These 
smaller  3-domain protoxins do not have an extended C-terminal region(Schnepf et al., 
1998).  
 
There are four theories that hypothesise Cry mode of action, these will be discussed in 
section 2.4. It is generally accepted that 3-domain toxins are proteolytically activated by 
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proteases in the midgut of insects; the crystalline protoxin is solubilised in alkaline 
conditions allowing cleavage of the N- and C-terminal by gut proteases that results in an 
active protease resistant core of ˜60 KDa. The active toxin binds to the brush-border 
membrane of the insect gut epithelium. It can do so by the affinity it has for receptors 
present on the membrane of target cells, which also defines the specificity that Cry 
toxins exhibit to insect orders. Once bound, part of the toxin forms ion channels and 
aggregates in such a way that causes formation of larger pores within the membrane.  
Osmotic imbalance causes the cells to swell and subsequently lysis. Within min the 
insect stops feeding and eventually dies (Baum and Malvar, 2005, Nagamatsu et al., 
2010;  Katayama et al., 2005;  Mizuki et al.,  1999;  Ohba et al., 2009; Schnepf et al., 
1998). 
 
The 3-domain Cry toxins are composed of three distinctive domains, domain I, II, and III. 
Each of the three domains is thought to play a role in the mode of action of Cry toxins. 
Multiple-sequence alignments of different Cry toxins have highlighted the existence of 
five conserved blocks located in the active toxic core of the protoxins which 
encompasses the three domains. These blocks are typically found in the active toxin post 
activation by midgut proteases (Höfte and Whiteley, 1989) and are thought to play an 
important role in toxin stability and function and are located in the N-terminal of the 
larger protoxins ˜130   KDa (Pigott and Ellar, 2007).  In addition to the five conserved 
blocks, there are three more conserved block sequences away from the active core and 
towards the C-terminal end of the protoxin (Schnepf et al., 1998). The C-terminal of the 
protoxin is thought to be involved in crystal formation and contains conserved blocks 
6,7, and 8 as shown in figure 5 page 29. 
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Domain I contains conserved block 1 and is thought to take part in pore formation and 
exhibits similarities to other pore forming toxins. Li et al. (1991) first described domain 
I of Cry3Aa as an α-bundle, where amphipathic helices (bigger than 30 Å) surround a 
central helix (Li et al., 1991). The helices are well charged with polar, and hydrophobic 
residues that seem to aim towards the central helix. The polar residues are present in 
interhelical spaces as hydrogen bonds or as part of salt bridges. These characteristics 
and the resemblance to the pore forming domain of colicin (an antibiotic released by 
bacteria to kill other bacteria of the same species) has proposed domain I as a key factor 
of pore formation in Cry toxins (Pigott and Ellar, 2007).  
 
Domain II is thought to interact with insect gut receptors and demonstrates similar 
properties to carbohydrate binding proteins. Three antiparallel β sheets are bundled to 
form a β-prism.  The conserved block 2 is partly found in domain I and in the first β sheet 
of domain II.  Two of the β sheets are made of four strands in a Greek key motif. The 
third is located against domain I and arranged in a similar Greek key motif with shorter 
stands.  
 
Of the three domains, domain II exhibits the biggest structural diversity particularly the 
apex loops which differ in length, structure, and sequence. Exposed loops 1,2,3, and α8 
have been identified as regions that affect the specificity of Cry toxins and modifications 
here have been known to alter the toxin’s ability to interact and kill target insects (Bravo 
et al., 2013). In addition to this, the length of β strands also vary from one Cry toxins to 
another. It is this diversity that is thought to determine toxin specificity. There appears 
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to be a structural similarity between domain II and other β prism proteins such as plant 
lectins, vitelline, Maclura pomifera agglutinin etc, which are known to have binding 
properties. Likenesses to complementary determining region of  immunoglobulins, 
studies have also supported the theory that domain II loops are involved in receptor 
recognition  (Pigott and Ellar, 2007). 
 
Domain III is thought to be involved in receptor binding and pore formation and is similar 
to carbohydrate binding protein domains. Ithas  a β-sandwich structure that contains 
conserved blocks 3, 4, and 5 in one of its three buried stands (de Maagd et al., 2003; 
Schnepf et al., 1998; Nagamatsu et al., 2010). Two long loops appear to reach out and 
interact with domain I.  Domain III demonstrates less diversity compared to the other 
two domains (Pigott and Ellar, 2007).  It is thought that domains II and III are involved in 
receptor binding and specificity (Lee et al., 1996; Pigott and Ellar, 2007).   
 
X-ray crystallography has helped to reveal the crystal structure of  the following Cry 
toxins Cry1Aa, Cry1Ac, Cry2Aa, Cry3Aa, Cry3Bb, Cry4Aa, Cry4Ba, Cry5Ba, and Cry8Ea (Li 
et al., 1991; Grochulski et al., 1995; Morse et al., 2001;  Galitsky et al., 2001;  Boonserm 
et al., 2006;  Guo et al., 2009;  Hui et al., 2012; Boonserm et al., 2005). The toxins share 
the 3-domain structure but differ in amino acid sequence and insect specificity. Figure 4 
illustrates examples of the 3-domain structure of Cry toxins (Pigott and Ellar, 2007). 
Figure 5 illustrates the five sequence blocks typical of 3-domain toxins which were first 
described by Höfte and Whiteley (1989), as well as the remaining three sequence blocks 
later added by Schnepf et al. (1998). Upon treatment with protease, conserved blocks 
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6-8 are usually lost leaving a protease resistant core with the five conserved blocks  
(Schnepf et al., 1998; Höfte and Whiteley, 1989; Palma et al., 2014).   
 
 
  
 
 
 
 
 
 
 
 
Figure 4 Crystal structure of 3-domain Cry toxins. 
Figure shows the crystal structure of 3-domian toxins: Cry1Aa, Cry2Aa, Cry3Aa and Cry4Ba. Domain I is shown in red, 
domain II is shown in green, and domain III is shown in blue. Taken from Pigott and Ellar et al. 2007.  
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Figure 5 conserved sequence block of 3-domain toxins. 
Figure illustrates the 5 conserved sequence blocks of 3-domain toxins of Cry1A in green and the later 3 sequence 
blocks in red. Upon treatment with trypsin enzyme blocks 6 to 8 are degraded leaving a protease resistant core of ˜60 
KDa. Adapted and taken from Palma et al. (2014)  
 
 
 
The number of different insecticidal proteins produced by Bt indicates  that their  genes are 
affected by  selective evolutionary pressures that lead to the development of a wide range 
of Bt targets (Pigott and Ellar, 2007). Bioinformatic investigations have revealed that each 
one of the 3-domains may be evolved at a different rate and therefore affect target 
specificity (Bravo, 1997). 
 
 
Domain 
I 
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1.2.2 Parasporins  
The number of Bt strains with no known insecticidal activity far outnumbers insecticidal 
Bt strains (Yasutake et al., 2005; Uemori et al., 2005; Mizuki et al., 1999; Ohba et al., 
2009; Schnepf et al., 1998; Nagamatsu et al., 2010; Kitada et al., 2005). This finding 
prompted a review of Bt toxin action against a range of invertebrate and vertebrate cell 
lines. For the first time,  Mizuki et al. (1999) reported a non-insecticidal parasporal 
inclusion,  isolated from a Bt strain,  that is cytocidal to human cancer cells (Mizuki et 
al., 1999; Ohba et al., 2009). Research has since discovered a number of different Bt 
proteins with a range of cytotoxicity against mammalian cell lines (Ohba et al., 2009).  
 
This has led to a new category of Bt toxins known as the parasporins which are 
genealogically heterogeneous to Cry proteins. The Committee of Parasporins 
Classification and Nomenclature was formed and classified parasporins into six families: 
PS1, PS2, PS3, PS4, PS5, and PS6 (Ohba et al., 2009; Chikawa et al., 2008; Okumura et 
al., 2010). Similar to the ranking of Cry toxins, parasporins were ranked according to 
their primary amino acid sequence and given a four rank name according to the level of 
sequence identity to known toxins as summarised in table 2 (Crickmore et al., 1998).  
 
They were purified from independent Bt strains and isolated from soil in Japan taken 
from Hiroshima, Fukuoka, and Tokyo (Kitada et al., 2005) as well India (Poornima et al., 
2010), the Caribbean islands (Gonzalez et al., 2011), and Malaysia (Nadarajah et al., 
2006). Parasporins differ from Cry and Cyt proteins, as they do not exhibit any 
insecticidal activity. Despite being non-haemolytic, they are  cytotoxic to some 
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mammalian cell lines (Yasutake et al., 2005; Katayama et al., 2005; Ohba et al., 2009; 
Kitada et al., 2005).  
 
Parasporins share low but significant sequence similarity with other Cry toxins (Ohba et 
al., 2009). They resemble Cry proteins in that they all require proteolytic processing. The 
activated form of Cry proteins have about 600 amino acids and some have the 3-domain 
structure (Nagamatsu et al., 2010). 
 
 Research has indicated that parasporins differ in their cytotoxicity mechanism and type 
of target cells. Katayama et al. (2005) argue that parasporins differ in their mode of 
action to Cry proteins. They propose that PS1 is not a membrane binding protein. 
Membrane binding protein usually cause irreversible permeability of ions in the 
membrane that lead to depolarization and change in membrane potential which 
subsequently results in cell death. Instead, they propose that PS1 induces Ca2+ influx in 
cells without a change in membrane potential. This increase disrupts Ca2+ homeostasis 
or other cell pathways that subsequently lead to apoptosis as a result of a drop in cellular 
protein and DNA synthesis (Yamashita et al., 2005; Kitada et al., 2005). In other words, 
it is not a pore forming toxin.  
 
Mizuki et al. (2000) argue that cytotoxicity mechanisms of Parasporins are not fully 
understood and it is uncertain if cell death is caused by induced apoptosis alone. Uemori 
et al. (2009) confirmed the ability of PS1 to discriminate between healthy uterine 
smooth cells and uterus cervix cancer cells. Furthermore, the general characteristic of 
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parasporins of having specificity for cancer cells lead to proposing them as a potential 
‘magic bullet’ in treating cancer (Ohba et al., 2009).   
 
Concerns regarding Bt specificity are a current debate. Uncertainties regarding Bt toxin 
synergism, efficiency and selectivity are being observed in their application as pest 
controls agents (Then, 2010). Mizuki et al. (2000) argue that Bt toxins are also cytocidal 
to normal mammalian cells line, highlighting the need for refinement of their specificity 
in order to reduce the potential danger. Yamashita et al. (2005) also observed ‘low 
toxicity’ to four non-cancerous human cell line by Cry41A proteins. The cytocidal activity 
of parasporin toxins varies in range and intensity, as well as the range of target cells. For 
example, PS4 is preferentially toxic to leukaemia T cells, however it shows low toxicity 
to normal T cells, whilst exhibiting no toxicity at all to uterus cervix cancer cells (Saitoh 
et al., 2006) 
 
1.2.3. Parasporin 1 /Cry31Aa1  
Parasporin 1 or Cry31Aa1 shares less than 25% sequence identity with Bt toxins, 
however,  it does contain the five conserved blocks typical of 3-domain Cry toxins 
(Mizuki et al., 2000). The crystal structure was resolved at 1.76 Å resolution and was 
revealed to have a 3-domain structure typical of most insecticidal Cry toxins. An N-
terminal region similar to Cry2Aa was also detected (Katayama et al., 2005; Kitada et al., 
2005; Akiba and Okumura, 2016).  
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Upon proteolytsis two active polypeptides of 15 and 56kDs were formed and were toxic 
towards HeLa, HL60, MOLT-4 and HepG2 cell lines (Katayama et al., 2007). An alternative 
mode of action has been proposed for Cry31Aa1 where interactions with Hela cells is 
thought to induce an apoptotic signalling pathway that causes a rapid influx of Ca2+. Cell 
viability decreased progressively and morphological indicators of cytopathology such as 
cell swelling were observed 8-10 h post incubation with Cry31Aa1 despite a dose of 10 
µg/mL. The cell membrane remains intact and no change in cell permeability was 
observed (Katayama et al., 2007). This is quite unusual for parasporins as membrane 
permeability is often observed with other parasporins (Ohba et al., 2009; Yamashita et 
al., 2005).  
 
In Cry31Aa1 susceptible cells the membranes were impermeable to DNA binding dye 
molecules and the cells remained polarized. Furthermore, no cytosolic markers such as 
LDH were observed even after 4 h of incubation with Cry31Aa1. However, within min, 
intracellular calcium probe fura-2 detected a sudden rise in intercellular Ca2+. It is 
thought that Ca2+ was depleted from the extracellular space as investigation with low 
Ca2+ levels correlated with reduced toxicity (Katayama et al., 2007). A number of Ca2+ 
influx inhibitors were applied to investigate if they affect Ca2+ levels and thus toxicity of 
Cry31Aa1.  Only suramin which inhibits G protein coupled receptors (GPCR) affected 
Ca2+ levels. Elevated levels of caspase 3 and PARP cleavage in treated cells were 
indicative of an activated apoptotic signalling where DNA and protein synthesis were 
prevented.  
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The findings led to the proposal that Cry31Aa1 causes cytotoxicity by the activation of 
GPCR, calcium influx and apoptosis due to ineffective calcium homeostasis without any 
form of pore formation (Katayama et al., 2007).  
 
Contrary to this, is a study by Narvaez et al. (2014) where they argue that parasporin 
1Aa2 or Cry31Aa2 has 94% sequence identity with Cry31Aa1 and has been observed to 
form pores in artificial membranes. In addition, it was found to induce calcium 
oscillations despite the lack of extracellular calcium and normal cell line HEK 293 (Gabriel 
Narvaez et al., 2014). It was suggested that Cry31Aa1 and Cry31Aa2 have the potential 
to form pores as evident with the formation of ion channels in artificial membranes.  
 
In response to this, further studies investigated the occurrence of an additional N-
terminal region which locks domain I and  stops it from forming pores (Akiba and 
Okumura, 2016; Akiba et al., 2005). Katayama et al. (2011) carried out an investigation 
in search of the receptor for Cry31Aa1 and discovered beclin-1 a tumour suppressor 
protein. Anti-beclin-1 antibody repressed toxin binding and toxicity. It was patented and  
reported as a receptor for Cry31Aa in Hela cell lines (Katayama et al., 2011).   
 
1.2.4. Parasporin 2 /Cry46Aa 
Parasporin 2 or Cry46Aa1 is a very toxic protein and shares very little amino acid identify 
with Cry toxins. The crystal structure of the activated protein was resolved and revealed 
an elongated form of 115 x 30 x 29 Å. Structurally it is similar to the ETX/MTX2 Cry family 
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and protein in the Toxin_10 family as well as hydralysin (Akiba et al., 2009; Xu et al., 
2014).  
 
It was mainly tested on HepG2, but also has shown toxicity to a number of different 
cancer cell lines such as MOLT-4, and Jurkat (Kitada et al.,  2006). In addition to being 
tested on cancer cell lines, it was also investigated for its effects on cancer tumour slices 
from differentiated hepatocellular carcinoma and colon cancer.  It was found to cause 
cell swelling in non -neoplastic cancerous cells (Kitada et al.,  2006; Ito Akio et al.,  2004).  
 
Kitada et al. (2006) demonstrated the toxin interaction through a number of 
experiments. Immunofluorescence visualised the plasma membrane of HepG2 cells 
where Cry46Aa1 caused cell swelling, blebbing and the breakdown of organelles and 
cytoskeleton. The release of LDH and PI staining cell demonstrated the instant damage 
to the cell membrane. This was confirmed by osmoprorective PEGs analysis which 
measured Cry46Aa1 induced pores with a diameter of 3nm (Kitada et al., 2006).  
 
In addition to pore formation, Cry46Aa1 was found to induce caspase activation and 
DNA degeneration in HepG2 cells. Further investigation by Ito Akio et al. (2009) and 
others indicated that Cry46Aa maintained cytotoxicity even after the application of a 
caspase inhibitor and suggested that its main mode of action is by pore formation (Ito 
Akio et al., 2004; Akiba et al., 2009). 
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Interactions with lipid rafts in HepG2 cells required GPI-anchored proteins for 
oligomerization and toxicity (Akiba et al., 2009; Okumura et al., 2011). Its structural 
resemblance to proteins that possess additional β trefoil motif in the head domain and 
aerolysin type β pore forming toxins gives weight to Cry46Aa1 being a pore forming toxin 
(Akiba et al., 2009; Sher et al., 2005).    
 
1.2.3 Parasporin 3 / Cry41Aa, Cry41Ab  
Parasporal inclusions were isolated from Bt strain A1462, parasporal inclusions were 
successfully solubilised in alkaline conditions, and two 88   KDa proteins were recovered. 
The proteins were respectively named Cry41Aa (PS3Aa) and Cry41Ab (PS3Ab).  
 
They were treated with proteinase K and analysed on SDS PAGE gel where each revealed 
a 64 KDa major protein and a minor 80   KDa protein.  The proteolytically active proteins 
were cytocidal activity against HepG2 (hepatocyte cancer) and HL60 (myeloid leukaemia 
cancer) cells. The two proteins were respectively named Cry41Aa and Cry41Ab.  
 
The proteins were expressed from three genes ORF1, OFR2, OFR3. ORF1Aa and OFR1Ab 
proteins are similar in weight and show 87% identity. ORF2Aa and ORF2Ab are 88% 
homologous and of analogous weight. OFR3Aa and ORF3Ab have 99% sequence 
homology and are of similar weight.  There were no transcriptional terminator 
sequences between ORF1 and ORF2 or ORF2 and OFR3.  
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OFR2 contained the five conserved block regions common to three domain Cry toxins, 
and ORF3 contained conserved Cry block regions 6, 7, and 8 also found in some 
insecticidal Cry toxins.  The N-terminal amino acid sequences of the proteolytically 
resistant purified 64 KDa proteins were found in ORF2Aa and ORF2Ab. The C terminal 
sequence of both ORF2’s resembles the Clostridium botulinum hemagglutinin HA-33 
sequence. 
 
 Yamashita et al. (2005) attempted to express the proteins using only ORF2 genes but 
observed that Bt could not form parasporal inclusion. This suggests that the expression 
of ORF3 may have a role in protein conformation and/ or packaging. It is important to 
note that alkali only treated proteins were cytocidal and proteolytic activation of both 
Cry41Aa and Cry41Ab was required for their characteristic toxicity towards HepG2 and 
HL60 cancer cell line.  
 
The study further suggests that Cry41Aa and Cry41Ab may have a specific receptor on 
susceptible cancer cells. The findings from cytotoxicity assay and microscope 
observations suggest that both Cry41Aa and Cry41ab kill slowly and are both likely to 
have a 3d-Cry structure common to some insecticidal Cry toxins (Yamashita et al., 2005).  
 
Yamashita et al. (2005) screened 1744 Bt parasporal protein against 124 human cell 
lines, of those Cry41Aa was toxic to HL60 and HepG2 cell lines. The EC50 for HepG2 cell 
was 1.86 µg/mL (2.4 µM/ml) and 1.25 µg/mL (1.6 µM/ml) for HL60 cell lines. Cell viability 
and membrane damage assay have suggested that Cry41Aa is more toxic than Cry41Ab 
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as indicated by the dramatic decrease in cell viability and an increase of LDH efflux.  In 
addition to MTT viability cell assay trypan blue staining highlighted morphological 
changes of the cells during their 24-h incubation with Cry41Aa and Ab toxins. Cells were 
observed to swell within the first hour followed by membrane damage in the hours that 
followed, as shown in figure 6 (Yamashita et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 The list of mammalian cell lines tested against proteinase K activated Cry41Aa and Cry41Ab. 
 MTT cell viability assay was applied post a 24-h incubation with toxins.  Data for HL60 and HepG2 cell lines highlighted 
in red. Taken and adapted from Yamashita et al.2005.  
 
 
 
list of mammalian cell lines tested against proteinase K 
activated Cry41Aa and Cry41Ab. 
 
 
 
Cell 
 
 
Origin 
 
  
EC50(μg/mL)  
  
 
Cry41Ab 
 
  
Cry41Aa 
 
  
Human        
    MOLT-4  Leukemic T cell  >10  >10  
    Jurkat  Leukemic T cell  >10  >10  
    HL60  Myeloid leukaemia  1.32  1.25  
    HeLa  Uterus cervix cancer  >10  >10  
    TCS  Uterus cervix cancer  >10  >10  
    Sawano  Uterus cancer  >10  >10  
    HepG2  Hepatocyte cancer  2.80  1.86  
    A549  Lung cancer  >10  >10  
    CACO-2  Colon cancer  >10  >10  
    T cell  Normal T cell  >10  >10  
    UtSMC  Normal uterus  >10  >10  
    HC  Normal hepatocyte  >10  >10  
    MRC-5  Normal lung  >10  >10  
Simian        
    Vero  African green monkey kidney  >10  >10  
    COS-7 African green monkey kidney  >10  >10  
Murine        
    NIH3T3-3  Mouse embryo  >10  >10  
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Figure 6 Morphological changes of HepG2 cells post incubation with Cry41Aa. 
Microscope images were taken of Trypan Blue stained HepG2 cell line after incubation with Cry41Aa and Cry41Ab at 
1 h and 24-h post-treatment. Adapted from Yamashita et al. (2005).  
  
 
The Cry41Aa gene was expressed by Krishnan, 2013 (Krishnan, 2013). Primers were 
designed to amplify the split toxin as ORF2 and ORF3. ORF2 encodes the active toxin 
with the five conserved Cry blocks typical of 3-domain Cry toxins, as well the N terminal 
and C-terminal region located within the ricin domain of the toxin as shown in figure 7.  
 
ORF3 encodes the remaining conserved Cry block 6,7, and 8. These are usually lost after 
protease treatment but are thought to play a role in crystal formation and the packaging 
of protoxin in Bt cell (Krishnan et al., 2017). In addition to the ORFs restriction sites for 
BamHI, Xhol, and Xbal were also subcloned into Bt shuttle vector pSVP27A. expression 
is driven by a strong Bt cyt1Aa promoter (Crickmore and Ellar, 1992). 
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The vector was introduced into Bt4D7 to express cry41Aa. Upon treatment with 
proteinase K Cry41Aa is cleaved at position 60 after an alanine which is necessary for 
the toxicity of Cry41Aa (Yamashita et al.,2005) However, N-terminal sequence analysis 
has indicated that trypsin cleaved Cry41Aa at position 63 after an arginine (Souissi, 2018, 
Krishnan et al., 2017). 
 
 
Figure 7 Amino acid sequence of Cry41Aa protoxin encoded by ORF2 and ORF3 
Figure shows the amino acid sequence for split toxin Cry41Aa as encoded by ORF2 and 3. The conserved Cry block are 
underlined in red. The N-terminal is underlined in black. The exta loop distinctive to Cry41Aa is underlined in dashed 
lines. The C-terminal/ricin domain are double underlined. Domain I is highlighted in grey, domain II in yellow and 
domain III in blue.  
 
1.2.4 Parasporin 4/ Cry45Aa1 
Okumura et al. (2008)  first described Cry45Aa1 as a pore forming parasporin that 
exhibits toxicity towards CACO-2, Sawano and MOLT-4 cells (Okumura et al., 2008). 
 It shares little homology to Cry toxins and does not have the five conserved blocks 
typical of 3-domain toxins. Structurally it is similar to aerolysin type β pore forming 
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toxins as a consequence of the high level of β structures as measured by CD spectrum. 
It has a low identity to other β pore forming toxins such as the α toxin from C.septicum, 
epsilon from C. perfringens, and aerolysin from A. hydrophila (Okumura et al., 2011).   
 
In MOLT-4 cell assay, cells demonstrated cytopathic characteristics within 10 min of 
incubation with Cry45Aa1; the nucleus fragmented within the hour, and cells completely 
erupted after a 24-h period. Membrane damage assay detected the formation of large 
pores that allowed the passage of 70  KDa dextrans and LDH efflux (Okumura et al., 
2011). 
 
Okumura et al. (2013) discovered additional proteins produced by the same A1470 Bt 
strain, the protein PS 2Aa2 which are almost identical to PS2 (differ by 4 amino acids) 
was observed to kill MOLT-4 cells with an EC50 of 0.47 µg/mL. Interestingly, Bt produced 
activated Cry45Aa1 was more toxic (EC50 = 0.13 µg/mL) than the recombinant activated 
Cry45Aa1 protein (Okumura et al., 2011;  Saitoh et al., 2006).  
 
Further investigations on Cry45Aa1 showed that it was activated in acidic conditions and 
was cleaved by pepsin. This alternative activation did not just  increase toxicity of the 
protein, but it was reported to yield more proteins than through typical alkali conditions 
(Okumura et al., 2008;  Okumura et al., 2014). 
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 Further investigation by Okumura saw the application of Cry45Aa in mice trials. Here, 
the ability of Cry45Aa to remain stable in low acidic conditions was exploited. It was 
assumed that the acidic conditions and the presence of pepsin in the digestive system 
of mice would solubilise and activate Cry45Aa1 which was administered orally. The study 
concluded that protoxin Cry45Aa1 was indeed activated in the digestive tract of mice 
and impaired kidney function (Okumura et al., 2014).  
 
1.2.5 Parasporin 5 /Cry64Aa1 
This toxin was first described by Ekino et al. (2014) as a parasporin with some sequence 
identity to Bt Cry toxins and aerolysin type β pore forming toxins. It is 34 KDa protoxin 
and was cleaved by proteinase K at the C-terminal to produce a 30   KDa toxin. It exhibits 
cytotoxicity to MOLT-4 (EC50 = 0.1µg/mL), HepG2, TCS, Hela, Sawano and two monkey 
kidney cell line COS7 and Vero. MOLT-4 cells were observed to swell within an hour of 
incubation with the toxin (Ekino et al., 2014). 
 
1.2.6 Parasporin 6/Cry63Aa  
Cry63Aa is cytotoxic protein with a protoxin of 84 KDa Which upon proteolytic 
processing produced two core resistant cores of 14 and 59 KDa. These were found to be 
active against HeLa and HepG2 cells. Structurally, the protoxin N-terminal shares 
identity with Parasporin 1, however this is lost during protease treatment. The resulting 
protein core shares 56% sequence identity with Cry2A toxin and in particular the region 
with the five conserve blocks of Cry toxins (Nagamatsu et al., 2010).  
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Table 2: Parasporin groups and their characteristics. 
Human cell line origins: Jurkat (leukemic T-cell), HepG2 (liver cancer), Sawano (cervical cancer resistant to cisplatin treatment), MOLT-4 (acute lymphoblasic leukaemia), HL-60 (myeloid- granulocyte precursor in bone marrow- leukaemia), CACO-2 
(epithelial colorectal adenocarcinoma cells), UtSMC (normal uterus smooth muscle cells), TCS (uterus cervix cancer).Adapted from Kitada et al. 2005 and Domanska, 2016  ( Akiba et al., 2009; Kitada et al., 2006; Ohba et al., 2009; Saitoh et al., 2006; 
Yamashita et al., 2005; Mizuki et al., 1999; Mizuki et al., 2000; Kitada et al., 2005; Gonzalez et al., 2011; Ammons et al., 2016; Ekino et al., 2014)
Summary of Parasporin members and their toxins 
 
 PS1/Cry31Aa1 PS2/Cry 46Aa1 PS3/ Cry41Aa1 
Cry41Ab1 
PS 4/ Cry45Aa1 PS 5/ Cry64Aa1 PS 6/Cry63Aa1 
Protoxin (KDa ) 81 37 88 31 33.8 84 
Toxin (KDa ) 15 and 56 heterodimer 30 64 27 29.8 14 and 59  
In vitro activated 
by 
Trypsin Proteinase K  Proteinase K  Proteinase K  Proteinase K  Trypsin  
Proteolytic 
activity site 
Two sites in N-terminal  N and C-terminal  N-terminal and possibility 
in C terminal 
C-terminal C-terminal N-terminal 
Cell death Ca2+ influx Cytolysis Unknown-potential pore 
formation  
unknown Unknown-potential β pore 
forming toxins 
Unknown-potential 
pore formation  
Receptors Belclin 1 GPI-Proteins unknown unknown unknown unknown 
Structural 
homology to Cry 
toxins 
Crystal structure resolved to 
reveal homology to 3- domain 
Cry structure and  
Crystal structure resolved to 
reveal homology to aerolysin 
type β pore forming toxins 
Potentially has a 3-
domain structure  
Potentially similar to aerolysin type β 
pore forming toxins  
Potentially similar to aerolysin 
type β pore forming toxins  
Potentially has a 3-
domain structure 
Conserved Cry 
block 
five conserved Cry blocks 
detected in 56 KDa -low 
homology in block 3 
No homology five conserved Cry blocks 
detected in 64 KDa  
No homology No homology five conserved Cry 
blocks detected in 
59 KDa  
Sequence 
homology to Cry 
toxins 
Low, less than 25% Low less than 25% and other 
pore forming toxins 
41% sequence identity with 
hydralysin from Ch. viridissima 
 
Low, less than 30%  
34% sequence identity 
with Cry3Ba ricin type 
domain detected 
Low, less than 30% and other pore 
forming toxins 
Homology to ETX/MTX2 56.4% homology to 
3-domain toxins 
Susceptible 
cancer lines 
(EC50µg/mL) 
HeLa (0.12), HL-60 (0.32), 
MOLT-4 (2.2), HepG2 (3).  
Jurkat (0.015), HepG2 (0.023), 
Sawano (0.041), MOLT-4 
(0.044),  
HL-60 (0.066).  
HL-60 (1.25),  
HepG2 (1.86).  
CACO-2 (0.12), Sawano (0.24), MOLT-
4 (0.47), TCS (0.71), HL-60 (0.72), 
HepG2 (1.9)  
MOLT-4 (0.075), HepG2 (0.049), 
TCS (0.046), Hela (0.80), COS7 
(0.045), Vero (0.050), Sawano 
(0.065) 
HeoG2 (2.3). Hela 
(7.2) 
Susceptible 
normal cell line 
 (EC50µg/mL) 
low to modest activity against 
lung cells.  
Less than 10 µg/mL towards 
UtSMC cells  
T cells (0.148),  
Less than 10 µg/mL towards  
Hepatocytes  
Less than10      µg/mL 
towards T cells  
Less than 10 µg/mL 
towards Hepatocytes.  
Substantial activity against T cells of 
native and recombinant PS-4. 
Recombinant PS-4 also cytotoxic to 
UtSMC.  
Less than 10   µg/mL towards 
human embryonic lung fibroblast, 
uterus, and hepatocyte 
Unknown  
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1.3 Mode of action of Bt toxins  
The vast number of Cry toxins, the type, number of target cells as well as receptors has 
led to a number of theories on how Cry toxins are able to target, interact and kill 
particular organisms or cell lines.  
 
Research has attempted to uncover the mode of action of Bt toxins and there is currently 
more than one theory on how the toxins are able to be toxic. Initially the general 
consensus accepted the model proposed by Knowles and Ellar. It was founded on studies 
carried out on 3-domain Cry toxins and their effect on lepidopteran larvae. They 
postulated that pathogenic bacteria usually exert cytolysis through pore formation and 
proposed the colloid-osmotic model (Knowles and Ellar, 1987).  
 
In this model the insect must first ingest the Bt crystal which is then solubilised in the 
alkaline environment of the insect’s digestive system. A study by Angus, (1954) 
highlighted the need for alkaline conditions as pre-requisite for solubilisation (Angus, 
1954). The findings were later supported by observations made by Du et al. (1994) 
where only insects with digestive juice capable of crystal solubilisation were susceptible 
to Cry toxins (Du et al., 1994;  Jurat-Fuentes and Crickmore, 2017). 
 
 Once solubilised the protoxin is cleaved by digestive proteases and results in protease 
resistant cores. This activated form binds to and interacts with specific receptors in the 
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gut border membrane. In vitro studies by Wolfersberger et al. (1984) demonstrated the 
correlation between binding and toxicity by using brush boarder membrane vesicles 
(BBMV). Early studies of Cry1Ba and BBMV from the susceptible Pieris brassicae found 
that Cry1Ba would specifically bind to insect BBMV and would not bind to rat intestine 
BBMV (Wolfersberger, 1984; Wolfersberger et al., 1987). Post toxin-receptor interaction 
the toxin undergoes oligomerization.  
 
A study by Gϋereca and Bravo, (1999) demonstrated that oligomerization of monomeric 
Cry toxins requires interaction with cell membrane (Gϋereca and Bravo, 1999). The 
events that follow have divided scientists and is the subject of a number of theories. In 
the colloid osmotic model, the toxin inserts itself into the membrane and as a 
consequence causes nonspecific pores in the membrane of the target cell. The presence 
of the pore induces changes in membrane potential, ion balance, influx of water, cell 
swelling, colloid-osmotic lysis of gut cells and eventual larval death (Knowles and Dow, 
1993, Knowles and Ellar, 1987). There are several mode of action models that have since 
taken into consideration newly found data on receptors toxin complexes as well as the 
revealed crystal structure of Cry toxins.   
 
1.3.1 The Bravo model  
The Bravo model is founded on the osmotic -lysis model by Knowles and Ellar, (1987). 
Bravo et al. (2004) investigated the binding of Cry1Ab to two different receptors, 
aminopeptidase N (APN) and cadherin-like protein (Bt-R1 in Manduca sexta).  
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The model suggests that Cry1A toxin binds sequentially to these receptors in order to 
cause toxicity. It details the different monomeric changes that the Cry1A protein 
undergoes in order to cause toxicity.  
 
The model addresses the first monomeric change where crystal Cry1A is solubilised to a 
130 KDa protoxin. It is followed by a second monomeric change when it is activated and 
cleaved into a ˜60 KDa protease resistant protein. The third monomeric change takes 
place after active Cry1A binds to Bt-R1 receptors and then to APN receptors on the 
membrane of midgut cells of insects to create a toxin-receptor complex. The fourth 
monomeric change takes place as the toxin forms a pre-pore oligomeric structure that 
inserts itself into the membrane and subsequently creates lytic pores (Bravo et al.,  
2004).   
 
This mode of action is based on findings from the co-immunoprecipitation investigation 
where it was demonstrated that Cry1Ab binds first to Bt-R1 and then APN. As a 
consequence of this binding, membrane-associated proteases cleave the α-helix 1 of 
domain I and expose a hydrophobic surface that subsequently leads to the 
oligomerization of Cry1Ab into pre-pore structures. 
 
 Experimental data by Soberón et al. (2007) demonstrated the formation of oligomeric 
structures by Cry1Ab and Cry1Ac mutant which lack the α-helix region. These mutants 
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exhibited in vivo toxicity in resistant insects with a mutated cadherin gene. Furthermore, 
the oligomeric state of Cry1Ab-Bt-R1 complex greatly increased binding affinity to APN 
which guides oligomers into the lipid rafts and enables insertion and the formation of 
tetrameric pores (Bravo et al., 2004; Soberón et al., 2007; Soberon et al., 2009; Bravo 
and Soberón, 2008). Figure 8 summarises and illustrates the pore forming mode of 
action of the Bravo model 
 
Figure 8 The two models for the mode of action of Bt Cry toxins.  
Cry crystal is solubilised and activated by proteases. The active toxin binds to receptor in steps 1-3.   The top model 
4-6 illustrates the Bravo model. Binding induces the cleavage of a-helix. The monomers undergo oligomerization and 
bind to GPI-anchored receptor (Bt-R1). It induces membrane insertion, and pore formation. The lower diagram 4a-5a 
illustrated the signalling model by Zhang et al. (2005) It suggests a mode of action by an adenylyl cyclase/ protein 
kinase A signalling pathway. Image taken from Bravo et al. (2008). 
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1.3.2 The Ping Pong model 
Similar to the Bravo model, and other mode of action models, the ping pong model 
agrees that Cry crystals must first undergo solubilisation, followed by protease 
treatment where the protoxin is cleaved resulting in a protease resistant core. 
In the case of Cry1Ab the active ˜60  KDa core encompasses the typical Cry 3-domain 
structure (Pardo-López et al., 2013). Pacheco et al. (2009) proposed the ping pong model 
where loop 3 of domain II Cry1Ab differentially participates in the binding of both Bt-R1 
and APN receptors depending on the oligomeric state of the toxin.  
 
Data from toxin overlay binding assay confirmed that amino acids from loop 3 in domain 
II interact with both receptors and that multi binding interactions take place which 
involves both receptors. ELISA binding assays suggested that loop 3 first binds to the 
high abundance low affinity APN receptor site followed by binding to the high affinity 
low abundance Bt-R1 receptor also known as a cadherin receptor (Pardo-López et al., 
2013). 
 
Previous research in the cadherin interaction with loops of domain II revealed the 
involvement of loops α8, 2, and 3 (Gomez et al., 2002; Gómez et al., 2003; Gomez et al., 
2006). Loop2 was found to act as the cognate binding epitope to the CR7 region of 
cadherin, in addition, loop α8 and 2 also interacted with region CR11 of cadherin. Loop 
3 was thought to bind to the CR12 region of cadherin receptor (Gomez et al., 2006; 
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Gomez et al., 2003). Pacheco et al. (2013) confirmed loop 3 binding to CR12 region after 
monomeric mutants of Cry1Ab loop 3 were affected in their ability to bind to CR12 
fragments of Bt-R1 but did affect interactions with APN receptor. Pacheco et al. (2013) 
also suggested that binding to high affinity Bt-R1 requires the participation of other 
domain II regions, e.g. loops 2 and α8. Once bound, the Bt-R1 loop 3 complex induced 
the cleavage of α-helix 1 to form an oligomer that increased binding affinity to APN via 
β16-22 of domain III. Whilst bound to Bt-R1 via loop 3 a Bt-R1-Cry1Ab-APN complex is 
created. However, it is APN that the facilitates oligomer insertion into the membrane. 
Figure 9 summarises the ‘ping pong’ model as proposed for Cry1Ab mode of action. 
 
 
Figure 9 The ‘ping pong’ model for Cry1Ab mode of action.  
Cry1Ab protoxin is activated with proteases. The monomeric toxin binds first to low affinity ALP or APN receptors via loop 3. This is 
followed by further binding to high affinity cadherin or Bt-R1. The N-terminal is cleaved and toxin monomers oligomerize into pre-
pore structures that bind APN or ALP to induce pore formation. Figure taken from Pardo-López et al. (2013). 
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91.3.3 The Zhang model 
The Zhang model is an alternative model that is based on the adenylyl cyclase (AC) 
protein kinase A (PKA) signalling pathway (Zhang et al., 2005). Zhang et al. (2005) argue 
that the toxic events take place as a consequence of the signalling pathways and not a 
result of pore formation.  
 
Once the crystal is solubilised and activated, the monomeric Cry1Ab binds specifically to 
Bt-R1 receptors. This would induce a signalling pathway where oligomers do not form 
lytic pores (Zhang et al., 2005). The model is summarised in the lower part of diagram 7.  
 
The research was carried out using undifferentiated ovarian cells of the cabbage looper 
Trichoplusiani which does not express cadherin Bt-R1 receptors. The cell line known as 
S5 was engineered to express Bt-R1 driven by an insect action promoter in a nonlytic 
insect expression vector. The receptor was expressed as a membrane protein and 
localised to the cytoplasmic membrane of cell as confirmed by immunofluorescent 
staining using anti-BT-R1 antibody. Western blot experiments concluded that the 
monomeric form of the toxin was taken into the membranes expressing Bt-R1 receptors.  
 
The uptake of monomeric toxin was fast and steady in contrast to oligomeric form of 
Cry1Ab which was not detected by either Bt-R1 expressing cells or other non-susceptible 
cells. In a dose dependent experiment oligomeric toxin was detected 15min post 
incubation in Bt-R1 expressing S5 cells and did not exert a toxic effect.  
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Zhang et al. (2005) concluded that it is the monomeric from that binds to Bt-R1 to exert 
toxicity in susceptible cells (Zhang et al., 2005). Zhang et al. (2006) proposed that this 
binding triggers a G protein-coupled receptor (GPCR) which in turn activates the AC/PKA 
pathway. extracellular ligand activation of GPCR causes a conformational change on the 
intercellular region of the membrane. The Gαs subunit switches GDP to GTP which in turn 
disconnects from the complex and binds instead to AC. AC induces the rise of a second 
messenger cAMP in the cytoplasm of susceptible cell that triggers PKA. 
 
 There was evidence of raised cAMP and PKA levels in susceptible cells. A decrease in 
toxicity levels was observed with the application of Gαs and AC inhibitors. Toxicity was 
completely abolished with the addition of EDTA pre-incubation with toxin. Loss of 
toxicity was not due to loss of binding as observed from western blots experiments but 
as a consequence of Mg2+ depletion. Toxicity was re-established with the addition of 
magnesium salt. Zhang et al. (2006) claimed that Mg2+ is critical to events that follow 
binding of monomer toxins to membranes of susceptible cells and that receptor-toxin 
interaction and pore formation are not enough to explain Cry1Ab mode of action (Zhang 
et al., 2006). 
 
A summary of the Zhang model is illustrated in figure 10.  This claim was supported by 
research carried out in modified Cry1 toxins that lacked the N-terminal ending including 
helix α-1, where cadherin interactions were skipped and did not take place. Despite this 
resistant insects with a defective cadherin gene were killed (Soberón et al., 2007).   
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Other studies have criticized the experimental data on which the Zhang model is based 
on. They claim that the S5 cell line does not represent the true nature of a susceptible 
insect’s midgut. Furthermore, EDTA amount used by Zhang et al. (2006) would not 
chelate all MgCl2 that would be present in an insect medium where low pH level would 
affect ion chelating by EDTA and EGTA. (Vachon et al., 2012; Soberón et al., 2007).   
 
 
Figure 10 The mode of action of Bt toxin according to the Zhang model. 
It implicates AC/PKA signalling pathway. It states that monomeric form of the toxin is required in binding to 
cadherin receptor. The binding induces coupled G protein which in turn activates adenylyl cyclase and a raise in 
cytoplasmic cAMP. cAMP levels activate kinase A which phosphorylates target proteins resulting the disruption of 
channels and eventual cell death. Figure taken from Zhang et al. (2006)  
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1.3.4 The Jurat-Fuentes interpretation 
The Jurat-Fuente, (2006) interpretation combines both the Bravo and Zhang models. It 
suggests that both pore formation and signalling pathway play a role in mode of action 
of Bt toxins and the presence of one does not eliminate the other.  
 
Jurat-Fuentes and Adang, based their alternative interpretation on Cry1Ac research 
carried out in the susceptible Heliothis virescens larvae. Previous research identified a 
number of receptors for Cry1Ac in H.virescens (Jurat-Fuentes and Adang, 2006, Jurat-
Fuentes and Adang, 2004). These included HevCaLP, HvALP, actin receptors and 
intracellular phosphatases. A gene knock out of the cadherin like HevCaLP receptor was 
found to cause resistance in certain insect strains and was implicated in the toxin mode 
of action (Gahan et al., 2001).  
 
HvALP is a GPI-anchored alkaline phosphatase receptor which was found at low levels in 
resistant H.virescens strains that exhibited reduced alkaline activity phosphatase in 
brush boarder membrane proteins (Jurat-Fuentes and Adang, 2004). Additional 
receptors were also implicated, the discovery of more receptors such as actin in BBMV 
proteome of M .sexta and H. virescens  (Krishnamoorthy et al., 2007; McNall and Adang, 
2003) and intracellular phosphatases (Jurat-Fuentes and Adang, 2006) has led to the 
proposal of two modes of action by Cry toxins.  
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In the first model, Cry1Ac binds to cadherin like HevCaLP, the binding causes a 
conformational change. Post oligomerization, the toxin binds to the HvALP receptor 
which subsequently results in pore formation in lipid rafts of the membrane. The 
presence of the pore creates an osmotic shock that eventually results in the cell death.  
 
The second model speculates that toxin binding to HevCaLP does not just induce pore 
formation but that it also activated signalling pathway regulated by intracellular 
phosphatases. This in turn activated the apoptotic pathway (Jurat-Fuentes and Adang, 
2006). Lilien and Balsamo. (2005) implicated the cytoskeleton protein actin in cadherin 
interactions. Jurat-Fuentas.  (2007) suggest that it binds to cadherin via its cytosolic 
domain which is aided by tyrosine phosphatases. It is also possible that actin binds to 
oligomerized toxin to induce the signalling pathway (Jurat-Fuentes and Adang, 2007., 
Lilien and Balsamo., 2005). The mode of action of Cry1Ac in H. virescens as interpreted 
by Jurat-Fuentas. (2007) is summarised in figure 11.  
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Figure 11 The proposed mode of action of Cry1Ac in H. virescens. 
 Once the crystal is solubilised and activated through protease, it binds to HevCaLP. The oligomerized toxins binds to 
second receptor HvALP the leads to membrane insertion and subsequent pore formation and cell death. Alternatively, 
the second model proposes that toxin bound to cadherin induces interactions between actin and cadherin that 
activate a signalling pathway. Taken from Jurat-Fuentes and Adang et al. (2006)  
 
 
1.4 Specificity of Bt toxins 
The topic of specificity in Bt toxins goes hand in hand with Bt toxin mode of action. A 
number of studies have implicated the structure of Bt toxins with their specificity to 
target particular insects (de Maagdet al., 2003; Jez, 2017; Moar et al., 2017).  
 
Adang et al. (2014) summarised the mode of action of 3-domain toxins where domain II 
and III interact with the midgut epithelial cell of insects whilst domain I was responsible 
for membrane insertion and subsequent pore formation (Adang et al., 2014). However 
in a recent review it was argued that there is not sufficient evidence which directly links 
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toxin structure and its specificity towards a target (Jurat-Fuentes and Crickmore, 2017). 
A review  by Palma et al. (2014) provided support to this notion where it stated that that 
Cry toxins can exhibit toxicity against a range of taxonomically diverse insects, and Cry 
toxins with a diversity in domain II and III  can still  target the same insect (Palma et al., 
2014; Palma and Berry, 2016). Jurat-Fuentes and Crickmore (2017) , argue that toxin 
structure alone is a poor indicator of specificity and that host factors may also play a role 
in determining specificity (Jurat-Fuentes and Crickmore, 2017). Previous studies on 
insects that demonstrate toxin resistance concluded that they are able to do this as a 
result of alternations to the receptor binding site on host cell, and  emphasising the 
specificity of toxins to target insect (Bravo and Soberón, 2008).  
 
Jurat-Fuentes and Crickmore, (2017) further speculate that parasporins or Cry toxin 
which exhibit toxicity to certain cancer cell lines may have insect targets that are yet to 
be discovered (Jurat-Fuentes and Crickmore, 2017; Krishnan et al., 2017). The authors 
defined specificity ‘as the condition of Cry proteins being toxic to a particular insect’ and 
propose that there are seven levels of specificity determinates (Jurat-Fuentes and 
Crickmore, 2017).  Figure 12 summaries the seven levels in the mode of action of Cry 
insecticidal proteins that determine toxin specificity.  Level I address an insect’s ability 
to access or come across a Bt crystal as the first level of determining specificity. The 
crystal form of the toxin limits the range of insects that can access it e.g. sap feeding 
hemipterans. Bt is also limited by the type of environments that it can successful inhabit. 
57 
 
 
 
For example, Bt do not usually colonize plant leave surfaces and insects that live there 
are unlikely to encounter Bt or its crystal.  
 
Parasporins which exhibit specificity to certain cancer cell lines are not thought to have 
evolved this specificity. Instead Jurat-Fuentes and Crickmore, (2017) suggest that 
parasporins may have undiscovered insect targets. This would not be unusual as 
previous Cry toxins have shown specificity to more one species in an insect order as is 
the case for 6 of 68 Cry toxin families (Jurat-Fuentes and Crickmore, 2017). 
 
Level II of specificity is the ability of a host to solubilise the Bt crystal. Early studies on 
crystal solubilisation confirmed that Bt crystals require alkaline pH conditions and 
insects which lack such a digestive environment were unaffected by Bt. Further 
investigation confirmed that previously non-susceptible insects were affected by pre-
solubilised Bt crystals (Angus, 1954; Du and Nickerson, 1996; Du et al., 1994).  
 
Specificity level III addresses toxin processing and the stability of protease cleaved Bt 
toxins. Once solubilised the protoxin is available to digestive juices in the insect gut. 
There digestive proteases cleaved the protein until a protease resistant protein(s) core 
remains. The speed and efficacy of processing determines a toxins level of toxicity 
towards an insect.   
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Specificity level IV requires that the active toxin remain available and stable in insect gut 
juices. Although the active protease core is not further processed by a given protease it 
is not protected from further processing by others e.g. elastase (Choristoneura 
fumiferana) or hexamerins (H. armigera) have both reduced toxicity in susceptible Cry1A 
insects by sequestering the active toxin.   
 
Specificity level V address the task of crossing the peritrophic matrix which protects 
epithelium cells of the insect gut. The layer is made of chitin and glycosylated proteins. 
Some Cry toxin domains recognise and interact with glycosylic residues which stall and 
hinder the intoxication process. It has also been observed that the type of glycosylated 
protein and their arrangement differ in insect’s species, making this a determining factor 
for the specificity to a particular target insect.  
 
The specificity level VI examines a toxin’s ability to recognise, bind and interact with 
insect cell receptor (Jurat-Fuentes and Crickmore, 2017). Previous studies in specificity 
have addressed receptor-toxin interaction as the Key determining factor of a toxin’s 
specificity towards an insect. Studies have identified Cry toxin receptors that include 
protein and glycolipids (de Maagd et al., 2001; Gomez et al., 2007; Vachon et al., 2012; 
Bravo et al., 2007). The specificity of parasporins to certain cancer cell line is not well 
understood, it is thought that parasporins recognise carbohydrate structures shared 
with the susceptible cancer cell line but which are absent in normal healthy cells (Jurat-
Fuentes and Crickmore, 2017). Studies carried out in Cry1Ab have shown that this 
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insecticidal Cry toxin is cytocidal to human embryonic kidney cell line 293. The authors 
suggest that it is not only parasporins that can interact with mammalian cell lines, but 
new specificity is emerging on typical insecticidal Cry toxins as research widens the range 
and type of cells being tested against Cry toxins (Mesnage et al., 2013). 
 
The final specificity level VII addresses events that follow toxin-receptor binding. The 
ability to bind does not necessarily guarantee pore formation and to induce a toxic 
effect.  Studies have shown high binding affinity in low susceptible insects. Different cells 
can have different responses to membrane insertion that do not always end in lysis of 
cell. In addition to this cells can activate different intracellular signalling pathways with 
different defensive response to toxicity (Jurat-Fuentes and Crickmore, 2017).   
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Figure 12 The flow chart diagram of the seven steps of the mode of action of Cry toxins and the determining 
specificity factors.   
Figure depicts factors that play a role in determining host specificity. Transgenic Bt crops produce soluble Cry toxins 
and thus are excluded from the first two specificity determinants. Taken from Jurat-Fuentes and Crickmore, (2017) 
(Jurat-Fuentes and Crickmore, 2017). 
 
 
 
1.4.1 Domain II loops in Cry toxins 
A number of studies have implicated domain II loops in specificity and initial binding of 
Cry toxins (Dean et al., 1996; Pacheco et al., 2009; Abdul-Rauf and Ellar, 1999; Pardo-
Lopez et al., 2009; Abdullah and Dean, 2004; Lu et al., 1994).  
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Pacheco et al. (2009) demonstrated that mutations in domain II loops affect binding to 
the cadherin (Bt -R1) and aminopeptidase-N (APN) receptors in the lepidopteran 
Manduca sexta. The study suggested that both receptors interact differently to different 
oligomeric states of the Cry1Ab toxin. Domain II exposed loop regions were probed and 
mutations in loop 3 were found to severely affected its insecticidal activity in both 
monomeric and oligomeric states of the activated toxin. Pacheco et al. (2009) proposed 
a ping pong binding mechanism to explain the toxin activity and its dependency on loop 
3 of domain II.  
 
Toxin overlay binding analysis of loop 3 regions of Cry1Ab indicated that it has 
hydrophobic profile. Furthermore, single double and combination substitution in this 
region revealed that this region is involved in interaction with both Bt -R1 and APN 
receptors as binding to both receptors was significantly reduced in mutants. More 
analysis suggested that the Cry1Ab mode of action may involve multiple binding 
interactions with both receptor molecules. Both receptors are present at different 
concentrations with APN at a higher concentration in M. sexta mid gut.  
 
Initially a 65 KDa proteolytic active monomer binds to APN through loop 3 of domain II. 
This bound monomer goes on to bind to high affinity Bt -R1 receptor through loops 2, α-
8, and 3 of domain II creating an oligomer. Mutants of loop 3 were noted to significantly 
affect oligomeric binding to Bt -R1. The resulting oligomeric structure has binding affinity 
to APN through domain III regions but continues to be bound to Bt -R1 through loop 3. 
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The interactions result in a Bt -R1 -Cry1Ab-APN complex. The specific role of this complex 
is unclear, but the study observed that loop 3 mutants affect toxicity of Cry1Ab 
oligomers and thus implicated the complex in toxicity. It further suggested that loop 3 
can induce structural changes prompted by APN and it is involved in membrane insertion 
of Cry1Ab oligomer.  
 
Previous research on loop 3 have also suggested that it binds to CR12 region of cadherin 
receptors in H.virescens and B. mori (Xie et al., 2005; Atsumi et al., 2008; Pacheco et al., 
2009).  Rajamohan et al. (1996) carried out alanine substitution on Cry1Ab, which is toxic 
to M. sexta and H. virescens. Two mutants F440A, and G439A were noted to have 
reduced toxicity and binding analysis on brush boarder membrane vesicles from insect 
gut membranes implied that this reduction in toxicity is due to loss in the initial binding 
by as much as 3.5 times less than wild type Cry1Ab.  
 
Alanine substitutions made to hydrophobic residues 440 AAGA443 in loop 3 of Cry1Aa also 
resulted in reduced toxicity to B. mori and M. sexta due to a decrease in initial binding 
to vesicles from insect midgut. The study proposed that residues of loop 3 of both 
Cry1Ab and Cry1Aa ascertain hydrophobic interactions with receptor molecules; and it 
is the hydrophobic nature of these residues that affected the initial binding to receptor. 
To investigate further, an alanine cassette was created in the loop 3 region of Cry1Aa 
and resulted in the deletion of hydrophobic residues in the loop 3 region. This lead to a  
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reduction of binding affinity (Kcom) by 15 times to B. mori and 9 times to M. sexta, 
implicating the loop 3 region in initial binding to receptor (Rajamohan et al., 1996c).  
 
Alanine substitutions of the predicted loop 3 of Cry1C residues indicated that single 
point mutations S438F and G439A eliminated most or all toxicity and binding to S. 
littoralis and A. aegypti. The mutants expressed a stable proteolytic resistant protein 
similar to that produced by insect gut juices, and thus the loss of toxicity was not thought 
to be due to protein mis-folding (Abdul-Rauf and Ellar, 1999).  Cry4Aa is toxic to B. mori 
and M. sexta.  Studies which investigated the effects of alanine substitutions in loop 3 
in Cry41Aa concluded that mutants T512A and Y513A have a reduced toxicity to 
susceptible insects (Howlader et al., 2010; Howlader et al., 2009). 
 
In a study carried out in Cry1Aa to investigate the hydrophobic nature of loops in domain 
II, it was questioned whether hydrophobic profiles of loop residues were conserved in 
Cry toxins or necessary for initial binding to the Bt -R1 cadherin receptor. Seven mutants 
of loop 3 of Cry1Aa were created, and none exhibited a reduction in receptor-binding 
affinity. Five recombinants out of the seven produced 75% mortality rate in third instar 
B. mori within 72 h of ingesting recombinant toxins. One recombinant (439EPPA442) 
caused a 35% mortality rate, whilst recombinant 439TLRT442 was completely non-toxic 
with zero morality at both 48 and 72 h post ingestion of the recombinant. The study 
concluded that the critical residues are not required for binding. However, the study 
emphasised the natural flexibility of loops of Cry1Aa and the possibility that mutants 
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may change conformation to present hydrophobic profiles to the cadherin receptor and 
thus averted a reduction in receptor binding affinity (Fujii et al., 2013).  
 
Fujii et al. (2013) speculated that the natural flexibility of loop allowed for multipoint 
attachments by exposing hydrophobic profiles to receptors, without the need for 
specially conserved amino acid sequence in the loop region. Furthermore, the study 
suggested that larger conformational flexibility of loops involved in binding allowed for 
a larger available fraction of loop conformation compatible with toxin-receptor complex 
formation. This may explain their observations whereby some of loop 3 mutants 
exhibited higher binding efficiency by up to 42 times.  
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2.0 Objectives  
A number of studies have suggested that the loops of domain II are involved in initial 
binding and specificity of Cry toxins. This study aims to identify domain II loop regions of 
Cry41Aa in order to investigate the specificity that it has towards HepG2 cancer cell lines.   
Cry41Aa is one of the least studied parasporins. Little is known about what gives rise to 
its specificity towards some mammalian cancer cell lines. This study will apply functional 
and structural approaches that have been typically used to study insecticidal Cry toxins, 
in order to unravel Cry41Aa specificity. Bioinformatic tools and findings from previous 
research on insecticidal Cry toxins will server to identify and narrow down Cry41Aa gene 
regions corresponding to domain II loops regions. Once identified the domain II loops 
will undergo the following mutagenesis approaches: (I) a loop exchange between 
cytocidal Cry41Aa and an insecticidal Cry toxin. (II) the production of hybrids as a result 
of domain swapping between Cry41Aa and other insecticidal Cry toxins. (III) the creation 
of Cry41Aa loop mutants via residue substitutions. The above approaches will contribute 
to building a picture of Cry41Aa specificity and identify key gene regions or residues that 
are significant to its specificity.  
 
The long-term project outcomes of this study aim to contribute to the current discussion 
on the safe application of Cry toxins as biopesticides and the discovery that Cry toxins 
can and do interact with vertebrate cell lines. Findings from this study may reveal 
alternative or unknown HepG2 receptors targeted by Cry41Aa. Any further information 
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learnt on the specificity of Cry41Aa can be used to assess its potential contribution to 
the pharmaceutical industry and drug design in the fight against cancer.   
 
The long-term project outcomes of this study aim to contributes to the current 
discussion on the safe application of Cry toxins as biopesticides and the discovery that 
Cry toxins can and do interact with vertebrate cell lines. Findings from this study may 
reveal alternative or unknown HepG2 receptors targeted by Cry41Aa. Any further 
information learnt on the specificity of Cry41Aa can be used to assess its potential 
contribution to the pharmaceutical industry and drug design in the fight against cancer.   
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3.0 Material and Methods  
3.1 Materials  
3.1.1 Bacteria Strains and Plasmids 
Genomic DNA of A1462 Bt strain was used as a DNA template to amplify Cry41A operon 
(Yamashita et al., 2005). DNA inserts were ligated into pBluescript or E.coli/ Bt shuttle 
vector pSVP27A (Crickmore et al., 1994). B. thuringiensis/Escherichia coli shuttle vector 
(Bt-shuttle vector) pSVP27A is characterised by its ability to replicate in both E.coli and 
Bt (Liu et al., 2009). It has a promoter and a selective marker DNA sequence that can 
function in Bt.  
 
In this study the Bt-shuttle vector pSVP27A was modified from vector pSV2 which is 
partly derived from pBR322 vector (Crickmore and Ellar, 1992; Crickmore et al., 1994). 
E. coli JM109 strain was transformed with plasmid to establish constructs. Other 
plasmids include pGEM which is high-copy-number vectors containing T7 and SP6 RNA 
polymerase promoters flanking a multiple cloning region within the α-peptide coding 
region of the enzyme β-galactosidase.  A list of host bacterial strains is presented in table 
3. Table 4 lists the buffers used in this study. Table 5 lists the regents and kits employed 
in this study.  
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Bacteria Host List 
Bacterial strain  Description  Bacterial host   
JM109 high efficiency 
transformation 
strain used for 
routine cloning 
E. coli   
GM2163 dam-/dcm- 
chloramphenicol 
resistant strain used 
to obtain non-
methylated dna for 
transformation of 
Bt4D7 
E. coli   
Bt4D7 crystal minus 
derivative of bt 
subspecies kurstaki, 
obtained from the 
bacillus genetic 
stock centre 
Bt 
 
Table 3 lists the bacterial strains used in this stud 
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3.1.2 Buffers and Solutions 
 
Table 4 Lists buffers used in study  
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3.1.3 Reagents, kits, enzymes, plasticware 
Table 5 lists the reagents, kits, enzymes and plasticware used in study. 
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3.1.3. Cell lines   
HepG2, human hepatocyte carcinoma cell line was purchased from ECACC, Salisbury, 
UK. HeLa, lymphoblastoid (GM12878, IB4) and Burkitt's lymphoma (MUTU1, BL31) cells 
were gifts from Dr Michelle West (University of Sussex, UK). HL-60 cell line was a gift 
from Dr Helen Stewart (University of Sussex, UK). Another batch of HL-60 cells was 
purchased from ECACC, Salisbury, UK. Cell lines used in electrophysiology experiments 
were provided by Prof Jean-Louis Schwartz (University of Montreal, Canada). 
 
3.1.4 Storage of biological material  
Bacterial strains were storage in LB with 15% glycerol at - 80°C.  Once defrosted bacteria 
were stored on agar plates at 4°C. Toxins were stored at - 20°C. Cancer cells were kept 
in liquid nitrogen at - 197°C, once defrosted for use they stored at - 80°C in complete 
medium with 10% glycerol.  
 
3.2 Methods  
The steps and experimental procedures taken to create Cry41Aa constructs are 
summarised in figure 13.  
 
3.2.1 Agarose Gel Electrophoresis 
All Agarose gels and DNA samples analysed by agarose gels in this study were prepared 
as followed unless otherwise indicated.  1% DNA agarose gel was made by weighting   
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0.3 g of agarose and added to 30 mL of TBE x1 and heated until all dissolved. A 1.5 µL of 
GEL RED dye was added and the solution was allowed to cool and solidify. A 1µL of 
purified product was added to 9µL of water, 2 µL of loading buffer was added to mixture 
and a total volume of 12 µL for each sample was loaded onto gel. A 1 Kb DNA ladder 
(New England Biolabs) was ran on gel at 120v in TBE buffer to make appropriate DNA 
band size comparisons. The bands of amplified products were visualised under 
ultraviolet light.  
 
3.2.2 Amplification of Cry41Aa Operon and other DNAs via PCR 
Genomic DNA of A1462 Bt strain was used as a template to amplify ORF2 and ORF3 
(Krishnan, 2013). OFR2 of Cry41Aa was cloned into pBluescript SK2+ plasmid to create 
pBS41Aa. A BamHI restriction site at the 5’ end and an XhoI site at the 3’ end flanks the 
gene. The restriction enzymes allow for subcloning of ORF2 into pSVP2741Aa. The PCR 
amplification was carried out using high fidelity polymerase in the presence of dNTPs.  
The protocol for the PCR was as follows: initial denature was carried out at 94°C for 15s, 
the annealing temperature was 50°C for 30s, extension was carried out 68°C for 5 min 
with a final extension at 72°C for 7 min. This was repeated for 30 cycles. The PCR reaction 
was set up as follows: 0.5 µL of 100 µg/mL of each primer, 25 µL of high-fidelity PCR 
master mix (Roche), 0.5 µL of template DNA obtained from pBS41Aa plasmid, 2.5 µL of 
PCR nucleotide mix, and 23.5 µL of water. Amplified products then visualised using 1% 
agarose gel. All constructs were created using this protocol with occasional adjustments 
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to extension time and annealing temperatures. Primer are listed for each construct in 
the results chapter 5,6, and 7. 
 
3.2.3 PCR Product gel purification 
QIAquick PCR Purification Kit (QIAGEN) was used to purify PCR products according to 
manufactures recommendations. PCR products were run on agarose gel. The bands 
were visualised and excised. 600 µL of QG buffer was added and placed in a 60°C water 
bath until agarose gel solubilised. 200 µL of isopropanol was added and the solution was 
thoroughly mixed.  5x volume of chaotropic buffer PB is added to 1x volume of PCR 
product and mixed. QIAquick spin column is placed in 2 mL collection tube. The sample 
was added to column and spun for 1 min at 13,000rpm; this step binds DNA onto the 
membrane in the column. The flow through was discarded and column placed back in 
the same collection tube. A total of 750 µL of PE buffer was added to column and spun 
for 1 min. Second round of flow through is now discarded. Column is placed back on 
collection tube and further centrifuged for 1 min. Final round of flow through was 
discarded. The column is placed in a new 1.5 mL eppendorf tube. A total of 10 µL of EB 
buffer (10 mM Tris-Cl, pH 8.5) was added to centre of membrane and allowed to stand 
for 1min to maximise product recovery. Then it was centrifuged for 1 min. Each purified 
PCR product was collected and ran on 1% agarose gel.   
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3.2.4 DNA ligation  
All purified linear DNAs were ligated overnight at room temperature. This will allow the 
linear DNA to become a circular one, and thus a plasmid that can be introduced into host 
bacteria. Further ligations were carried out where two separated linear DNAs were 
ligated together to form a plasmid 
- PCR product was setup to self-ligate as follows: 8.5 µL of purified DNA, 1 µL of 
ligase buffer, 0.5 µL of T4 ligase enzyme.  All ligations were incubated overnight 
at room temperature. 
- Gel Purified fragments (2.5kb/7.8kb) were ligated overnight as follows:  1 μL of 
pSVP2741Aa 7.8kb fragment (ORF3), 3 μL of insert DNA 2.5kb fragment (ORF2), 
0.5 μL ligase enzyme, 1 μL of ligase buffer, and 4.5 μL of distilled water were 
mixed and incubated overnight at room temperature.  
 
3.2.5 DNA digestion  
- Removal of methylated DNA  
DpnI enzyme was used to remove methylated DNA prior to transformation with 
bacterial cells. A total of 1 μL of DpnI was added to 45 μL of PCR product. This 
mixture was incubated for 1 h at 37C.  
- Double digest and Isolation of ORF2 (2.5kb fragment) and ORF3 (7.8kb fragment) 
0.5 μL of BamH enzyme, 0.5 μL of Xhol enzyme, 2 μL of DNA, 1 μL of buffer2, and 
6μL of distilled water were mixed and incubated for 1 h in a 37⁰C water bath. 
75 
 
 
 
The mixture was then loaded and run on an agarose gel, where desired bands 
were visualised under UV light and excised.  
- HaeIII enzyme was applied to digest plasmids and confirm whether DNAs were 
desired constructs. Digestion tube contained: 1 μL of DNA, 7.5 μL of dH2O, 1 μL 
of Buffer C, 0.5 μl of HaeIII enzyme. Tube was incubated for a minimum of 30 
min at 37°C. Experimental restriction banding patterns were compared with the 
pattern predicted by the NEB web cutter.  
 
3.2.6 DNA desalting 
The salt was removed from DNA samples in preparation for Bt transformations. A 0.1M 
of glucose in 1% agarose gel was made as follows: 0.54g of glucose, 0.30g of agarose, 
and 30mL of distilled water were mixed and heated. The solution was aliquoted into 
eppendorf tubes and allowed to solidify. To desalt, 20-30µL of DNA was added to set 
agarose and allowed to sit for 30mins.  
 
3.2.7 Bacterial transformation 
A 100 mL broth solution of bacterial strain was incubated until OD600 0.4. sample 
centrifuged in SLA1500 at 10 rpm for 10 min. The pellet was washed several times in 
cold dH2O and finally aliquoted into 50 µL volumes.  A 1µL of DNA was added the mixture 
and transferred to electroporation cuvettes. Gene pulser was set to 1.8Kv, 200ohms, 25 
µF.  The mixture was plated onto ampicillin (100 µg/mL) treated LB agar plates and 
incubated overnight at 37°C.   
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3.2.8 Bacterial Plasmid Miniprep using QIAprep Spin Miniprep Kit Protocol 
An eppendorf tube with bacteria in 250 µL of buffer P1 was prepared. A total of 250 µL 
of buffer P2 was added, followed by, 350 µL of neutralising buffer N3. The mixture was 
centrifuged, and supernatant transferred to column. This was spun and flow through 
was discarded. A total of 500 µL of PB buffer was added to bound DNA and spun followed 
by and 750 µL of PE buffer. The DNA was eluted with 50 µL of EB buffer.  
 
3.2.9 Rapid Size Screen (RSS) 
RSS solution was prepared as detailed in section 3.1.2. Individual colonies were pick 
suspended in 25 µL of RSS solution. The samples were spun, and supernatant was loaded 
onto 1 % agarose gel.  Colonies with potential mutants were selected for further 
analysis.  
 
3.2.10 Protein harvesting  
After 3days of incubation at 30 ⁰C, Bt cells were analysed under a light microscope (Leica 
DMLS). The cells were harvested once spores and crystals were observed. Cells were 
scraped from agar plates and suspended in 30 mL of cold distilled water. The cells were 
lysed by repeated sonication at 150 Watt (four cycles of 1 min) on ice. The pellet was 
collected by centrifugation at 12,000 x g for 10 min at 4 °C and re-suspended in 1 mL of 
distilled water.  
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3.2.11 Protein analysis using SDS-PAGE 
Protein gels for this project were set up as follows unless otherwise indicated. RGB, SGB 
and 2x SDS loading buffers were made according to section 3.1.2.  Reducing SDS/ME was 
made up of 95 µL of x2 SDS buffer and 5 µL of 2.5 % reducing β-Mercaptoethanol (ME). 
A total of 10 µL of protein sample was added to 10 µL of reducing SDS/ME and boiled 
for 3- 4min. The samples were spun and loaded onto SDS PAGE gel at 120 v for 30 min. 
Gel stain was made according to section 3.1.2. The gel was stained for 20 min and later 
treated with gel destain. Molecular masses of proteins were estimated by comparison 
with molecular standard protein marker (new England Biolabs).  
 
3.2.12 Solubilisation and activation of Protein  
Crude protein was spun, and pellet resuspended in carbonate buffer. Protein crystals 
were solubilised in 5x volume of carbonate buffers made according to section 3.1.2. One 
µL of   0.1 M of DTT was added to 20 µL of sample giving a final concentration of 5 mM 
of DTT. The mixture was incubated for an hour in 37 ⁰C water bath. The samples were, 
spun and supernatant retained. Solubilised sample were analysed on protein gels. A 
total of 10 mg/mL of trypsin solution in carbonate was used for activation at the ratio of 
1:10 (v/v) enzyme to supernatant and incubated in a 37 °C water bath for 1 h. Complete 
mini EDTA-free protease inhibitor was later added to stop further proteolysis. 
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3.2.13 Dialysis of Protein 
Dialysis is designed to eliminate small molecular weight substances that might interfere 
with a subsequent step in the experimental procedure. It also used when large 
molecules such as proteins require different buffer environment for an experimental 
step (Glick and Pasternak, 1998). Here it was carried out in preparation for protein 
purification with AKTA –FPLC. The protein was dialysed against 1L volume of different 
Tris concentrations of pH 8.  The protein was first dialysed against 1 L of 10mM Tris was 
made by dissolving 1.2 g of Tris-HCL solute in 1 L of water and pH adjusted with 
hydrochloric acid (HCL). The solubilised protein was loaded into a 350 µL volume 
capacity microanalysis button and covered with dialysis tubing which retains proteins 
with a molecular weight of 12,000KDa and above.  
 
Large scale dialysis was carried out with 50mM Tris made by dissolving 6.0 g of Tris –HCL 
solute in 1 L of water. The solubilised protein was loaded into a 5mL capacity dialysis 
tube which retains proteins with a molecular weight of 12,000KDa and above. All 
samples were dialysed overnight in cold room gently stirred by magnetic stirrers.   
 
3.2.14 Protein Purification  
- Ion Exchange chromatography  
Solubilised dialysed protein toxin was purified using AKTA FPLC according to 
manufacture protocol.  The following cold solutions were prepared and filtered 
overnight in cold room.  One litre solution of 50mM Tris pH 8 was made by 6.0 g 
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of Tris-HCL solute in 1 L of water and split into two 500 mL flaks.  A 500 mL of 1M 
sodium chloride in Tris was made by dissolving 30 g of NaCl in 500 mL of 50 mM 
Tris. A 500 mL of water and a 500 mL of 50 mM Tris were also prepared.  A Millex 
GP micro-pore filter of 0.22 µM/ml was used to filter protein sample as it was 
injected. This was transferred to an anion exchange column Resource Q 
(amersham pharmacia biotech, UK). The toxin was eluted with an increasing 
linear gradient of NaCl in Tris at a flow rate of 1 mL/min. Fractions were collected 
and analysed on protein gels.   
 
- Gel filtration 
One mL of the solubilised trypsin treated protein was loaded to a Sephacryl S-
200 High Resolution (Amersham) gel filtration (15 mL) column. The activated 
recombinant protein eluted with 50 mM sodium carbonate (pH 10.5).  Fractions 
collected and quantified using BioRad kit. Fractions were also analysed on 7.5 % 
SDS-PAGE gels. 
 
3.2.15 Protein concentration  
Protein concentration was determined by the Bradford method (Bradford, 1976) using 
a Bio-Rad Protein Assay Kit (Bio-Rad) with BSA as the standard. Coomassie Brilliant Blue 
G-250 was added to a protein solution, which in acidic conditions binds to basic amino 
acids and can be measured at 595 nm with a spectrophotometer. The mixture was 
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incubated for 5 - 10 min at room temperature before measurement. Concentration of 
the unknown sample was determined by comparing its absorbance value against a 
plotted BSA standard curve. The standard curve showed near linear response 
(R2=0.9975) over 0 - 1 mg/mL BSA concentration range. 
 
SDS PAGE gel was also used to estimate protein concentration. Protein samples were 
loaded onto gel and the band intensities were compared against each other. The 
samples were diluted or concentrated by Vivaspin 20 centrifugal concentrator MWCO 
100 kDa until bands appeared to be the same intensity.   Further analysis of band density 
was carried out by BIO Rad software programme which measure band density and 
compares it to a control band density. It also estimates the molecular weigh of proteins 
against a protein marker in the same gel. Three such gels were analysed in this manner 
and average results are listed in results chapter 6.  
 
3.2.16 Microscopy  
Cell viability observation and post-treatment monitoring of swelling were carried under 
Nikon Eclipse TS100 inverted microscope. 
 
3.2.17 Cell culture conditions  
The cells were maintained under the conditions recommended by the supplier. For 
adherent cells, culture medium DMEM with high glucose (4.5 g/L) was supplemented 
81 
 
 
 
with 10 % FCS, and with 1 % PSG (100 U/mL penicillin, 100 μg/mL streptomycin, 292 
μg/mL L-glutamine). Suspension cells were cultured in RPMI 1640 supplemented with 
10 % FCS and 1 % PSG. For the culture of BL31 cells, RPMI 1640 was additionally 
supplemented with sodium pyruvate (100 nM) and 1-thioglycerol (100 nM).  
 
The cells were cultured in sterile polystyrene 75 cm2 flasks (Nunc) in standard cell culture 
conditions (37 °C and 5 % CO2 humidified air). Medium was changed twice a week. When 
adherent cells reached confluency (between 70-80 %) they were washed with DPBS and 
detached by trypsinization (trypsin/EDTA containing 0.05 % trypsin and 0.53 mM EDTA) 
at 37 °C for 5 - 10 min. This was followed by centrifugation (100 - 200 x g for 5 min). 
Adherent cells were dispersed by banging and re-suspension in fresh medium. Cells 
were counted and split depending on the desired seeding ratio.  
 
For electrophysiology experiments HepG2 cells were cultured in DMEM and low glucose 
(1 g/L). HeLa cells were cultured in MEM. Both mediums were supplemented with 10 % 
FCS and 1 % PS. Media were buffered with 25 mM Hepes and cultured in the absence of 
CO2 in non-coated 60 mm plastic dishes. 
 
3.2.18 Cell assays  
Fluorescent cell assays were carried out in 96-well plates. Each well was loaded with 90 
μl of cell suspension at a density of 5,000 or 22,500 cells per well (equivalent to 5.5 x 
104 or 25 x 104 cells/mL) in complete DMEM (DMEM supplemented with FCS and PSG) 
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and incubated overnight under standard cell culture conditions. After incubation, 10 μl 
of toxin was added to each well. control wells contained 90μl of cell suspension and 10 
μl of the appropriate buffer were set up. The following control buffers were used: for 
gel filtered toxin - 25 mM tris-HCL, 150 mM NaCl (pH 7.4), for ÄKTA purified toxin - PBS 
(7.4 pH). For background fluorescent control 100μl of cell culture medium was loaded 
into well. An additional control containing 90 μl of medium and 10 μl of toxin was also 
loaded into well. Generally, each treatment was tested in triplicate (three technical 
replicates). The viability of the cells was measured using CellTiter-Blue, usually after 24 
h of treatment. For CellTiter-Blue assays cell density and incubation time with the 
reagent were optimised for each cell line. Twenty μl of the reagent was added at the 
end of toxin exposure period and the reading was taken after additional 2 h (end-point 
method). Fluorescence was measured with a green filter with excitation wavelength at 
525 nm and emission wavelength range of 580-640 nm.  
 
CellTox-Green assays were used for evaluation of cytotoxicity by measuring changes in 
membrane permeability. For CellTox-Green assays ‘Express, No-Step Addition at Seeding 
Method’ was selected. In brief: to 5 mL of cell suspension 10 μl of CellTox Green dye was 
added and then 90 μl of the mixture was dispensed into each well and allowed to adhere 
overnight. The next day each well was loaded with 10 μl of toxin. Fluorescence was 
measured before toxin addition and at regular 30 min time-points post-toxin addition 
using a blue filter with excitation wavelength at 490 nm and emission wavelength range 
of 510-570 nm.  CellTox-Green values before toxin addition were subtracted from the 
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readings after treatment in that same well. Background fluorescent signals were 
subtracted from each well. 
 
3.2.19 Statistical analysis 
Results were expressed as means ± SEM for each experimental triplicate. To establish 
Cry41Aa and Y514A LC50 in HepG2 cells statistical analysis was carried out using SPSS 
software version 22.0, Probit Regression analysis (IBM, 2013). Dose response curves 
were claculated using nonlinear regression analysis and the equation ‘Dose response 
Stimulation, log (agonist)vs. response-variable slope’ in GraphPad prism version 7 for 
windows, GraphPad software, La Jolla California, USA, www.graphpad.com. 
 
3.2.20 Planar lipid bilayer 
A lipid mixture was created that contained phosphatidylethanolamine (PE), 
phosphatidylcholine (PC) and cholesterol (Avanti Polar Lipids) in a ratio of 7:2:1 (w/w). 
first, lipids were dried with N2 to evaporate chloroform and then dissolved in n-decane, 
at a final concentration of 20 μg/mL. 1 mL of KCl buffer (150 mM KCl, 1 mM CaCl2, 10 
mM Hepes, pH 7.5) was added to each of the artificially made disposable chambers. A 
250 μm diameter hole present at the junction of both chambers was painted with the 
lipid mixture using a blunt end glass pipette. However, only the central area of ˜ 100 μm 
in diameter created a functional bilayer. Chambers were connected to electrodes 
through conducting agar bridges and located inside a Faraday cage to decrease electrical 
interference. Voltage was applied to the cis chamber (trans chamber was grounded).  
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Membrane activity was recorded for 30 min before toxin(s) was added. Capacitance of 
the membrane was between 180 - 200 pF and the painted membranes remained stable 
for a couple of hours. Cry41Aa and F509A were dosed at a concentration between 4-8 
μg/mL, the current was recorded at different applied voltages. At the end of each of the 
three experiments, concentration of KCl in the cis chamber was increased to 450 mM to 
test if the pore was more cation or anion selective.  
 
All experiments were performed at room temperature. Voltage was applied using 
Axopatch – 1D (Molecular Devices). Detected current was recorded and amplified by the 
same instrument and converted into a digital signal with Axon Digidata 1440A 
(Molecular Devices). Currents were filtered at 5 kHz and digitized at 50 kHz. Recordings 
were analysed using pCLAMP 10.5 (Molecular Devices). Conductance was measured by 
recording 20 to 25 current jumps for each voltage and averaged. Currents were plotted 
versus applied voltages (I/V curves) and the data points were fitted by linear regression. 
Conductance (G) was read from the slope of each I/V curve regression line. Probability 
of channel opening was evaluated from recordings by digital analysis of the distribution 
of all current values and plotted for each voltage as a histogram using pCLAMP 10.5 
software. 
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3.2.21 Patch clamping   
A day  before the experiments, cells were seeded at a low density on 24 mm circular 
glass coverslips inside 35 mm dishes, prior to patching, cells were washed three times 
with buffer and mounted inside a coverslip holder that was fitted to the stage of an 
inverted microscope (IMT-2, Olympus). 1 mL of either NaCl (140 mM NaCl, 5 mM KCl, 
1.1 mM MgCl2, 1.1 mM CaCl2, 10 mM Hepes, pH 7.4) or KCl buffer (140 mM KCl, 1.1 mM 
MgCl2, 0.1 mM EGTA, 10 mM Hepes, pH 7.4) was added.  
 
Pipettes were prepared using a Narishige glass capillary puller in a two-step heating 
process that required two types of pipettes. The borosilicate LG16 (Warner Instruments) 
for some of the single channel recording and soda lime 200 (Kimble Chase) for single 
channel and whole cell recordings. The heater was set to 84/77 for borosilicate and 
84/74 for soda lime pipettes.  
 
The following steps were used in patch clamp experiments: cell attached, whole cell, 
inside out. Pipettes were mounted inside a holder attached to an automatic 
micromanipulator. Ag/AgCl pellets created an electrical connection between the pipette 
and the amplifier. The bath solution was grounded. In some experiments, the pipette 
was first filled with buffer, followed by toxin(s) addition on top to allow slow diffusion 
towards the tip of the pipette. In other experiments, the toxin(s) was added straight to 
the bath. The filled pipettes had the resistance of about 4 MΩ and the resistance of the 
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seal was in the range of 2 - 10 GΩ. A voltage of -20 or -40 mV was applied to facilitate 
the transition from the attached cell into the whole cell mode.  
 
Currents were launched as a set of seventeen 1 s depolarizing potential steps from −20 
to 140 mV (10 mV increments). Current values between 0.95 – 1 s were analysed at each 
voltage, counting from the launch of each recording. Values were corrected for the 
averaged baseline current measured just prior to the applied potential. Current – 
voltage curves in the whole cell experiments were generated from each data set for each 
time point and conductance was calculated from the slope of regression line of each I/V 
curve.  
 
In the single channel experiments, with excised patches conductance was calculated as 
described for PLB experiments using the slopes of the I/V curves. The following equation 
was used for cell attached mode: G=I/(V-Vr) to correct for the intracellular voltage, were 
Vr is a reversal potential. After plotting data points, Vr was calculated from the 
intersection of the voltage axis with the linear regression at zero current.  
 
All experiments were performed at room temperature. Voltage was applied using 
Axopatch – 1D (Molecular Devices). Detected current was amplified and converted into 
a digital signal with Axon Digidata 1550 (Molecular Devices). Currents were filtered at 
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10 kHz and digitized at 50 kHz. Recordings were analysed using pCLAMP 10.6 (Molecular 
Devices). 
 
3.2.22. Western blots  
Cells were seeded in 6, 12, 24-well plates. the cells were lysed with RIPA, NP-40 (1 mL of 
lysis buffer per 2.8 x 107 cells) or 1.5% NOG (1 mL of lysis buffer per 2 x 107 cells). Each 
lysis buffer contained protease inhibitors: Complete protease inhibitor mixture, 1 mM 
EGTA, 1 mM EDTA and phosphatase inhibitors: 2 mM sodium orthovanadate and 1 μM 
microcystin. HepG2 cells were seeded at the density of 25 x 104 cells/mL in 6 well-plates 
(75 x 104 cells/dish). Sodium arsenite was added once cells reached >70% confluency. 
They were then incubated for 15-30 min with buffer, or toxins followed by 2 washes 
with DPBS. Complete cells were scraped, spun at low speed (200 x g) and supernatant 
was discarded. Pellet containing complete cells was re-suspended in 100 μl of NP-40 
with protease and phosphatase inhibitors (1 mL of lysis buffer per 7.5 x 106 cells). 
Samples were vortexed for 10 s, left on ice shaking for 20 min and spun at 16,873 x g for 
15-30 min at 4°C. Supernatant was collected and diluted protein concentration was 
assayed by Bradford.  
 
For a p-p38 western blot 5-30μg of protein were loaded per well. The proteins were 
resolved on SDS-PAGE gels. The gel was drenched in dry blot buffer and proteins were 
transferred to a nitrocellulose membrane (HyBond ECL or Bio-Rad, pore size 0.45 μm) 
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via a Bio-Rad Trans-Blot Semi-Dry Transfer Cell system. The membrane was washed with 
PBS and blocked with PBS containing 0.02% Tween-20 (PBS-T) and 3% BSA for 1-3 h at 
room temperature. Further membrane washes with PBS-T.  
 
Probing was done overnight at 4°C by incubating the membranes with rocking in a fresh 
blocking solution containing 3% BSA and primary antibody diluted in PBS-T (1:1000 
dilution for antibodies against total and phosphorylated ERK and p38; 1:50000 dilution 
for anti-CD59 antibody). In pCREB and N-cadherin western blots both blocking and 
incubation with primary antibody (1 μg/mL final) was done using 5% non-fat dry milk 
instead of BSA. Post overnight incubation, the membranes were washed 3 x 10 min with 
PBS-T, followed by 1 h incubation with an appropriate horseradish peroxidase-
conjugated secondary antibody diluted 1:2000 in PBS-T containing 5% non-fat dried 
skimmed milk. lastly, the membranes were washed again (3 x 10 min, PBS-T) and 
saturated in chemiluminescent detection solution and exposed to X-ray film (FUJI 
medical X-ray film). 
 
The following antibodies were acquired: Rabbit monoclonal antibody against phospho-
p38 (Thr180+Tyr182) and rabbit polyclonal antibodies against phospho-ERK, total p38 
and total ERK were from Cell Signalling Technology (9215S, 9101S, 9212 and 9102 
respectively). Second vial of rabbit monoclonal antibody against phospho-p38 
(Thr180+Tyr182) was obtained from Thermo Fisher Scientific (MA5 15182). The 
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following primary antibodies were purchased from Abcam: rabbit monoclonal against 
CD59 (ab126777).  
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 Design 
Mutagenesis 
 
Decide on mutagenesis, such as deletion, substitution, or creating a hybrid. 
Mutagenesis took place in domain II loops of Cry41Aa, located in ORF2 of pBS41Aa   
Design primers for mutagenesis. 
Prepare template and PCR mix; optimize annealing temperature for PCR.  
Run PCR products on 1% agarose gel, excise, and purify product. Allow linear DNA to self-ligate overnight at room temperature. 
 Transformation 
with E. coli   
 
Ligation mixuture are introduced into E. coli   and plated onto 100µg/ml ampicillin plates. 
Colonies were picked and incubated in LB with ampicillin.  
Plasmids were extracted using mini prep extraction kit  
 Confirmation of 
mutagenesis in 
E. coli 
expression 
vector 
 
Plasmids undergo a Hae III digest and fragments are visualised on 1%agarose gel 
NEB cutter software provides Hae III digestion profile for each mutant plasmid. These were compared against gels of plasmid Hae III 
digests. Mutant plasmids were further confirmed by sequencing. 
 Creating Bt 
expression 
vector 
 pBS41Aa lacks ORF3 of Cry41Aa required for packaging and crystal formation. Mutant OFR2 were isolated and taken into a Bt 
expression vector pSVP2741Aa. 
Two double digests were carried out (i) BamHI and XhoI double digest to isolate mutant ORF2 fragment (2.5kb) from Blue Script.  
(ii)  a BamHI and XhoI double digest to isolate ORF3 from pSVP2741Aa. This is 7.8kb fragment. All fragments were visualised, excised 
and purified from agarose gel.  
The liner DNAs were ligated overnight to form construct.  
 Transformation 
with E. coli   
 
Ligation mixture were introduced into E. coli   and plated onto 100 µg/ml ampicillin and 5 µg/ml chloramphenicol agar plates. 
Colonies harbouring potential mutants are picked and incubated in LB with antibiotics. 
Plasmids were extracted by mini prep kit and subjected to further analysis  
 Confirmation of 
mutagenesis in 
Bt expression 
vector 
 
Hae III digests profiles on potential construct revealed potential candidates on 1.5% agarose gel. 
Sequencing analysis confirmed desired construct.  
 Transformation 
with E. coli   
 
Constructs in Bt shuttle vector was introduced into E. coli   GM2163 to remove methylated DNA. Transformation was plated onto 100 
µg/ml ampicillin agar plates.  Colonies were picked and incubated in LB with antibiotics. Mini preps were carried out to isolate 
plasmids. Hae III digest were carried out on recovered plasmids and run against control DNAs on 1.5% agarose gel.  
Constructs were confirmed by Hae III digests. 
Construct were ready for transformation with Bt4D7. 
 Transformation 
with Bt4D7 
 The DNA is desalted to improve rate of successful Bt transformation. 
Mutant constructs in Bt shuttle vector were introduced with Bt4D7 and plated out in 5 µg/ml chloramphenicol agar plates for 
overnight incubation at 30˚C. Colonies were picked and incubated in LB with 5 µg/ml chloramphenicol.  The plasmids were extracted 
with mini prep kit for further analysis. The remaining LB with colony was plated out in 5 µg/ml chloramphenicol agar plates for 3 days 
at 30˚C. 
 Confirmation of 
Bt crystals and 
mutant DNA 
 Extracted plasmids were first visualised in agarose gel to confirm that DNA was obtained from Bt cells.  The plasmids were introduced into E. coli and plated on agar prepared with 100 µg/ml ampicillin and 5 µg/ml chloramphenicol and 
incubated overnight at 37 ˚C. Cell lawn was scraped, and DNA was extracted with mini pre-kit. Hae III digests confirmed that DNA 
which was introduced with Bt4D7 is the same one that was extracted from Bt4D7. Hae III digest were not carried out directly in Bt 
recovered plasmids as the presence of native plasmids digest profile would make HaeII digest profile of construct difficult to 
interpret. 
Light microscope observations confirmed the presence of crystals and spore from Bt after 3days of incubation. 
Bt cells were harvested and crystals were characterised 
Figure 13 Methods schematic diagram  
Schematic diagram of the steps, and experimental procedures taken to create Cry41Aa constructs 
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4.0 Bioinformatic analysis of Cry41Aa  
4.1 Introduction 
To study the function and structure of Cry proteins bioinformatic tools were used, which 
resulted in a growing nomenclature system that hosts over 300 Cry proteins (Crickmore 
et al., 2018).  
 
Key characteristics have been revealed, for instance many Cry proteins have five 
conserved sequence blocks (Höfte and Whiteley, 1989). In addition, molecular modelling 
has shown that Cry proteins with this feature tends to have a similar 3domain fold 
(Adang, et al., 2017; de Maagd et al., 2003; Pardo-López,2013; Soberón and Bravo, 
2013).  
 
Cry proteins tend to have high occurrence of homologous genes, however, the active 
form of the Cry protein tends to be active against a limited number of targets (Schnepf 
et al., 1998; Crickmore et al ., 2013; de Maagdet al., 2003; Bravo, 1997). Research studies 
have taken advantage of the specificity of Cry proteins and their ability to target certain 
insect orders to commercially explore their application as bio-pesticides.  The ability of 
Cry toxin to recognise and to bind to different types of cells is a determinant of its 
specificity.  
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Studies on the adaptive evolution of Cry proteins have revealed potential positive 
selection for certain residues and positions that increase the diversity of specificity of 
Cry toxins. It was suggested that this increase on the type of target cell allowed Cry 
toxins to be active against a wider range of hosts where spores can germinate, ensuring 
their continued existence in the environment and their ability to overcome resistant 
adaptations of hosts (Wu et al. , 2007; de Maagdet al., 2003).  
 
A study by Mizuki et al. (1999) attempted to address the high rate of occurrence of Cry 
proteins without a known insect target cell. As a consequence, this class of Cry protein 
were named parasporins and allocated Cry protein names. Parasporins are non-
haemolytic but active against certain cancer cell lines (Kitada et al., 2005; Mizuki et al., 
1999; Ohba, Mizuki and Uemori, 2009; Mizuki et al., 2000; Akiba et al., 2009; Yamashita 
et al. 2005).  
 
Among the parasporins,  parasporin 3 and 5 are the least studied (Nagamatsu et al., 
2010; Yamashita et al., 2005). Yamashita et al. (2005) first reported Cry41Aa also known 
as parasporin 3 as a 3-domain Cry protein of Bt that has cytocidal activity on myeloid 
leukaemia (HL60) and liver cancer (HepG2) cell lines. Molecular modelling suggests it 
has a secondary structure that is closely associated with the typical 3-domain structure 
of many insecticidal Cry proteins.  
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Cry41Aa is expressed from two open reading frames ORF2 and ORF3. Sequence 
alignments of ORF2 against protein sequences of revealed Cry structures has shown that 
the protein sequence of Cry41Aa encompasses the five conserved characteristic of 
insect targeting Cry proteins. Furthermore, ORF3 was found to contain conserved block 
6, 7 and 8 which are also present  in some larger insecticidal Cry proteins  (Yamashita, 
2005; Kitada et al., 2005; Yamashita et al., 2005; Nagamatsu et al., 2010). Despite these 
similarities, Cry41Aa has no known insect target and its ability to identify, interact and 
kill HL60 and HepG2 cell lines points to a novel specificity not seen before in typical 3-
domain Cry toxins (Kitada et al., 2005;  Ohba et al., 2009).  
 
Receptor recognition and binding specificity in 3-domain Cry proteins are usually 
associated with domain II (de Maagd et al., 2001; Crickmore et al., 1998; de Maagd et 
al., 2003). It has been noted that domain I which is associated with membrane insertion 
and pore formation is highly conserved, allowing the majority of genetic divergence to 
occur elsewhere (Boonserm et al., 2005; Schnepf et al., 1998; Bravo., 1997). Another 
study has shown that mutations carried out in domain I resulted in reduced or total loss 
of toxicity (Saraswathy and Kumar., 2004).  
 
Domain II is where much divergence occurs as it is associated with receptor recognition 
and binding specificity, and therefore its diversity within Cry proteins allows for a diverse 
range of target cells (Wu et al., 2007). This is particularly true of the exposed loops 
typical of domain II, where loops 1, 2, and 3 vary in length and amino acid sequence  
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(Schnepf et al., 1998; Smedley and Ellar, 1996; Tuntitippawan et al., 2005; Adang, 
Crickmore and Jurat-Fuentes, 2014). Cross resistance by target cells is a consequence of  
high sequence homology of the loops in domain II among three domain Cry proteins 
which can bind to the same binding sites in midgut brush border (Adang, Crickmore and 
Jurat-Fuentes, 2014). A number of studies have identified residue positions in loop 
regions of domain II and domain III that are positively selected for, and mutagenesis  
resulted in loss or reduced toxicity (Wu et al., 2007; Herrero et al., 2004). 
 
Other studies have investigated Cry toxin specificity and its improved specificity to target 
cell. These studies were also geared at the introduction of new specificity by addition to 
pre-existing one which resulted  in the creation of novel toxins with the consequence of 
a quicker killing response (Wu et al., 2000; Abdullah et al., 2003; Pardo-López et al., 
2009; Dean. H and Sylvis L, 2006). 
 
Pardo et al. (2009) carried out mutagenesis of loop2 and 3 on Cry1Ab to improve its 
insecticidal activity. It was discovered that these loops have important interactions with 
cadherin like transmembrane proteins CADR 11 and 12 binding sites and that the loops 
are critical for receptor interactions. Site mutagenesis on domain II loops of Cry3Aa and 
Cry1Ab, were reported to have a 10-fold increase toxicity of Cry3Aa towards its target 
insect Tenebrio molitor, and a 34-fold increase toxicity towards Lymantria dispar by 
Cry1Ab (Wu et al., 2000).  
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Studies on domain II loops of Cry4Ba have shown that deletions and substitutions have 
resulted in a novel toxicity against Culex mosquitoes (Abdullah et al., 2003). It is also 
possible to eliminate native toxicity and introduce novel activity against another target 
insect as illustrated by complete removal of Cry1Aa’s activity to caterpillar larvae (Dean 
and Sylvis., 2006) and to introduce toxicity to Culex pipiens by replacing Cry1Aa’s native 
loop1 and 2 with loop regions of Cry4Ba (Tuntitippawan et al., 2005; Abdullah et al., 
2003; Dean. H and Sylvis L, 2006)  
 
Early studies on loop 3 of domain II have implicated its role in target specificity, receptor 
recognition, and binding. Hussain et al. (1996) proposed that loop 3 residues have 
hydrophobic interactions with receptor and mutations in this loop can affect the toxins 
ability to bind. Indeed, Fujii et al. (2012) carried out research on conserved amino acids 
of Cry1Aa. The 30 amino acid loop that covers all its binding loops were substituted with 
hydrophobic residues and resulted with an increase in binding affinity towards cadherin 
BT-R1 receptor (Hussain et al., 1996; Fujii et al., 2012).   
 
Pacheco et al. (2009) demonstrated that mutations in domain II loops affect binding to 
the cadherin (Bt -R1) and aminopeptidase-N (APN) receptors in the lepidopteran 
Manduca sexta. These studies point at the implication of loop 3 of Cry1Ab in its mode 
of action. Mutations in loop 3 of Cry1Ab were found to severely affect the toxin’s 
insecticidal activity in both monomeric and oligomeric states of the activated toxin. A  
“ping pong” binding mechanism to explain the toxin activity and its dependency on loop 
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3 of domain II was proposed (Pacheco et al., 2009). Such studies have highlighted the 
important role of domain II loops in the specificity of 3-domain Cry proteins.  
 
In order to gain an understanding of the specificity that Cry41Aa has towards HL60 and 
HepG2 cell lines it is vital to explore the secondary structure of domain II loops In this 
study comparisons were made between the predicted Cry41Aa secondary structure and 
that of resolved 3-domain Cry protein structures. Bioinformatic tools were employed to 
carry out the comparative analysis. 
 
4.2 Identification of the putative loops of domain II in Cry41Aa using 
bioinformatic tools 
Information gathered from protein sequence and structure is often used to explore 
protein function. Sequence homology between proteins can suggest similar functions of 
proteins particularly if they share putative homologous regions and similar structural 
arrangements. Bioinformatic software uses a wide range of data gathered from known 
protein sequences and structures to present a model summary of an unknown protein 
sequence.  
 
Information on protein sequence, structure, and function is ample.  Some bioinformatics 
tools collate data to trace evolutionary patterns of proteins in an attempt to improve 
the understanding of protein function. Naturally, proteins diverge; domain swapping, 
97 
 
 
 
matching or mixing is another way of obtaining novel function. Bioinformatic tools aid 
to make sense of the vast array of information and collates it in a form so that it may 
predict protein function.  
 
Scientists have employed computer programmes to assist with the comparisons and 
analysis of patterns and evolutionary relationships between biological sequences. 
Clustal is one of the bioinformatic tools that is comprised of computer programs for 
multiple sequence alignment of sequences. Protein, DNA, or RNA sequences can be 
aligned against a query or unknown sequence and depending on the algorithm; a 
sequence homology is detected and a phylogenic analysis is carried out to assess the 
links between the query sequence and that of known sequences. Multiple alignments 
are used to find diagnostic patterns to characterise protein families and determine 
homology between new sequences and existing families of sequences; in order to 
predict the secondary and tertiary structures of new proteins. Its takes advantage of the 
fact that homologous sequences are evolutionarily related.  
 
The programme builds a multiple alignment progressively by a series of pairwise 
alignments, following the branching order in a phylogenetic tree.  There are many 
versions of Clustal, operating systems and tools. It has evolved and progressed from its 
early 1988 version by Des Higgins. This study has applied ClustalW, the third version of 
a series of Clustal software. This version has sequence weighting, position-specific gap 
penalties and the automatic choice of a suitable residue comparison matrix at each stage 
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in the multiple alignment as well as more sensitive programming algorithm (Thompson 
et al., 1994; Chenna et al., 2003). 
 
However, the accuracy and reliability of this output information varies from one tool to 
another (Whisstock and Lesk, 2003). Bioinformatics tools have narrowed down regions 
involved in specificity, receptor recognition, and binding by analysing  unresolved Cry 
protein sequences against resolved Cry protein structure in attempt to understand Cry 
toxin mode of action (Li et al., 1991). In an attempt to understand, which regions of 
Cry41Aa are responsible for its activity against HepG2, bioinformatics tools were 
employed as a starting guide in an effort to locate sequence(s) responsible for its 
specificity towards HepG2.  
 
Clustal alignment analysis was applied to narrow potential loop regions in protein 
sequence of Cry41Aa. The protein sequences of resolved 3-domain Cry structures listed 
in table 6 were used in bioinformatics analysis of Cry41Aa protein sequence to identify 
its domain II loops.  
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Table 6 List of resolved domain II loops 
 Table lists loops 1, 2, and 3 of domain II of the protein sequences of resolved structures of Cry proteins used for 
alignment against Cry41Aa.  
 
 
 
The following is a list of crystal resolved Cry toxins: Cry1Aa (Grochulski et al., 1995), 
Cry1Ac (Evdokimov et al., 2014), Cry2Aa (Morse et al., 2001), Cry3Aa (Li et al., 1991),  
Cry3Bb (Galitsky et al., 2001),  Cry4Aa (Boonserm et al., 2006), Cry4Ba (Boonserm et al., 
2005), and Cry8Ea (Guo et al., 2009).   An alignment of Cry41Aa against these Cry 
structures was carried out to locate putative loop region of domain II associated with 
specificity and shown in  figure 14 a and 14 b (Likitvivatanavong et al., 2009; Adang et 
al., 2014; Crickmore et al., 1998).  The beta-trefoil domain of Cry41Aa was deleted from 
List of resolved domain II loops 
 
 
 
Cry 
toxin 
name 
 
Domain II loop sequences 
Loop 1 Loop 2 Loop 3 
Cry1Aa  
311RG312 
 
368RIILGSGPNNQE379 
 
435TMLSQAAGAVYTLRAPT451 
Cry1Ac  
311RG312 
 
369RPFNIGINNQQ379 
 
438SGFSNSSVS446 
Cry2Aa  
322NIGGLPG328 
 
378LDSGTDREGVA388 
 
440RPLHYNQIRNIESPGTPGGAR461 
Cry3Aa  
356PGYYNDS363 
 
420PS421 
 
489MQGSR493 
Cry3Bb  
349PGYFGKDS356 
 
412WPNGK416 
 
484MQDRRG489 
Cry4Aa  
371KAQTTPNNF379 
 
460AGSGQITYD468 
 
508SIPATYKTQ516 
Cry4Ba  
330TI331 
 
410SNITPTPEG418 
 
455YN456 
100 
 
 
 
the sequence before alignment as it has earlier been demonstrated that its removal has 
no impact to susceptible cell line (Krishnan, 2013). The alignment has highlighted the 
similarities between Cry41Aa and 3- domain Cry toxins. The alignment has been 
significantly narrowed down regions of putative loops of domain II in Cry41Aa where it 
aligned against known putative domain II loop of resolved Cry sequences.  
 
The alignment was further analysed by Box shade where amino acids that are the same 
or similar are highlighted, increasing the confidence of predications made about 
Cry41Aa. From this, similar or identical amino acids are likely to have similar structural 
roles, and thus provide evidence of analogous structural role of Cry41Aa sequences as 
those of the resolved Cry sequences. The alignment highlights the distinctive extra loop 
not found in other 3-domain Cry proteins as noted in Figure 14 a and 14 b. It also 
indicates the poor alignment of Cry41Aa loop2 against the resolved Cry sequences when 
compared to how well loop1 and loop 3 of Cry41Aa align with loop 1 and loop 2 of 
resolved Cry sequences.  Further tools were employed to identify the domain II putative 
loops of Cry41Aa.  
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Figure 14a ClustalW alignment analysis of Cry41Aa 
Clustal alignment analysis of Cry41Aa against the protein sequences of revealed crystal structures of Cry2Aa, Cry3Aa, 
Cry3Bb, Cry4Aa, Cry4Ba, and Cry8Ea. Box shade secondary structure analysis highlights identical amino acids in black 
and similar amino acids in grey. A unique sequence distinctive only to Cry41Aa known as the extra loop is highlighted 
in pink named the extra loop of Cry41Aa with the following sequence 261NVSDYSRYPWTQYNQSGGFSYREAKGEYRGT291 
. Loop1 is boxed in red for the known Cry toxins, and highlighted in red for predicted loop1 of Cry41A with the 
following sequence 384SITS387 . Loop2 is boxed in yellow for known Cry toxins, and highlighted in yellow for predicted 
loop2 of Cry41Aa with the following sequence  416QNTSYTRIDRP426 . Loop 3 is boxed in blue for the known Cry proteins, 
and highlighted in turquoise for predicted loop 3 of Cry41Aa with following sequence 503VRDNCPFAWPGYKQL517 . 
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Figure 14b Analysis of Cry41Aa by ClustalW alignment and Box shade  
ClustalW alignment analysis of Cry41Aa against the protein sequences of revealed crystal structures of Cry2Aa, 
Cry3Aa, Cry3Bb, Cry4Aa, Cry4Ba, and Cry8Ea. Box shade secondary structure analysis highlights identical amino acids 
in black and similar amino acids in grey. For all Cry proteins listed, Loop1 is highlighted in red, Loop2 is highlighted in 
yellow, loop 3 is highlighted in blue. β sheets are highlighted in green.  
 
 
PSIRED web server predicted the secondary structure of Cry41Aa, where sequences 
are predicted as β- strands, α- helixes, or coils and given a level of confidence as the 
accuracy of its predication as shown in figure 15, and 16.  The PSIRED protein structure 
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predication server incorporates three key programmes that predict secondary 
structures of globular and membrane bound proteins. In addition to secondary protein 
structure analysis, it incorporates the GenTHEADER program which recognises protein 
folds as well as the MEMSAT 2 program which predicts structure and topology of 
transmembrane proteins (McGuffin et al., 1999). 
 
The overall secondary protein is predicted to be highly helical in particular domain I. The 
analysis complements findings from the other bioinformatics tool and suggested that 
the three putative loops of domain II of Cry41Aa are found as coils structures. Loop 1 is 
predicated to sit in a coil between two β-sheets and is made up of four amino acids. Out 
of the three domain II loops, loop1 has the highest confidence score that is predicted 
loop structure is more likely. Loop 2 is the least confident predication of the three loop 
regions. It is made up of 11 amino acids found in a coil region made up of 31 amino acid.  
β-sheets here have the furthest proximity from loop region compared to the other two 
predicated loop regions.  Loop 3 is predicated with a good level of confidence.  It is made 
up of 15 amino acids flagged up by two β-sheets immediately either side of it. It is 
predicated to be in coil conformation made of a total of 17 amino acids that include the 
15 amino acids that make up loop 3 detailed in figure 15. The extra loop is flagged by 
helical structures either side.  
 
Figure 16 summarises the secondary structure of PSIPRED analysis. The three loops were 
mapped out onto the ClustalW alignment including the β-sheets that fall either side of 
105 
 
 
 
the three predicted putative of Cry41Aa as well these of the resolved 3-domain Cry 
proteins.  
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Figure 15 PSIRED webserver secondary structure image prediction of Cry41Aa based on amino acid sequence. 
Loop1 is underlined in red, loop2 underlined in yellow, and loop 3 underlined in blue. The extra loop distinctive to 
Cry41Aa is underlined in pink (Jones, 1999; Buchan et al., 2013). 
 
 
 
 
 
 
Figure 16 PSIRED webserver secondary structure image prediction of Cry41Aa structure based on amino acid 
sequence. 
Helical amino acids are highlighted in dark grey. β-sheets are highlighted in light grey.   Loop1 is boxed in red, loop2 
in yellow, loop 3 in blue. The extra loop distinctive to Cry41Aa is boxed in pink  
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X-ray crystallography remains the main method for the determination of protein 
structure, however it is time consuming and it is successful only when specific conditions 
for growing crystals are optimised. Thus, the main method to predict protein structure   
takes advantage of  computational homology modelling which  can  predict  the 
secondary     structure  of  a protein from  its  sequence (Shokry et al., 2018).   
 
Protein modelling servers SWISS-MODEL and the Protein Homology / 
analogY Recognition Engine V 2.0 or PHYRE2 were used to analyse the secondary 
structure of Cry41Aa. The PSIPRED analysis predicted the secondary structure based on 
the protein sequence of Cry41Aa highlighting  helixes, coils and β sheet strands in 
Cry41Aa with a score of confidence. Of the three loops, loop1 aligned better than any of 
the other loops predicted in the alignment.  
 
Many homology-modelling methods involve template selection, target template 
alignment, model building, and evaluation of the model as steps in their modelling 
approach. The named processes are repeated and reassessed until a model structure is 
created. The SWISS-MODEL server is based on the rigid fragment assembly approach, 
where the framework of the unknown protein is calculated on the basis of the family of 
homologous proteins, or an appropriate subgroup (Schwede et al., 2000; Schwede et al., 
2003). The program then aligns fragments of the known protein structures of high 
sequence homology with the unknown. This alignment provides a basis for building the 
model’s the structure. The server implements four main steps: template superposition, 
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target-template alignment, model building and energy minimization. In brief, the server 
first makes a template selection by searching a template library database. Quality 
indicators such as empirical force field energy removes low matching templates.  An 
alignment is then created. A local pair-wise alignment of the target sequence to the main 
template structure is calculated and a root mean square differences (RMSD) between 
pairs of homologous structures score can be obtained.  A model of the unknown protein 
sequence is built using information from the averaged backbone atom positions of 
templates. Loops are built based on scoring schemes, that consider field energy, steric 
hindrance and interactions such as hydrogen bond formations. The model is complete 
once energy minimization is carried out. In this final step, parts of the model with 
conformational errors are detected. Empirical force fields are used by the SWISS-MODEL 
server to regularise the built model (Biasini et al., 2014; Schwede et al., 2000; Schwede 
et al., 2003). 
 
The Protein Homology / analogY Recognition Engine V 2.0 or PHYRE2 is also a protein 
homology modelling server. It applies homology modelling principles to build a model 
of an unknown protein sequence. It is based on the understanding that the structure of 
proteins is conserved in evolution and that a model of an unknown protein can be made 
from its sequence based on related known protein sequences or templates (Kelley et al., 
2009; Kelley et al., 2015). The server applies four main stages to create a model. The 
server first scans the unknown protein sequence against a protein database where it 
gathers homologous sequences that have at least 20 % sequence identity with the query 
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sequence to build a multiple sequence alignment using the HHblits algorithm method. 
The resulting alignment is then assessed in PSIPRED a software that predicts the 
presence of α-helices, β-strands and coils with an accuracy of 75–80% (McGuffin et al., 
1999). It assesses both the predicted secondary structure and the alignment. HMMs 
output proceeds to create the backbone of the model. This is followed by loop modelling 
and finally side chain placement before a model is presented (Kelley et al., 2009; Kelley 
et al., 2015). 
 
Two protein-modelling servers SWISS-MODEL and PHYRE2 were applied to predict the 
secondary and tertiary structures of Cry41Aa.  Assisted by UCF chimera software to 
visualise the structures.  SWISS-MODEL generates 3D models for proteins using a 
template library in order to put together complete structural models matching Cry1Aa 
as the closest homologue at the time of the analysis. (Biasini et al., 2014). 
 
The SWISS-MODEL server created a model of Cry41Aa using its ‘first approach mode’ 
(Biasini et al., 2014). Here the sequence of Cry41Aa was screened against a number of 
suitable templates obtained from the ExPDB library. The automated modelling system 
then produced a model against a template that shares at least 25 % sequence identity 
with Cry41Aa. A number of insecticidal templates were identified against the sequence 
of Cry41Aa, however the template with the highest percentage of sequence identity was 
that of Cry1Aa with a 34 % sequence identity with Cry41Aa. it has a Global Model Quality 
Estimation (GMQE) score of 0.48. The GMQE is usually a number between 0 and 1 that 
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represents the accuracy of the alignment, template and built model. The higher the 
score the more reliable the alignment and thus the model built (Waterhouse et al., 
2018). Figure 17 illustrates the SWISS-MODEL model of Cry41Aa. Similar to insecticidal 
Cry1Aa the SWISS-MODEL modelled Cry41Aa has a domain I is made up of -helixes and 
domain II is a β-sheets sandwich both typical of 3 domain insecticidal Cry protein. 
Domain III is made up of β-sheets and a network of exposed loops, however Cry41Aa 
differs as it has a distinctive partial - helical extra loop (shown in pink, figure 17) that 
appears to protrude away from the main structure. Here, loop1 is short and tucked 
under, loop2 and loop 3 appear to extend out from the main structure. The model and 
Cry1Aa template were superimposed and were calculated to have an RMSD value of 0.7.  
 
PHYRE2  server applies template based homology modelling and fold recognition 
methods to predict secondary and tertiary structures to produce a PDB file for 
visualisation and analysis (Kelley et al., 2015) . The bioinformatic PHYRE2 tool has 
analysed the Cry41Aa sequence. It modelled 68% of the Cry41Aa sequence with 100% 
confidence. Furthermore, it suggested that the resolved crystal structure of Cry3Aa is 
the optimum structural template despite sharing 32% sequence identity with Cry41Aa 
sequence.  
 
The PHYRE2 server has modelled Cry41Aa to be structurally similar to insecticidal 3-
domin Cry protein such as Cry3Aa in figure 18. Domain I has the typical -helices of 
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insecticidal Cry proteins. Domain II is made up of β-sheets sandwhich that appears to be 
in a looser confromation to that seen in Cry3Aa. Similarly, domain III of Cry41Aa is made 
up of β-sheets and a network of exposed loops. Here, the extra loop  appears to be closer 
to the main structure and it is not helical but rather in a coil formation. Loop1 and loop 
2 appear to be positionally similar to those of Cry3Aa. when the model was 
superimposed onto the Cry3Aa template is had a RMSD value of 0.6.  
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    Cry1Aa                                  RMSD=0.7      SWISS-MODEL Cry41Aa
                              
Figure 17 SWISS-MODEL visulaised Cry41Aa structure.  
On the left is the 3D structure of crystallography resolved Cry1Aa shown in light grey. Loop1 is shown in red, loop2 in yellow, and loop 3 in blue. On thr right is the SWISS-MODEL generated 
predictaed strructure of Cry41Aa shown in dark grey. Loop1 is shown in red, loop2 in yellow, loop 3 in blue, and the extra loop exclusive to Cry41Aa in pink.                                       
Domain I:  helix bundle 
Domain I:  helix bundle 
Domain III: β sheets sandwich  
Domain III: β sheets 
sandwich  
Domain II: β sheets and 
exposed loop region  
Domain II: β sheets and 
exposed loop region  
Loop 1  
Loop 2 
Loop 3 
Extra Loop  
Loop 1  
Loop 2 
Loop 3 
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CRY3Aa           RMSD=0.6      PHYRE2 Cry41Aa 
                                             
Figure 18 UCF chimeria visulaised Cry41Aa structure.  
On the left is the 3D structure of crystallography resolved Cry3Aa shown in light grey. Loop1 is shown in red, loop2 in yellow, and loop 3 in blue. On thr right is the Phyre 2 generated predictaed 
strructure of Cry41Aa shown in dark grey. Loop1 is shown in red, loop2 in yellow, loop 3 in blue, and the extra loop exclusive to Cry41Aa in pin
Domain I:  helix bundle 
 
Domain III: β sheets sandwich  
 
Domain III: β 
sheets sandwich  
 
Domain II: β sheets and 
exposed loop region  
Loop 3 
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Loop 1 
Loop 1 
Extra Loop 
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The servers created similar but different models of Cry41Aa. The servers applied slightly 
different algorithms and programmes to analysis Cry41Aa sequence and resulted in each 
server’s use of a different template. It worth analysing how different or similar the 
models are when each server applies the same template when analysing the Cry41Aa 
sequence. Thus, SWISS-MODEL analysed Cry41Aa sequence using Cry3Aa as template 
instead of Cry1Aa its highest scoring homologue. PHYRE2 analysed Cry41Aa sequence 
using Cry1Aa as a template instead of Cry3Aa. The two models were superimposed onto 
each relevant template and an RMSD value for each model was calculated as shown in 
figure 19.  
 
SWISS-MODEL server created a new model of Cry41Aa. the most obvious change was 
observed in the extra loop that changed from its previous helical formation when Cry1Aa 
was template to a coil. The model and template were superimposed, and the RMSD was 
calculated as 1.5. The structure appears less compacted than the Cry41Aa model created 
with Cry1Aa as a template. The loops of domain II appear to project away from the main 
structure. The PHYRE2 server also created a new model of Cry41Aa based on the Cry1Aa 
template. The model and template were superimposed and the RMSD was calculated as 
1.3.  The model appears to be very similar to that made by SWISS-MODEL based on the 
same Cry1Aa template.  
 
The RMSD values for each one of the four models made by both servers were compared. 
Both RMSD values for the given templates were above one (PHYRE2=1.3, SWISS-MODEL 
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=1.5), indicating that the models share little similarities to templates. The original 
templates chosen by the servers had RMSD scores closer to zero an indication that the 
similarities to those templates are greater. The lowest RMSD score was 0.6 by PHYRE2 
server modelling Cry41Aa on the Cry3Aa template. This result indicates that this model 
shares the most similarities with its template and is thus the better model of Cry41Aa.    
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Figure 19 UCF chimeria visulaised  structure of the two Cry41Aa models based on diffrent templates.  
The superimposed models of Cry41Aa. In gold is the Cry41Aa model as predicted by SWISS_MODEL server based on Cry3Aa template. In light pink in the Cry41Aa model as predicted by PHYRE2 
server based on Cry1Aa template . Loop1 is shown in red, loop2 in yellow, and loop 3 in blue and the extra loop exclusive to Cry41Aa in pink.
PHYRE2 Cry41Aa model based 
on Cry1Aa template     
RMSD=1.3     
SWISS-MODEL Cry41Aa model 
based on Cry3Aa template 
RMSD=1.5 
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4.3 Discussion 
Bioinformatic tools have highlighted similarities between Cry41Aa and the typical 3-
domain insecticidal Cry toxins. It is thought to have a typical 3-domain structure as 
originally suggested by Yamashita et al. (2005).  
 
Studies have highlighted two key points regarding the specificity of 3-domain Cry toxins. 
Firstly, domain II and its exposed loops are directly implicated in interactions with target 
receptors as well as being the region where most genetic variation is observed in 3-
domain toxins. Secondly, the diversity that allows Cry toxins to have such a narrow 
specificity as is the case with Cry41Aa. research has suggested that receptors can 
recognise activated Cry toxins from more than one region of the protein.  For example, 
monomeric Cry1Ab toxin is thought to bind to ALPs and APNs through loop 3 of Domain 
II and β16 of Domain III (Pacheco et al., 2009, Arenas et al., 2010). This is very different 
to the oligomeric form of Cry1Ab which interacts with ALP and APN through loop 2 of 
Domain II. In addition, studies have also suggested that Cry1Ab binds cadherin receptors 
through interactions with loop 2 and loop 3 and α8 of Domain II (Gomez et al., 2003, 
Gomez et al., 2006).  Thus, it is important to explore regions associated with toxin 
specificity and the determinant of the toxin ability to interact with one cell type and not 
others. 
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The combined findings from the bioinformatics tools employed here, suggest that 
Cry41Aa has a 3-domain structure, with domain I, II and III maintaining the typical 3-
domian arrangement of   and β sheets observed in insecticidal Cry toxins. ClustalW 
alignments and box shade analysis of Cry41Aa against protein sequences of resolved 
crystals structure of 3-domain Cry toxins have narrowed down the regions where the 
three loops of domain II Cry41Aa may occur. PSIPRED web server further analysed these 
regions predicting with a level of confidence to the location of β-sheets which typically 
fall either side of a loop.  
 
Modelling tools in combination with the sequence analysis tools were able to model the 
putative exposed loops in the domain II region of Cry41Aa.  Bioinformatics has suggested 
the following sequence for loop1 384SITS387, loop2, 416QNTSYTRIDRP426 and loop 3 
503VRDNCPFAWPGYKQL517 as the exposed loops of domain II in Cry41Aa. Homology 
modelling is a consistent  trustworthy method to predict the 3-domain structure of a 
protein however it  is not without  errors; despite this even very inaccurate models  are 
useful due to  some aspects of function that is  predicted from key  structural features 
(Mahadeva Swamy et al., 2014).  
 
It has been argued that the diversity observed for some Cry toxins is due the variation 
of its domain II sequence. This domain has typically shown more variation compared 
with the other two domains.  It is also argued that is this  variation which  is implicated 
in specificity and initial binding of Cry toxins (Dean et al., 1996, Pacheco et al., 2009, 
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Abdul-Rauf and Ellar, 1999, Pardo-Lopez et al., 2009, Abdullah and Dean, 2004, Lu et al., 
1994). Therefore, it was not surprising that both protein modelling servers were able to 
model domain I well. Cry toxins share high amino acid sequence identity and similar 
tertiary structures (Lucena et al., 2014). Previous research which used phylogenetic 
trees to study the domains of Cry toxins suggest that of the three domains, domain I is 
the most conserved. Genetic variation is likely to exist in the other two domains, 
particularly at the three exposed loops of domain II, which are thought to be critical sites 
for receptor recognition and binding. Thus genetic alterations in domain II loop region 
can dramatically affect the specificity of a 3-domain Cry toxin (Bravo et al., 2018).   
 
The search for Cry41Aa domain II loops began with a ClustralW alignment against 
resolved crystal Cry structures. This led to the predicted locations of loop 1, 2 and 3. It 
highlighted the distinction of the extra loop which did not align with any resolved Cry 
crystal structures.  The smallest of loops, loop 1 aligned well with resolved Cry 
structures, followed by loop 3. Loop 2 was also predicted but it aligned the least with 
resolved Cry structures.  PSIRED analysed the secondary structure of Cry41Aa. It 
indicated the location of β-sheets that fall either side of loop 1 and loop3, whose 
structures were predicted with high confidence. The secondary structure of loop 2 was 
predicted with low confidence and there were no immediate βsheets such as those 
observed for loop 1 and loop 3. Therefore, it was unclear where loop 2 began or where 
it ended. Due to this uncertainty, the study focused on the exploration of loop 1, 3 and 
the extra loop. The Cry41Aa was modelled by SWISS-MODEL and PHYRE2 servers. The 
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servers use different programmes and algorithms to build a model and therefore used 
different templates on which to base their Cry41Aa model.  Both servers used 
insecticidal 3-domain Cry toxins as templates. However, in both cases sequence 
percentage identity was less than 37 %.  The Cry41Aa models created by the servers 
indicated that Cry41Aa has 3-domain structure similar to insecticidal 3-domain Cry 
toxins. The extra loop was modelled to be helical by the SWISS_MODEL server whilst 
PHYRE2 modelled it as a coil.  Domain I and III of both models appear very similar, in 
particular the α helical bundle of domain I. Loop 2 of the SWISS-MODEL Cry41Aa model 
has modelled the sequence as partially β sheet. This is supports findings of low 
confidence in the loop 2 structure.   
 
The SWISS-MODEL server modelled Cry41Aa and matched it to Cry1Aa as its best 
homologue. When the model and Cry1Aa template were superimposed to calculate the 
RMSD it gave a value of 0.7.  The closer the RMSD value is zero the more similar the two 
structures are.  The SWISS-MODEL servers also calculated a GMQE score which is an 
estimate of the reliability of the alignment between a model and template. This model 
had a GMQE value of 0.48. The more reliable the estimate the closer the value to zero. 
Further analysis was carried out to calculate the QMEAN value of the model. This score 
indicates whether the model is comparable to experimental structures of similar size.  
The model had a QMEAN score of -4.0, which is consistent with a model of poor quality 
or low agreement with experimental structures of similar size. SWISS-MODEL server also 
modelled Cry41Aa based on Cry3Aa template. When the model was superimposed onto 
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the template the RMSD had a value of 1.5. This is indicative there is low similarity 
between this model and Cry3Aa.  
 
The PHYRE 2 server modelled Cry41Aa where it covered 68 % of the sequence with 100 
% confidence and modelled Cry41Aa to its nearest evolutionary fingerprint Cry3Aa. The 
model and template were superimposed and the RMSD was valued at 0.6. which is an 
improved RMSD score than that of the model by SWISS-MODEL server.  The PHYRE 2 
server modelled Cry41Aa on Cry1Aa the highest scoring homologue template used by 
SWISS-MODEL. It produces a model that did not differ greatly from that made by the 
SWISS-MODEL server. The model and Cry1Aa template were superimposed and the 
RMSD was valued at 1.3. RMSD value above one suggest low similarity between two 
structures.   
 
In order to analyse the models by both servers it was important to standardise the 
values. There are no general standards for analysing models made by different protein 
modelling servers as the values are based on each servers’ individual algorithms. 
However, a Q score is a value that considers the alignment length and the RMSD value. 
Q values above 0.4 indicate that the precision value for both the alignment and the 
RMSD are over 90 %. In order to analyse the models by both servers a Q score was 
calculated for each model. The SWISS-MODEL server modelled Cry41Aa with Cry1Aa as 
a template and had a Q score of 0.5, that is higher than the Q score of Cry41Aa with 
Cry3Aa as template which had a score of 0.3. The PHYRE2 server modelled Cry41Aa with 
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Cry3Aa as a template and had a Q score of 0.8. This is in contrast to the Q score of 
Cry41Aa model and Cry1Aa as a template which had the same score as the SWISS-
MODEL best homologue template score of 0.5.  
 
It is difficult to state which of the two servers provided the more accurate or more 
reliable model of Cry41Aa. The accuracy of a model can vary even within different 
regions of the same protein. It is usual that highly conserved regions are modelled with 
more accuracy than surface or loop regions. Generally, much of the error in modelling 
of unknown proteins comes from poor alignments with templates. Sequence similarities 
between a sequence and its template that have less than 40 % sequence identity tend 
to produce unreliable models. Both SWISS-MODEL and PHYRE2 have less than 37 % 
sequence identity with both Cry1Aa and Cry3Aa templates (Schwede et al., 2003; Rother 
et al., 2011). 
 
Research on the specificity of 3-domain Cry toxin has applied mutagenesis techniques 
as an approach to gain insight into what makes a region or even an amino acid from a 
toxin affect the toxin’s ability to interact with target receptors in such a way that it 
results in cell death.  
 
Studies on loop 2 and loop 3 of Cry1Aa suggested that these loops play key role in their 
specificity and toxicity towards Bombyx mori larvae. Here, a mutation in Y445C of loop 
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3 reduced binding to BtR175 receptor and a deletion of N372 amino acid also reduced 
binding and resulted in a lower morality rate. However, when the same amino acid was 
substituted with an alanine residue the recombinant toxin exhibited enhanced toxicity 
to Lymantria dispar in vitro (Atsumi et al., 2008, Rajamohan et al., 1996a, Lucena et al., 
2014). Further evidence from studies conducted on loop 3 of domain II of Cry1Aa has 
shown that substitutions between its native loop 3 with that of Cry4Aa resulted in an 
identical toxicity against Culex pipiens larvae (Abdullah et al., 2003). This approach may 
ultimately lead to the understanding of toxins specificity and shed light at least in part 
regarding its mode of action. This holds true particularly in the case of Cry41Aa where it 
has so far proved to have a narrow target cell (HL60 and HepG2) and is one of the least 
studied parasporins (Nagamatsu et al., 2010).  
 
Such studies have highlighted the important role that domain II plays in the specificity 
of toxins and that identification and manipulation of domain II loops can introduce 
specificity as well as reduce or increase binding affinity and thus the toxicity of a toxin. 
It is clear that in order to learn about the specificity of Cry41Aa, its domain II loops need 
to be identified and explored. Yamashita et al. (2005) described Cry41Aa as a cancer 
killing Cry toxin. It is important to shed light on the regions which are responsible for this 
specificity. This information can be used to assist in the long-term fight against cancer. 
Furthermore, for the safe application of Cry toxins as bio-pesticides since it is known 
that they are able to target and interact with vertebrate cells lines.  
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5.0 Production of Cry41Aa hybrids and 
their activity  
5.1 Introduction 
The 3-domain Cry toxins have loops at the base of domain II (Schnepf et al., 1998). In 
insecticidal Cry toxins, these are thought to recognise midgut receptors in target insects 
and bind irreversibly as a result of toxin insertion into the epithelia gut cell membrane 
resulting in subsequent pore formation and mortality (Pigott and Ellar, 2007; Smedley 
and Ellar, 1996; Rajamohan et al., 1996; Adang et al., 2014).  
 
Data from resolved crystal structures of Cry toxins has been used to shed light on the 
function and role of domain II loops (Li, Carroll and Ellar, 1991). Information from 
resolved crystal structures of insecticidal Cry toxins has pointed to some of the 
approaches used to investigate Cry toxins and their mode of action and thus in part their 
specificity. These approaches include: (i) domain swapping between different Cry toxins 
that result in recombinant or chimeric proteins with hybrid domains, (ii) domain II loop 
exchange between different Cry toxins that result in recombinant proteins with domain 
II loops from a different Cry toxin. 
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This chapter details the mutagenesis carried out to create domain II loop exchange 
mutants of Cry41Aa and Cry41Ab with loops of insecticidal Cry1Ac as identified from 
bioinformatic analysis seen in chapter 4. It also details the mutagenesis carried out to 
create hybrids of Cry41Aa with insecticidal Cry42Aa and Cry1Ie. The mutagenesis 
approaches are summarised in table 7. The first approach involves an exchange of 
loop(s) between an insecticidal Cry toxin and Cry41Aa. The second approach involved 
the creation of domain II hybrids made from both insecticidal Cry toxins and Cry41Aa.  
 
Table 7 Mutagenesis approaches used in this study. 
Table summarises the loop exchange and hybrid mutagenesis approaches employed to study Cry41Aa toxin specificity 
in this research.  
 
 
All initial mutagenesis took place in E. coli expression vectors, these plasmids were 
approximately 5 Kb in size. They contained an antibiotic resistant gene as well as the 
ORF of the gene in question. Introduction and amplification of mutagenesis in these 
small plasmids resulted in less errors compared to introduction and amplification of 
mutagenesis in the much larger (˜10 Kb) Bt expression vector.  
 
Mutagenesis approaches to study specificity of Cry41Aa 
 
Mutagenesis approach Toxin name Site of mutagenesis 
 
Loop exchange 
Cry41Aa 
Cry41Ab 
Cry1Ac 
 
Loop 3 
 
Domain hybrids 
 
Cry41Aa 
Cry42Aa 
Cry1Ie 
 
Hybrid ORF2 of Cry41Aa 
&Cry42Aa 
Hybrid ORF2 withCry1Ie 
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The presence of a mutant in a plasmid capable of expressing only in E. coli meant that 
additional steps were required in order to introduce the mutant in a plasmid that would 
express in a Bt host. Mutant (insert) DNA and Bt backbone fragments were isolated with 
a double enzyme digest and allowed to ligate in order to form a Bt expression vector 
capable of mutant protein expression in a Bt host. 
 
At each stage Hae III digest profiles and sequencing results confirmed the correct 
sequence of the mutant. This also meant that the mutant required confirmation after 
its introduction into a Bt shuttle vector.  It was important to confirm that the data 
collected on any expressed recombinant proteins was due to the intended mutagenesis. 
Thus, the plasmids were extracted from the Bt host. However, due to the presence of 
native Bt plasmids it was not possible to carry out Hae III directly on Bt extracted 
plasmids. A Hae III digest profile here would result in too many bands, rendering the 
profile illegible. Further E. coli transformations were carried out before Hae III 
digests/sequencing confirmed the correct sequence of mutagenesis in ORF of Cry gene 
from plasmids extracted out of Bt host. An overview of the key steps and check points 
of the mutagenesis are detailed in figure 20.
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Figure 20 Mutagenesis steps to create a mutant. An overview of the initial steps taken to create a mutant plasmid that can be expressed in a Bt host cell. The process begins with a PCR design 
and results in a mutant Bt shuttle vector. 
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For the purpose of this study, plasmids that acted as templates or where mutagenesis 
has been designed to take place, are referred to as wildtype. This is despite that fact that 
these plasmids are not strictly wildtype and do not exist in the natural genome of the Bt 
strain on which they originate from. Plasmids that have had alterations in their gene(s) 
because of the mutagenesis design are referred to as constructs.  
 
Cry41Aa and Cry41Ab were expressed from ORF2 and ORF3 genes. First, ORF2 of 
Cry41Aa was cloned into pBluescript SK2+ plasmid to create wildtype pBS41Aa. ORF2 of 
wildtype Cry41Aa is flanked by a BamHI 5’ and an XhoI enzyme restriction site at the 3’ 
end. It contains an ampicillin resistance gene as well as an E. coli   origin of replication 
as shown in figure 21. Similarly, Cry41Ab was also cloned into pBluescript SK2 to create 
wildtype pBS41Ab also shown in figure 21. All mutagenesis was initially carried out using 
wildtype pBS41Aa and pBS41Ab which acted as template DNA. Other plasmids were also 
used to create mutants of Cry41Aa and Cry41Ab these were introduced accordingly with 
each mutagenesis approach.   
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Figure 21 Schematic diagram of plasmids involved in insecticidal and cytocidal loop 3 exchange.  
 On the left wildtype plasmid pBS41Aa with ORF2 of Cry41Aa shown in blue. On the right is wildtype pBS41Ab with ORF2 of Cry41Ab shown in dark green. Ampicillin resistance genes 
shown in red and bacterial origin of replication in yellow. BamHI and XhoI restriction sites flank either side of OFR2.  
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Figure 22 Schematic diagram of pGemCry1Ac plasmid 
Wildtype pGemCry1Ac plasmid, with Cry1Ac ORF in orange, and an ampicillin resistance gene shown in red. Bacterial origin of replication shown in yellow. Restriction sites for BamHI 
and XbaI shown.  
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5.2 Cry41Aa loop exchange mutagenesis in loop 3 of domain II  
Mutagenesis via loop exchange has been employed to explore Cry toxin specificity. Several 
studies have engineered Bt Cry toxins by exchanging loop regions of domain II and thus 
introducing a new specificity to the recipient Cry toxin.  (Abdullah et al., 2003, Liu and 
Dean, 2006, Howlader et al., 2009, Pardo-Lopez et al., 2009).  
 
Cry toxins differ in their primary sequences and target specificities. The 3-domain 
structure of Cry toxins have a similar structure but can differ in their primary sequence 
and have different cell target specificities (Crickmore et al., 1998, Bravo et al., 2011). 
Their shared structural similarity has been taken to explore the three loops at the apex 
of domain II, and studies that have modified this region have resulted in novel 
specificities, potent toxicity, and changes to the stability of a toxin (Bravo et al., 2011, 
de Maag et al., 2001; Lucena et al., 2014; Pigott and Ellar., 2007; Bravo et al., 2011; Bravo 
et al., 2013; Nachimuthu and Polumetla Ananda., 2004; Florez et al., 2012) .  
 
In a study aimed to determine the role of domain II loops in the specificity of Cry1Ah and 
Cry1Ai, a loop exchange investigation was carried out.  Cry1Ah is toxic to Helicoverpa 
armigera but not toxic to Bombyx mori larvae. The closely related Cry1Ai is toxic against 
B. mori but is not active against H. armigera. A loop 2 and 3 exchange between these 
Cry toxins resulted in hybrid toxins with an enhanced toxicity, confirming that it is loops2 
and 3 of Cry1Ah that are responsible for receptor binding and toxicity to H. armigera 
(Zhou et al., 2017).  
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This part of the study aimed to introduce a new insecticidal specificity to Cry41Aa in an 
attempt to locate the regions responsible for its specificity towards the HepG2 cell line.  
 
Cry1Ac is an insecticidal 3-domain Cry toxin of ~130   KDa and has toxicity towards 
Manduca sexta and other lepidopteran insects (Alouf, Ladant and Popoff, 2015; Schnepf 
et al., 1998; de Maagd et al., 1999; de Maagd, Bravo and Crickmore, 2001; Crickmore et 
al., 1998). This insecticidal Cry toxin is not known to be toxic to vertebrate cell lines or 
HepG2. It has a typical 3-domain structure and the wildtype pGEMCry1Ac plasmid was 
readily available at the time of this study. Here, Cry1Ac acted as the negative control for 
Cry41Aa’s target cells HepG2. The mutagenesis design aimed to remove the loop 3 of 
both cytocidal Cry toxins (Cry41Aa and Cry41Ab) and replace it with loop 3 of insecticidal 
Cry1Ac.  If successfully expressed, the loop exchange mutants would be investigated for 
potential newly acquired specificities that they did not possess before, by testing on 
them on various mammalian cell lines. In other words, whether cytocidal Cry41Aa has 
acquired a new specificity as a consequence of the introduction of loop 3 from Cry1Ac 
and vice versa.   
 
The wildtype plasmid pGEMCry1Ac acts as template DNA in a PCR reaction designed to 
introduce loop 3 of Cry41Aa and Cry41Ab into Cry1Ac and replace its own loop 3.  The 
wild type pGEMCry1Ac is shown in figure 22. It contains a single ORF with conserved 
blocks 1 to 8 and has a BamHI 5’ site and three XbaI restriction sites together with an 
ampicillin resistant gene. The wildtype loop 3 of Cry1Ac is made up of seven residues 
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428SGFSNSS433. The primers were designed to amplify the entire plasmid except for loop 
3 of Cry1Ac, here the seven residues are replaced by loop 3 of Cry41Aa which is made 
up of fifteen residues 503VRDNCPFAWPGYKQL517. Figure 23 details the Primer design for 
the PCR reaction that introduced the loop 3 exchange mutagenesis approach. The new 
sequences are incorporated into the 5’ end of primers. Table 8 lists the primers used to 
create the constructs. 
 
Loop 3 primer list. 
 
Table 8 Loop 3 primer list.   
Table lists the primers used to create loop 3 exchange constructs. The sequence belonging to Cry41Aa is underlined 
in green. The sequence belonging to cry1Ac is underlined in orange.  
 
 
 
 
Template 
DNA 
 Primer 
name 
Oligonucleotide/ Primer sequence 5’-
PHO 
pBS41Aa  41Ac L3F 5’AGT AGT GTA AGT AGT CGT TTG TTA TTT GGT TG 3’ Yes 
 4111AcL3
R 
5’GTT ACT AAA GCC TGA AGG TTC AAA TTT AAT CCA AG 3’  
 
Yes 
 
pBS41Ab 
 41Ac L3F 5’AGT AGT GTA AGT AGT CGT TTG TTA TTT GGT TG 3’ Yes 
 41AcL3R 5’GTT ACT AAA GCC TGA AGG TTC AAA TTT AAT CCA AG 3’  
 
Yes 
 
pGEMCry1Ac 
 1Ac41L3F 5’TGGCCTGGTTATAAACAATTATAAGAGCTCCTATGTTCTC3’ Yes 
 1Ac41L3R 5’GGCGAAAGGGCAATTATCCCGTACACGAAACATTGAAACATG
G3’ 
Yes 
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Figure 23 PCR primer design for loop 3 substitution.    
ORF2 of Cry41Aa is shown in blue with loop 3 of Cry1Ac in orange. ORF3 of Cry41Ab is shown in green with loop 3 of Cry1AC in orange. ORF of Cry1Ac shown in orange with loop 3 of Cry41Aa in 
blue. 
Primer to introduce Cry1Ac loop3 
5’ 5’ 
3’ 3’ 
5’ 
 
5’ 
3’ 3’ 
PCR reaction 
 
  
Cry41Aa Cry1Ac Cry41Aa 
Cry41Ab Cry1Ac 
Cry41Ab 
Cry1Ac Cry41Aa 
Cry1Ac 
Primer to introduce Cry41Aa loop 3 
Primer to introduce Cry1Ac loop 3 
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The resulting linear DNA was gel purified, allowed to ligate overnight and introduced 
into E. coli and plated onto ampicillin LB agar plates. Potential colonies were picked and 
allowed to grow in ampicillin LB broth or re-streaked on ampicillin agar plates. A mini 
prep was carried out to isolate plasmids with potentially correct loop 3 exchange 
construct. To check for correct configuration of the construct, Hae III digests were 
carried out on both the wildtype pGEMCry1Ac plasmid and the pGEMCry1Ac41 loop 3 
constructs. This construct has the ORF of insecticidal Cry1Ac with loop 3 of Cry41Aa. The 
resulting Hae III digest profile of pGEM1Ac41loop3 was analysed by NEB cutter online 
software. The NEB cutter predicated 21 fragments as a result of a Hae III carried out in 
correct construct pGEMCry1Ac41loop3. It further predicted 20 fragments as a result of 
a Hae III carried out in the wildtype pGEMCry1Ac plasmid. Figure 24 shows the picture 
of the agarose gel analysis of the both Hae III digests. Table 9 lists the key fragments for 
both digests, which were identified in the gel picture of the Hae III digest of both 
wildtype and construct plasmid. The construct pGEMCry1Ac41loop3 has two distinct 
Hae III digest fragments 1035 bp and the 348 bp. The 289 and 285 bp bands appear as a 
doublet as shown in figure 24 and their absence in the wildtype pGEMCry1Ac lane is 
clear. The construct was then confirmed by sequencing analysis.  
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Hae III digest profile by NEB web  cutter 
 
 
Table 9 Hae III digest profile by NEB web  cutter 
Table lists the key fragements of the Hae III  digest profile for wiltype pGEMCry1Ac and the construct 
pGEMCry1Ac41loop3.  
 
 
 
 
 
 
 
 
 
 
Figure  24 Banding profie of construct in agrose gel 
Agarose 1.5% gel showing  DNA marker in lane 1. Hae III  digest banding profile for wildtype pGEMCry1Ac in lane 2 
and hybrid construct in lane 3.   
 
Hae III fragments  
 
Wildtype pGEMCry1Ac 
(bp) 
pGEMCry1Ac41loop3 Construct 
(bp) 
1 1542 1542 
2 1365 1035 
3 908 908 
4 654 654 
5 434 458 
6 289 434 
7 285 348 
8 279 289 
9 267 285 
10 174 279 
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Once confirmed, the construct pGEMCry1Ac was incubated in ampicillin LB for 3 days at 
37 ⁰C to express and produce the loop 3 exchange hybrid pGEMCry1Ac41loop3. The cells 
were then harvested and sonicated to collect the hybrid toxin for further analysis. Figure 
25 is the SDS PAGE gel picture of the crude hybrid crystals of pGEMCry1Ac41loop3. The 
crude crystals were characterised in a similar process as conditions used to characterise 
other 3-domain Cry toxins. The samples were solubilised in carbonate buffer pH 10.5 
and treated with trypsin 1 mg/mL. The resulting solubilised trypsin activated hybrid 
protein was visualised in SDS PAGE gel as shown in Figure 26. This trypsin stable hybrid 
was analysed in HepG2 cell assay to assess whether it had gained cytocidal activity as a 
consequence of the replacing of its wildtype loop with that of Cry41Aa.   
 
 
 
 
 
 
 
 
 
Figure 25 SDS-PAGE analysis showing crude sample for hybrid crystals.  
Lane 1 contained protein marker. Lane 2 contained wildtype Cry1Ac crude crystals harvested from E. coli   cells yellow 
arrow indicated ˜130 KDa band. Lane 3 contained crude crystals harvested from E. coli   cells containing the hybrid 
plasmid pGEMCry1Ac41loop3, yellow arrow indicating ˜130 KDa band.  5µL of parasporal inclusion protein samples 
were loaded in each lane.  
 
1                     2                    3  
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Figure 26 SDS-PAGE gel showing 65 KDa solubilised trypsin treated Cry1Ac41loop3.  
Lane 1 contained protein marker. Lane 2 contained a 65 KDa solubilised trypsin treated hybrid protein expressed from 
pGEM1Acloop3 plasmid in E. coli. Lanes 3, 4, and 5 contained. BSA concentrations range 1 mg/mL, 0.5 and 0.1 
respectively.  
 
 
 
Preliminary cell assays were carried out on the recombinant pGEM1Ac41loop3. The 
recombinant was incubated with HepG2 cell lines for 24 h , thereafter the cell viability 
was measured using CellTiter-Blue assay as shown in figure 27. It approximates the 
metabolic activity of cells using a fluorometric method. The resazurin dye is nontoxic but 
permeable to cells. Once it enters viable cells, it is reduced  to high fluorescent resorufin 
and the signal is measured to give an estimate of viable cells (O’Brien et al., 2000). 
Insecticidal wildtype Cry1Ac acted as a negative control and did not demonstrated any 
toxicity towards HepG2 cells. Cry1Ca acted as a control for 3-domain crystal proteins 
made in host Bt4D7. Wildtype Cry41Aa demonstrated toxicity to the HepG2 cell. It 
showed similar toxicity to etoposide which acted a positive control. Triton -X100 is a 
1                   2                       3                   4                5 
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detergent that permeabilises cell membranes and here it also acted as positive control. 
The protein concentrations were not optimised. The recombinant protein made by 
construct pGEM1Ac41loop3 did not gain toxicity to HepG2 cells.  
 
 
Figure 27   24hr CellTiter-Blue HepG2 cell viability assay of loop 3 mutant   
Graph of the fluorescent signal measurements from HepG2 cell line 24 h after toxin exposure. Cry1Ca act as negative 
controls. TX-100 and Etoposide act as positive controls. Approximately 100μg /mL of protein was added.  
 
 
Wildtype pBS41Aa and pBS41Ab were used as DNA templates for primers designed to 
remove native loop 3 from their domain II and introduce loop 3 of insecticidal Cry1Ac in 
its place via PCR as detailed in the loop exchange primer design, figure 23. The PCR 
products were gel purified and allowed to ligate over night at room temperature before 
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transformation into E. coli cells. The mixtures were plated onto ampicillin LB agar plates 
and were incubated overnight. Colonies with potential constructs pBS41Aaloop3 and 
pBS41Abloop3 were picked and allowed to incubate in ampicillin LB broth or re-streaked 
onto ampicillin LB agar plates for overnight incubation.  A mini prep was carried out to 
extract construct plasmids from E. coli cells. Hae III digests were carried out to 
authenticate the correct constructs.  The construct pBS41Aaloop3 was digested by the 
Hae III enzyme. The NEB web cutter predicted the fragment sizes, this digest profile is 
shown in table 10. Figure 28 shows the agarose gel analysis of pSB41Aaloop3 construct. 
It has the distinctive 684 bp fragment absent in the Hae III digest profile of wildtype 
pBS41Aa plasmid (wildtype not shown in the gel image).  
 
Similarly, pBS41Abloop3 construct was subjected to a Hae III digest. Table 11 lists the 
predicted Hae III digest profile for wildtype pBA41Ab and the pBA41Abloop construct. 
As suggested from the predicted fragment sizes it would be difficult to distinguish the 
wildtype apart from the construct. Figure 29 shows the agarose analysis of Hae III digest 
performed on plasmid mini prepped from colonies 2b, 1a, 1c, and 1e alongside the Hae 
III digest of wildtype pBS41Aa that acts as reference, but not a comparison, to construct 
pBA41Abloop3. Both constructs were later further confirmed by sequencing protocol. 
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Hae III digest profile by NEB web cutter. 
 
Table 10 Hae III digest profile by NEB web  cutter. 
Table lists the key fragements of the Hae III  digest profile for wiltype pBS41Aa  and the construct pBS414a1loop3  
 
 
 
 
 
 
 
 
 
 
Figure 28 banding profie of construct in agrose gel 
Agarose 1.5% gel showing  Hae III  digest banding profile for pBS41Aaloop3  in lane 1.  DNA marker in lane 2 
 
 
 
Hae III fragments  Wildtype pBS41Aa (bp) pBS41Aaloop3 Construct (bp) 
1 767 767 
2 629 684 
3 558 629 
4 549 549 
5 458 458 
6 434 434 
7 340 340 
8 306 306 
9 267 267 
10 254 254 
1                     2                     
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Hae III digest profile by NEB web cutter 
Table 11  Hae III digest profile by NEB web cutter  
lists the key fragements of the Hae III  digest profile for wiltype pBS41Aa  and the construct pBS414b1loop3   
 
 
 
 
 
 
 
 
 
Figure 29 Banding profie of construct in agrose gel. 
Agarose 1.5% gel showing  Hae III  digest banding profile for pBS41Aaloop3  in lane 2, 3, 5,6, control pBS41Aa in lane 
4. DNA marker in lane 1 
 
Hae III fragments  Wildtype pBS41Ab (bp) pBS41Abloop3 Construct (bp) 
1 1001 1106 
2 767 767 
3 629 629 
4 458 458 
5 436 436 
6 434 434 
7 378 378 
8 267 267 
9 254 254 
10 174 174 
1           2            3          4             5          
6     
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Both, pBS41Aaloop3 and pBS41Abloop3 construct plasmids lack a Bt origin of replication 
and cannot be expressed in Cry41Aa cells. Furthermore, the constructs lack the ORF3 
gene associated with crystal formation in Cry41Aa. Therefore, the loop 3 constructs 
required subcloning into a vector with a Bt origin of replication and Cry41Aa ORF3 gene 
in order to express the recombinant Bt crystal. For the purpose of this study, a Bt shuttle 
vector was used and referred to as wildtype pSVP2741Aa plasmid. pSVP2741Aa is a Bt 
expression vector ˜10 Kb in size.  
 
To create it, both OFR2 and ORF3 were cloned into the Bt shuttle vector pSVP27. The 
ORF2 gene was flanked by two restriction sites, a BamHI and XhoI site on either side of 
the gene. In the same manner the OFR2 in pBS41Aa/Ab was also flanked by the same 
restriction sites for BamHI and Xhol enzymes.  This allows for the subcloning of the 
mutant OFR2 from blue script plasmid into the Bt shuttle vector. Previous attempts to 
perform mutagenesis directly on the Bt expression vector pSVP2741Aa have proven 
difficult due to its large size (Krishnan., 2013). The ORF3 of Cry41Aa and Cry41Ab have 
99% sequence homology (Yamashita et al., 2005), for the purposed of this study the 
same ORF3 from Cry41Aa was used to express potential hybrids of both Cry41Aa and 
Cry41Ab. Figure 30 shows the schematic representation of wildtype pSVP2741Aa and 
pSVP2741Ab. Both Bt expression vectors have a strong Bt Cyt1Aa promoter that drives 
ORF2 and ORF3 expression in the acrystalliferous Bt 4D7 host strain. Furthermore, they 
contain ampicillin and chloramphenicol resistant genes that allow for selection for 
colonies of interest with potential correct constructs.  
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Figure 30 Schematic presentation of wildtype pSVP2741Aa and pSVP2741Ab.pSVP2741Aa (left) and pSVP2741Ab (right) with ampicillin resistant gene (red) and chloramphenicol resistance 
gene (brown), as well as bacterial origin of replication.  ORF2 of Cry41Aa shown in blue in pSVP2741Aa. ORF3 of pSVP2741Ab shown in green. ORF3 of Cry41Aa shown in both plasmids in blue.   
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The next step of the loop 3 mutagenesis was to introduce the mutated ORF2 from 
constructs pBS41Aaloop3 and pBS41Abloop3 into the larger pSVP2741Aa/Ab expression 
vector. The restriction enzymes BamHI and Xhol allow for subcloning of ORF2 into the 
pSVP2741Aa Bt expression vector.  
 
The constructs pBS41Aaloop3 and pBS41Abloop3 underwent a double digest by BamHI 
and XhoI. The linear DNA was run on an agarose gel and the 2.5Kb linear DNAs encoding 
loop 3 exchange ORF2 were cut out and the gel purified in preparation for ligation. 
Similarly, the wildtype pSVP2741Aa plasmid also underwent a double digest by BamHI 
and Xhol enzymes. The linear DNAs were also run on an agarose gel, and the 7.8 Kb 
linear DNA encoding OFR3 was cut out and the gel purified in preparation for ligation. 
The 2.5Kb linear DNAs from constructs were allowed to ligate overnight with 7.8kb 
backbone DNAs from Bt expression vector pSVP2741Aa. When correctly ligated these 
fragments form pSVP2741AaXhoI1Acloop3 (OFR2 of Cry41Aa with loop 3 of Cry1Ac) and 
pSVP2741AbXhoI1Acloop3 (ORF2 of Cry41Ab with loop 3 of Cry1Ac) constructs.  
 
E. coli cells were transformed with ligation mixtures and plated out on LB agar plates 
prepared with both 5   µg/mL chloramphenicol and 100   µg/mL ampicillin for overnight 
incubation at 37 ⁰C. Colonies harbouring the potential constructs were picked and 
incubated in antibiotic LB or streaked onto antibiotic LB agar plates.  
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Mimi preps were carried out to extract potential constructs from E. coli cells. These were 
subjected to Hae III digest to check for the correct loop 3 exchange constructs in Bt 
expression vectors.  
 
Table 12 lists the Hae III digest profiles for wildtype pSVP2741Aa and both loop 3 
exchange constructs. The agarose gel analysis of both constructs is shown in figure 31 
and 32.  Figure 31 is the agarose gel image of the Hae III digest of construct 
pSVP2741AaXhoI1Acloop3, here the distinct 684bp band is seen when compared to 
wildtype. This construct was further confirmed by sequencing.  
 
Figure 32 is the agarose gel image of the Hae III digest of construct 
pSVP2741AbXhoI1Acloop3 which has the distinct 1155bp band absent in wildtype 
pSVP2741Aa. The construct was further confirmed by sequencing. Once confirmed, both 
constructs were introduced into E. coli strain GM2163, which removes methyl groups 
from the DNA and facilitates transformation of the Bt 4D7 host and then plated out on 
antibiotic agar plates.   
 
The cells were scraped and mini prepped to extract the construct plasmids. Construct 
plasmids pSVP2741AaXhoI1Acloop3 and pSVP2741AbXhoI1Acloop3 were now ready for 
Bt4D7 transformation. The transformation mixtures were plated onto 5 µg/mL 
chloramphenicol prepared LB agar plates and were incubated overnight at 30⁰C. 
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Transformations with Bt are notoriously difficult and it took numerous attempts to 
introduce the Bt expression constructs to Bt cells.  
 
The colonies harbouring potential constructs were picked and incubated in 2-3mL of LB 
antibiotic broth for 2-3 h. The mixture was divided for the following usage. First it was 
poured and spread out in 5 µg/mL chloramphenicol plates and incubated for 3 days at 
30 ⁰C. The remaining mixture was centrifuged, and pellet was miniprepped to extract 
plasmids from Bt cells.   
 
Hae III digest profile by NEB web cutter 
 
Table 12  Hae III digest profile by NEB web cutter 
Table lists the key fragements of the Hae III  digest profile for wiltype pSVP2741Aa  and the constructs 
pSVP2741AaXhoI1Acloop3 and pSVP2741AbXhoI1Ac1loop3.  
Hae III  
fragments  
Wildtype 
pSVP2741Aa 
 (bp) 
pSVP2741AaXhoI1Acloop3 
 Construct (bp) 
pSVP2741AbXhoI1Acloop3 
Construct (bp) 
1 2469 2469 2469 
2 1895 1895 1895 
3 1007 1007 1155 
4 879 879 1045 
5 629 684 879 
6 598 629 629 
7 587 598 587 
8 558 587 458 
9 458 458 436 
10 434 434 434 
11 306 306 267 
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Figure 31 banding profie of construct in agrose gel 
Agarose 1.5% gel showing Hae III fragment sizes of hybrid pSVP2741AaXho1Acloop3. Lane 1 contained DNA marker, 
lane 2 wildtype pSVP2741Aa, lane 3 had hybrid pSVP2741AaXho1Acloop3. Lane 4 contained DNA marker.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 banding profie of construct in agrose gel 
Agarose 1.5% gel image of Hae III digest of pSVP2741AbXho1Acloop3 hybrid. Lane 1 contained DNA marker, lane 2 
wildtype pSVP2741Aa and lane 3 contained pSVP2741AbXho1Acloop3 hybrid  
1             2             3           4                 
1                2    
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A Hae III digest was not be performed directly on Bt extracted plasmids as the mini prep 
mixture included both native Bt plasmids and the plasmid of interest. In order to 
eliminate native Bt plasmids from the mini prep mixture, a final transformation of E. coli   
cells was carried out and plated out on LB agar plates prepared with both 5 µg/mL 
chloramphenicol and 100 µg/mL ampicillin for overnight incubation at 37⁰C. Here the 
plate should only have E. coli cells that harbour the construct plasmids only. The 
bacterial lawn was scraped, and a mini prep was performed to extract the plasmids. A 
Hae III digest was carried out on these plasmids to confirm the integrity of the construct 
after Bt cells transformation.  
 
After 3 days, sample plates were analysed under a light microscope to check for the 
presence of crystals and spores. The presence of crystals and spores are signs that Bt 
cells have undergone the  sporulation  stage as a result of limited nutrition (Crickmore 
et al., 1998, de Maagd et al., 2003). Once confirmed the cells were harvested and 
sonicated to obtain hybrid crystals for characterisation. Crude crystals of loop 3 
exchange hybrids were analysed in SDS PAGE gels and compared to wildtype Cry41Aa 
and Cry41Ab crude samples, as shown in figure 33. SDS PAGE analysis indicated there is 
no obvious difference between wildtype Cry41Aa/Ab crystals and their loop 3 exchange 
hybrids.  
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Figure 33: SDS-PAGE gel showing crude samples of loop 3 exchange 
 Crude samples of loop 3 exchange hybrid crystals from constructs pSVP2741Aa XhoI1Acloop and pSVP2741Ab 
XhoI1Acloop. Lane contained crude Cry41Aa. Lane 2 crude recombinant pSVP2741Xho1Acloop3Aa. crude 
recombinant pSVP2741Xho1Acloop3Ab. Lane 4 contained crude Cry41Ab. Samples in lanes labelled respectively, each 
lane contained 5µL of parasporal inclusion protein. ORF2 is a ˜88 KDa band is indicated with yellow arrows. ORF3 is 
˜120 KDa band indicated with yellow arrow. 
 
 
All crystals were solubilised in carbonate buffer pH 10.5 and activated with trypsin (1 
µg/mL). Despite changing the conditions, it was not possible to activate loop 3 exchange.  
Proteins from the hybrids of Cry41Aa/Ab with loop 3 of Cry1Ac were not stable and 
degraded in the presence of the trypsin. This suggests that hybrids were structurally 
unstable due to the loop exchange which affected the stability of the hybrid.  
 
5.3 Cry41Aa ORF2 hybrids with other Cry genes 
In previous studies Cry toxin hybrids have been constructed in attempts to learn more 
about their specificity and exploit their toxicity (Crickmore et al., 1998; Dean et al., 1996; 
de Maagd et al., 2003). It usually involves the mutagenesis of loops by either deletion or 
1                2             3              4 
ORF3 
ORF2 
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substitution of residues (Adang, et al., 2014). Domain hybrids created by the deletion, 
addition, and or exchange of domains have played a key part in the improvement of 
known Cry bio pesticides as well as the creation of novel toxins. The removal, addition 
and exchange of Cry toxin domains has revealed information about the regions 
responsible for toxin specificity and toxicity. 
 
 In a study to improve toxicity towards sap sucking insects (Hemiptera), a 12 amino acid 
sequence peptide known to bind to the epithelial gut of pea aphid insects was added to 
the loops of the cytolytic toxin Cyt2Aa. This addition resulted in the improved binding 
and toxicity towards Acyrthosiphon pisum (pea aphid) and Myzus persicae (peach aphid) 
(Chougule et al., 2013; Bravo et al., 2013).  
 
Interactions of structural domains I, II, and III were investigated by the creation of 
chimeric proteins from domain I and III combinations of Cry1Ab, Cry1Ac, Cry1C, and 
Cry1E. The effects of the chimeric toxins were tested on Sf9 cells, a clonal isolate of S. 
frugiperda Sf21 cells commonly used in insect cell culture. Of the parental Cry toxins, 
only Cry1C was known to affect cell viability and membrane permeability. The study 
found that chimeric proteins with domain II of Cry1C showed activity against cells. 
Further investigation indicated that domain II from an active toxin is required for toxin 
stability but did not result in an active toxin capable of cell death. Pore size caused by 
chimeric toxins in the Sf9 cells membrane varied depending on which domain I was 
present in the chimeric toxin. The study suggested that pore properties are a direct 
result of interactions between domain I and domain II or III. It further speculates that it 
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is domain III which regulates the level of toxicity exhorted by chimeric toxins when a 
chimeric toxin made up of domain III from Cry1Ab and domain II and III from Cry1C was 
more toxic than the paternal Cry1C toxin (Rang et al., 1999).   
 
In a study to improve the biological control of pest insects Tecia solanivora (Lepidoptera: 
Gelechiidae), and Hypothenemus hampei (Coleoptera: Scolytidae), a hybrid toxin from 
toxic Cry strains was created by domain swapping between Cry1Ba and Cry1Ia. The 
resulting chimeric toxin had an improved toxicity when compared to the parental Cry 
toxin strains (López-Pazos et al., 2010) . In an attempt to apply this approach, Cry41Aa 
hybrids with Cry42Aa and Cry1Ie were designed.  
 
5.3.1 Cry41Aa ORF2 hybrid with Cry42Aa 
The gene for Cry42Aa was previously identified from the genome of Bacillus thuringensis 
A1462 (Krishnan, 2013). Little is known about Cry42Aa, except that it is very similar to 
Cry41Aa. It is a split toxin with two open reading frames, whereby ORF2 produces a 70 
KDa peptide and ORF3 produces a 120 KDa peptide.  
 
It is not clear whether the expression of Cry42Aa was silenced or if the protein produced 
from its expression led to an inactive toxin.  Previous experiments on Cry42Aa have 
shown that it solubilises in alkaline conditions. However, despite various attempts to 
activate the protoxin of Cry42Aa it was not possible to obtain a protease resistant core.  
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In an attempt to learn more about the specificity of Cry41Aa and also produce a stable 
active toxin from Cry42Aa a hybrid of Cry41Aa and Cry42Aa was designed as follows.      
A multiple sequence alignment was carried between the protein sequences of Cry41Aa 
and Cry42Aa as shown in figure 34.   
 
The construct design aimed to have a full length ORF2 made up of both cry41A and 
cry42Aa. This is to ensure that the five conserved of Cry toxins present in both cry41Aa 
and cry42Aa are complete and propagate protein folding of the hybrid crystal.   
 
Höfte and Whiteley, (1989) first described the five conserved blocks of 3-domain Cry 
toxins as sequences that encompass the Cry protein active core of domain I, II, and III. 
Schnepf et al. (1998) later described the remaining conserved blocks (Höfte and 
Whiteley, 1989; Crickmore et al., 1998). Conserved block 1 is situated in the central helix 
of domain I, block 2 is found at the domain I and domain II interface, and block 3 is 
located at the boundary between domains II and domain III. Block 4 is in the central β-
strand of domain III and block 5 is found at the end of domain III (Xu et al., 2014;  Palma 
et al., 2014).  
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CLUSTAL 2.1 multiple sequence alignment 
 
 
Cry41Aa         MNQNCNNNGYEVLNSGKGYCQPRYPFAQAPGSELQNMGYKEWMNMCTSGDPTVLGEG--Y 
Cry42Aa         MNQNYNNNGLEILDSG-GVCSPRYPLANAPGSELQNMGYKEWLEMCSIKGAETFADKSTL 
                **** **** *:*:** * *.****:*:**************::**:  .. .:.:     
 
Cry41Aa         SADVRDAVITSINIASYLLSVPFPPAGVAAGILGALLGLLWPTNTQAVWEAFMNTVEALI 
Cry42Aa         SAQSQEGLRTAITIALSLLSNLPGPFGYPAKLLSIIFPFLWPTNTQAQWEAFMKVVEELV 
                **: ::.: *:*.**  ***    * * .* :*. :: :******** *****:.** *: 
 
Cry41Aa         NQKLDEYARSKAISELNGLKNVLELYQDAADDWNENPGDLRNKNRVLTEFRNVNGHFENS 
Cry42Aa         DQKIETFARDQAIQRLRGIQDVISLYQRDAKNFNDYPTSEPIQRQLLSQFTATNTFIVGS 
                :**:: :**.:**..*.*:::*:.***  *.::*: * .   :.::*::*  .* .: .* 
 
Cry41Aa         MPSFAVRNFEVNLLPVYAEAANLHLLLLRDAVKFGEGWGMSTDPGAERDDMYRRLRSRTE 
Cry42Aa         MSLFRVGRHEVPLLTTFVQAANLHLLLLRDAIMFGESWGMCPVTVAGYQNDFN---NRIA 
                *. * * ..** **..:.:************: ***.***.. .  *  :: :.   .*                  
*. * * ..** **..:.:************: ***.***.. . 
 
Cry41Aa         IYTDHCVNTYNQGLQQAKSLQANVSDYSRYPWTQYNQSGGFSYREAKGEYRGTENWNLYN 
Cry42Aa         DYTDYSVSIYNQGLQKAKTLKANLRDYEKYPWARYYN----SSVGPEFAYGDMENWNLYN 
                 ***:.*. ******:**:*:**: **.:***::* :    *   .:  * . ******* 
 
Cry41Aa         AFRRDMTILVLDIIAQFPTYDPGLYSRPVKSELTREVYTDIRGTTWRSDANLNTIDAIEN 
Cry42Aa         NYRRDMTLMVLDLVALWPTYNPQQYPIAPKIQLTREIYTELRGNAG--NTKRPSMDAIDA 
                 :*****::***::* :***:*  *. .                 :*****::***::* :***:*  
*. . * :****:**::**.:   :::  ::***:  
 
Cry41Aa         RMVGSRQLQLFTWLTEMKFYIRNTGSITSYTHGDLMVGLEKKIRKTNDNDQWLPLEGQNT 
Cry42Aa         ELIPPP--RLFTWLESVDMHRWPT-SAGYYYYTFQNAGIKHRYKYTLDS-QTLTSSLRGA 
                .:: .   :***** .:.::   * *   * :    .*:::: : * *. * 
*. . :.:                .:: .   :***** .:.::   * *   * :    .*:::: : * *. * 
*. . :.: 
 
Cry41Aa         SYTRIDRPGIELGKNYWYYARTQQWFETRLLQLWANTDVLSLNAGTVGNEFWVRDVPDYR 
Cry42Aa         SGNNFNLVPAEETINRVQNQHGEGLYTFSFYRSGQ--SDPFLNIGTTADKPYVSTMNRIP 
                * ..::    *   *     : :  :   : :      .   ** **..:: :*  :     
 
Cry41Aa         NIYARSTRNHFIENHRLSWIKFEPVRDNCPFAWPGY--KQLSALLFGWTHNSVDLNNIIS 
Cry42Aa         -----VEGDQTQANHRLSWITGMVIPELSIPAFGHYNPTYISCAAEGWTHLSVERSNEIK 
                        ::   *******.   : : .  *:  *  . :*.   **** **: .* *. 
 
Cry41Aa         QYRITQIPAVKAYWNRGAFSVIRGPGSTGGNLVQLGTGG----EVSVKVRPEQTGS-DWY 
Cry42Aa         SDKITQIPAVKAFQLSNNASVVRGPGSTGGDLVQFSATSSGNKQLWIKVKPTTIALGRRF 
                . :*********:   .  **:********:***:.: .    :: :**:*   .    : 
 
Cry41Aa         RVRIRYAAGSRGRLNVKKYVSSIHASVTYDYNMTMSSSTQGTYNSFQYLDVYNFRLAEPE 
Cry42Aa         KVRIRYAAAANVTFTVQKCVTGVACWETATKSVTTTYSGTLTYNAFKYVDIFEIPANESE 
                :*******.:.  :.*:* *:.: .  *   .:* : *   ***:*:*:*::::   *.* 
 
Cry41Aa         FEVWLTNESGGPIWIDKIEFIPLSPIPELPVYPGTYQIVTALNNSSVVTSEEFCMGIGLT 
Cry42Aa         FSLEFLSTSGGPIYIDKIEFIPVNPIPEPPVPEGIYQIVTALNNSSVVDMDPGTWGT--- 
                *.: : . *****:********:.**** **  * *************  :    *     
 
Cry41Aa         TRCGVNLWSNNGNTLQKWRFVYNGDQNAFQIKSTPNEDLVLSGSNSGTSVTAETNQNRPN 
Cry42Aa         -RHNVHLWQNNNTNNQKWRFVYNSSQGAYQIRNLADENLVLTREGANVKVVSYQNNN-TA 
                 * .*:**.**... ********..*.*:**:. .:*:***: ..:...*.:  *:* .  
 
Cry41Aa         QYWLIEEAGNGYVYLRSKGNPNLVLDVAGTSTANGTNIILWNYNGSTNQKFKLSMNYNVT 
Cry42Aa         QYWIIEDAGNEYVYLKSKADPSRVLDVTGSSTQNGTNIQVWSNYGTLNQKFKLVKL---- 
                ***:**:*** ****:**.:*. ****:*:** ***** :*.  *: ******        
 
Cry41Aa         KAREAVQALFSNPTTLQLKVTDHHVNQVARLVECIADQIHPKEKMCLLDQVKLAKRLSRE 
Extra Loop 
Loop1 
Loop2 
Loop3 
Ricin domain 
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Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         RNLLNYGDFESSDWVGTDGWNVSTNVYTVADNPIFKDHYLNMPSANNPILSDKIFPTYAY 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         QKVEESRLKPYTRYIVRGFVGSSKDLEILVARYDKEVHKRMNVPNDIIPTSPCTGEPVSQ 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         PTPYPVMPSNTMPQDMWCNPCGNGYQTAAGMMVQSTGMMCQDPHEFKFHIDIGELDMERN 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         LGIWIGFKVGTTEGMATLDNIEVVEVGPLTGDALTRMQKRETKWKQKLTEKRMKIEKAVQ 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         IARDAIQTLFTCPNQSCLQSAITLQNILRAEKLVQKIPYVYNQFLQGVLSAVPGEAYAYD 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         IFQQLSDAVATARALYNQRNVLNNGDFSAGLSNWNGTEGADVQQIGNASVLVISDWSASL 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         SQHVYVKPEHSYLLRVTARKEGSGEGYVTISDGTEENTETLKFMVGEETTGATMSTIRSN 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         IRERYNERNMATPDPDAYGGTNGYASNQNMVNYSSENYGMSAHSGNNNMNYQSESFGSKP 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         YGDGNSMINGSSNNYEANGYPGNNNINDQSENYGANAYSSNNMNYQSESSGFTPYGDENN 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         MTNYPSNNYEMNPYSSDMNMSMNRGSDCGCGCSANAYPGGNMMMNNYSSSTYEMNTYPSS 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         TNMTNHQGMGCGCHYSTNEYPMIEENIPDFSGYVTKTVEIFPETNRVCIEIGETAGTFMV 
Cry42Aa         ------------------------------------------------------------ 
                                                                             
 
Cry41Aa         ESIELIRMDCE 
Cry42Aa         ----------- 
 
 
 
 
Figure 34 Alignment of Cry41Aa and Cry42Aa 
The clustal W alignment of the protein sequences of Cry41Aa and Cry42Aa. The conserved blocks of both proteins are underlined and in 
colour font as follows: conserved block 1 in red, conserved block 2 in orange, conserved block 3 in green, conserved block 4 in pink, conserved 
block 5 in blue, (only Cry41Aa) conserved block 6 in grey, conserved block 7 in purple, conserved block 8 in brown. Domain II of Cry41Aa are 
highlighted as follows: Loop1 in red, loop 2 in yellow, loop 3 in navy and extra loop in pink. The ricin domain is highlighted in teal.  
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The five conserved blocks of 3-domain toxins are usually found in the proteolytic active 
core post activation. Domain I is associated with pore formation and is comprised of 
conserved block 1 and part of conserved block 2.  Domain II is associated with specificity; 
it is comprised in part of conserved block 2 and conserved block 3. Domain III is 
associated with binding and receptor recognition. It is usually comprised in part of 
conserved block 3, and the whole of conserved block 4 and 5 (Palm a et al., 2014).  
 
The construct was designed to contain conserved blocks 1 and 2 from Cry42Aa and 
conserved blocks 3, 4, and 5 from Cry41Aa. Cry42Aa and Cry41Aa share homology in the 
domain I region. Introducing this homologous region from Cry42Aa into Cry41Aa will 
indicate if this region of Cry42Aa is functionally active.  Conserved block 3, 4, and 5 from 
Cry41Aa, where less homology between the Cry42Aa and Cry41Aa is observed, ensures 
the presence of regions associated with specificity in insecticidal 3-domain toxins. Their 
inclusion also aims to maintain in part the structural integrity of Cry41Aa.  
 
The hybrid was initially made by using primers to amplify conserved block region for 
blocks 3, 4, and 5 from the pBS41Aa plasmid (figure 21) used as template DNA in chapter 
5.1 In addition to this, the construct also had an ampicillin resistant gene and an E. coli 
origin of replication. Similarly, the conserved blocks 1 and 2 of Cry42Aa were amplified 
using primers for the DNA fragment from pSVP2742Aa template DNA. The primers are 
listed in the table 13 below. The two linear DNAs were run on an agarose, cut out and 
the gel was purified. The fragments were allowed to ligate overnight before an E. coli. 
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Transformation. The ligations formed a compete ORF2 that was made up in part from 
Cry42Aa (block1 and 2) and Cry41Aa (blocks 3, 4, and 5).  
 
Figure 35 is the schematic representation of the pBS41Aa_Cry42Aa construct. ORF2 is a 
hybrid gene that is flanked on either side by BamHI and XhoI restriction sites and allows 
for subcloning of the hybrid gene into a Bt shuttle vector at a later stage. The 
transformation mixture was incubated overnight on 100 µg/mL ampicillin prepared LB 
plates at 37⁰C. If correctly ligated, it would create the pSVP2741Aa_Cry42Aa construct. 
Colonies that potentially harboured the construct were picked and incubated in 
antibiotic LB broth for 2-3 h. The samples were centrifuged and resuspended the pellet 
underwent a mini prep to extract plasmids from the bacterial cells.  
 
PCR primer list to create construct 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13 PCR primer list to create construct  
 lists the PCR primers to create hybrid construct Cry41-42Aa  
 
Template DNA Primer 
name 
Oligonucleotide/ Primer sequence 5’-
PHO 
pBS41Aa CP41AaF 5’ GATCCGGGACTTTATAGTAGGC3’ No 
CP41AaR 5’TGACAATCCTCCATTCCATTTG3’  
 
No 
pSVP2741_Nhe CPCry42F 5’ATGAATCAAAATTATAACAACAATGG3’ Yes 
CPCry42R 5’ATATGTTGGCCATAACGCAAC3’ 
 
Yes 
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Figure 37 schematic presentations of hybrid construct. 
 pSVP2741Aa_Cry42Aa with ampicillin resistant gene (red) and chloramphenicol resistance gene (brown), as well as 
bacterial origin of replication.  OFR2 is hybrid gene made up of both Cry41Aa and Cry42Aa. ORF3 of Cry41Aa is shown 
in blue.   
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Colonies with potential construct were picked and incubated in antibiotic LB broth for 
2-3 h. The mixture was centrifuged, and pellet resuspended for extraction of plasmids. 
A mini prep was performed to extract potential constructs from bacterial cells. These 
were subjected to Hae III digests and analysed in agarose gel. The NEB web cutter 
website has predicted the fragment sizes for both the wildtype pSVP2741Aa and 
correctly ligated construct pSVP2741Aa_Cry42Aa. The information is detailed in table 
15.  
 
Figure 38 is the gel picture of the different Hae III carried out at different stages of the 
pSVP2741Aa_Cry42Aa construct. First the construct was confirmed after Hae III was 
performed in plasmids extracted from E. coli JM109. The distinctive 959bp and 759bp 
bands were observed.  
 
Once sequencing data had confirmed the construct, it was introduced into E. coli 
GM2163 in preparation for transformation of Bt4D7. Bt4D7 transformants were plated 
out on 5 µg/mL chloramphenicol LB agar plates and incubated overnight 30⁰C. Bt 
colonies were picked and incubated in 3mLs of antibiotic LB broth for 2-3 h. The mixture 
was divided, 2mLs was distributed between 5 µg/mL chloramphenicol LB agar plates for 
a 3-day incubation period at 30⁰C. The remaining 1 mL was centrifuged down, and the 
pellet was resuspended in water to extract the construct from Bt cells.  
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Mini preps carried out in Bt4D7 would simultaneously extract native Bt plasmids. Hae III 
performed on such a sample would produce many fragments making the digest profile 
for the construct difficult to confirm. Therefore, the miniprep from Bt cells was 
introduced into E. coli JM109 and incubated overnight in 5 µg/mL chloramphenicol and 
100 µg/mL ampicillin LB agar prepared plates. The lawn should only have the construct 
pSVP2741Aa_Cry42Aa. The cells were scraped off and miniprepped to prepare the 
extracted plasmids with a Hae III digest.  The outcome of the Bt profile of the 
pSVP2741Aa_Cry42Aa construct was consistent and confirmed the integrity of the 
construct. After 3-day incubations samples of the Bt agar plates were analysed under 
the light microscope for crystals and spores. 
 
 Hae III digest profile by NEB web  cutter 
Table 15 Hae III digest profile by NEB web  cutter 
 lists the key fragements of the Hae III  digest profile for wiltype pSVP2741Aa  and the construct pSVP2741Aa_Cry42Aa   
 
Hae III  
fragments  
Wildtype pSVP2741Aa 
(bp) 
pSVP2741Aa_Cry42Aa Construct (bp) 
1 2469 2469 
2 1895 1895 
3 1007 959 
4 879 879 
5 629 601 
6 598 587 
7 587 558 
8 558 458 
9 458 434 
10 434 332 
11 306 306 
162 
 
 
 
 
 
 
Figure 38 banding profie of construct in agarose gel 
Agrose 1.5% gel picture of Hae III digest profile of construct pSVP2741Aa-42Aa. All lanes labelled with contents. Lane contained DNA 
marker Wildtype pSVP2741Aa acts as control in lane 2 1 . Lane 3 contained JM109 E. coli   strain is where the construct is first 
confirmed, before it was introduced into GM2163 (lane 4) to remove any methylated DNA and later extracted in preparation for 
transformations with Bt4D7. The construct was lastly introduced into JM109 after mini prep from Bt cells to confirm integrity of the 
construct as shown in lane 5. 
 
Microscopic observations of samples taken from Bt4D7 expressing the 
SVP2741Aa_Cry42Aa plasmid confirmed the presence of crystals. The samples were 
harvested and prepared for characterisation. Crude samples of the hybrid crystals were 
analysed on SDS PAGE gel. The hybrid expresses both the ~120 KDa (ORF3) and ~80 KDa 
(ORF2) proteins as seen in the control wildtype sample as shown in figure 39 and was 
indistinguishable from crude wildtype Cry41Aa.  
 
1       2       3        4        5 
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Figure 39 banding profie of construct in agrose gel  
SDS-PAGE of crude pSVP2741Aa_Cry42Aa hybrid protein of different volumes 5,2, and 3 µL respectively in lane 2,3, and 4.. Protein 
marker in lane 1. Control crude Cry41Aa in lane 5.   All lanes are labelled with contents and volumes.    
 
The hybrid crystal was solubilised in sodium carbonate pH10.5 and digested with trypsin 
(1 mg/mL). A soluble form of the hybrid SVP2741Aa_Cry42Aa protein was obtained and 
evident in the SDS PAGE gel image shown in figure 40. However, despite changing the 
experimental conditions, it was not possible to obtain a stable protease resistant hybrid 
protein. The solubilised hybrid is shown in lane 3 where DTT and carbonate have worked 
together to solubilise the hybrid crystal.  A protein thought to be ORF2 and known to 
have an approximate size of 88 KDa was seen and indicated by a yellow arrow.  
 
Furthermore, an upper band, thought to be ORF3, known to have an approximate size 
of 120 KDa was also observed and indicated by a yellow arrow. The same band was 
observed in carbonate and DTT treated control samples of Cry41Aa in lanes 2 and 4.     
1        2          3        4        5 
ORF3 
ORF2 
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However, no proteins were observed for hybrid samples incubated with trypsin as 
indicated by lane 7. Lane 6 was loaded with trypsin treated Cry41Aa. Here a protease 
resistant protein was observed about ˜80 KDa or slightly less. the shift in size was 
indicated by a red arrow.  
 
Figure 40 SDS PAGE gel showing pSVP2741Aa-42Aa hybrid protein in various characterisation conditions.  
Lane 1was loaded with 5µL of hybrid protein in 50mM carbonate buffer at 10.5pH. Lane 2 was loaded control wildtype 
Cry41Aa protein in 50mM carbonate buffer at 10.5pH and 0.01mM DTT. Lane 3 was loaded with 5µL hybrid protein 
in 50mM carbonate buffer at 10.5pH and 0.01mM DTT. Lane 4 was loaded with 5µL of control wildtype Cry41Aa 
protein in 50mM carbonate buffer at 10.5pH and 0.01mM DTT. Lane 5 was loaded with 5µL of hybrid in 0.1 µg/mL 
trypsin in 50mM carbonate buffer at 10.5pH and 0.01mM DTT. Lane 6 was loaded with control wildtype Cry41Aa 
protein in 0.1 µg/mL trypsin in 50mM carbonate buffer at 10.5pH. lane 7was loaded with 5µL of hybrid protein in 0.1 
µg/mL trypsin in 50mM carbonate buffer at 10.5pH. yellow arrows indicated ORF2 and ORF3 in control Cry41Aa and 
solubilised and DTT treated hybrid sample. Red arrow indicated protease resistant core of Cry41Aa 
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5.3.2 Cry41Aa ORF2 hybrid with Cry1Ie 
Cry1Ie is an insecticidal three domain toxin with a protoxin of ~81 KDa. It lacks the C-
terminal conserved block 6-8 present in 130 KDa full-length three domain Cry toxins 
(Song et al. 2003). Its specificity has been altered through manipulations that include 
domain II substitution with Cry1Aa resulting in a stable toxin with a new toxicity towards 
Spodoptera exigua (de Maagd et al., 2000).  
 
A pGEM plasmid with the 2160bp ORF gene was created (figure 41). George, 2011 
successfully expressed the Cry1Ie protein which was partially solubilised at pH 11. 
Protease treatment resulted into a ~55 KDa protease resistant core (George, 2011). In 
an attempt to understand Cry41Aa specificity, a hybrid with Cry1Ie was designed and 
constructed.  
 
A sequence alignment was carried out and a suitable region for hybrid formation was 
determined (figure 41).  A region of homology was found, primers were designed to 
amplify conserved block 2, 3, 4, and 5 from Cry1Ie and conserved block 1 from Cry41Aa. 
As previously mentioned, conserved block 1 and part of conserved block 2 are usually 
found in domain I which is associated with pore formation. Whilst the remaining part of 
conserved block 2 and part of conserved block 3 make up domain II which is associated 
with specificity, binding and receptor recognition. Domain III also associated with 
binding and pore formation includes part of conserved block 3 and both conserved 
blocks 4 and 5 (Palma et al., 2014).  
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In other word this hybrid retained domain I of Cry41Aa, with the intention to investigate 
it for its ability to exert a toxicity via pore formation. The previous Cry42Aa hybrid did 
not result in a protease resistant core, perhaps the mutagenesis was too drastic and 
affected the structural stability of the hybrid. The Cry1Ie hybrid has a large section which 
comes from Cry1Ie, with the aim that this provides structural stability in the hybrid.   
 
Table 16 below lists the primers used to construct the hybrid. The presence of native 
Cry41Aa conserved blocks 2, 3, 4 and 5 may ensure better structural stability and thus 
increase the likelihood that a protease resistant core is obtained post trypsin treatment.  
 
PCR primer list to create construct 
Table 16 PCR primer list to create construct  
 lists PCR primers used to create construct pGEMCry1Ie_Cry41Aa 
 
 
Template DNA Primer name Oligonucleotide/ Primer sequence 5’-
PHO 
pBS41Aa 41Aa Hybrid F 5’ ATGAATCAAAATTGTAAGTAATAACAATGG3’ Yes 
41Aa Hybrid R1 5’ATGTAGATTCGCAGCTTCTGC3’  
 
Yes 
pGEMCry1Ie 1Ie HybridF1 5’ATGAATCAAAATTATAACAACAATGG3’ No 
1Ie HybridR1 5’AAGTTACCTCCATCTCTTTTATTATTAAGATACC3’ 
 
No 
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Figure 41 schematic representation of pGemCry1Ie plasmid. 
Wildtype pGemCry1Ie plasmid, with Cry1Ie ORF in light blue, and an ampicillin resistance gene shown in red. Bacterial 
origin of replication shown in yellow. Restriction sites not shown for this plasmid 
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Extra Loop  
Loop 1 
Loop 2 
Loop 3 
CLUSTAL 2.1 multiple sequence alignment 
 
Cry41Aa         MNQNCNNNGYEVLNSGKGYCQPRYPFAQAPGSELQNMGYKEWMNMCTSGDPTVLGEGYSA 
cry1Ie          MKLKNPDKHQSLSSNAKVDKIATDSLKNETDIELKNINHEDFLRMSEHESIDPFVSASTI 
                *: :  ::  .: ...*    .  .: : .. **:*:.:::::.*.   .   : .. :  
 
Cry41Aa         DVRDAVITSINIASYLLSVPFPPAGVAAGILGALLGLLWPTNTQAVWEAFMNTVEALINQ 
cry1Ie          QTGIGIAG-----KILGTLGVPFAGQIASLYSFILGELWPK-GKSQWEIFMEHVEELIDQ 
                :.  .:       . * :: .* **  *.: . :** ***.  :: ** **: ** **:* 
 
Cry41Aa         KLDEYARSKAISELNGLKNVLELYQDAADDWNENPGDLRNKNRVLTEFRNVNGHFENSMP 
cry1Ie          KISTYARNIALADLKGLGDALAVYHESLESWIKNRNNARATSVVKSQYIALELLFVQKLP 
                *:. ***. *:::*:** :.* :*::: :.* :* .: * .. * :::  ::  * :.:* 
 
Cry41Aa         SFAVRNFEVNLLPVYAEAANLHLLLLRDAVKFGEGWGMSTDPGAERDDMYRRLRSRTEIY 
cry1Ie          SFAVSGEEVPLLPIYAQAANLHLLLLRDASVFGKEWGLSNSQ---ISTFYNRQVERTSDY 
                **** . ** ***:**:************  **: **:*..     . :*.*  .**. *                
**** . ** ***:**:************  **: **:*..     . :*.*  .**. * 
  
Cry41Aa         TDHCVNTYNQGLQQAKSLQANVSDYSRYPWTQYNQSGGFSYREAKGEYRGTENWNLYNAF 
cry1Ie          SDHCVKWYSTGLNNLRGTNA-------------------------------ESWVRYNQF 
                :****: *. **:: :. :*                               *.*  ** * 
 
Cry41Aa         RRDMTILVLDIIAQFPTYDPGLYSRPVKSELTREVYTDIRGTTWRSDANLNTIDAIENRM 
cry1Ie          RKDMTLMVLDLIALFPSYDTLVYPIKTTSQLTREVYTDAIGTVHPNASFASTTWYNNNAP 
                *:***::***:** **:**. :*.  ..*:********  **.  . :  .*    :*   
 
Cry41Aa         VGSRQLQLFT---WLTEMKFYIRNTGSITSYTHGDLMVGLEKKIRKTNDNDQWLPLEGQN 
cry1Ie          SFSAIESAVVRNPHLLDFLEQVTIYSLLSRWSNTQYMNMWGGHRLEFRTIGGVLNTSTQG 
                  *    ..    * ::   :   . :: ::: : *     :  : .  .  *  . *.                  
*    ..    * ::   : . :: ::: : *     :  : .  .  *  . *. 
 
Cry41Aa         TSYTRIDRPGIELGKNYWYYARTQQWFETRLLQLWANTDVLSLNAGTVGNEFWVRDVPDY 
cry1Ie          STNTSINPVTLPFTSRDVYRTESLAGLNLFLTQPVNGVPRVDFHWKFATLPIAS-DNFYY 
                :: * *:   : : ..  * :.:   ::  * *   ..  :.::   .   :   *   * 
 
Cry41Aa         RNIYARSTRNHFIENHRLSWIKFEP-----VRDNCPFAWPGYKQLSALLFGWTHNSVDLN 
cry1Ie          LGYAGVGTQLQDSENELPPETTGQPNYESYSHRLSHIGLISASHVKALVYSWTHRSADRT 
                 .  . .*: :  **.  .  . :*      :  . :.  . .::.**::.***.*.* . 
 
Cry41Aa         NIISQYRITQIPAVKAYWNRGAFSVIRGPGSTGGNLVQLG-TGGEVSVKVRPEQTGSDWY 
cry1Ie          NTIEPNSITQIPLVKAFNLSSGAAVVRGPGFTGGDILRRTNTGTFGDIRVNINPPFAQRY 
                * *.   ***** ***:   .. :*:**** ***::::   **   .::*. : . :: * 
 
Cry41Aa         RVRIRYAAGSRGRLNVKKYVSSIHASVTYDYNMTMSSSTQGTYNSFQYLDVYNFRLAEPE 
cry1Ie          RVRIRYASTTDLQFHTSINGKAINQGNFSATMNRGEDLDYKTFRTVGFTTPFSFSDVQST 
                *******: :  :::..   .:*: .         ..    *:.:. :   :.*  .:.  
 
Cry41Aa         FEVWLTNESGG-PIWIDKIEFIPLSPIPELPVYPGTYQIVTALNNSSVVTSEEFCMGIGL 
cry1Ie          FTIGAWNFSSGNEVYIDRIEFVPVEVT-----YEAEYDFEKAQEKVTALFTSTNPRGLKT 
                * :   * *.*  ::**:***:*:.       * . *:: .* :: :.: :.    *:   
 
Cry41Aa         TTRCGVNLWSNNGNTLQKWRFVYNGDQNAFQIKSTPNEDLVLSGSNSGTSVTAETNQNRP 
cry1Ie          DVKDYHIDQVSNLVESLSDEFYLDEKRELFEIVKYAKQIHIERNM--------------- 
                 .:       .*     . .*  : .:: *:* . .::  :  .                 
 
Cry41Aa         NQYWLIEEAGNGYVYLRSKGNPNLVLDVAGTSTANGTNIILWNYNGSTNQKFKLS 
cry1Ie          ------------------------------------------------------- 
Figure 41 Protein sequence alignment of Cry41Aa and Cry1Ie.  
 Clustal W alignment of the protein sequences of Cry41Aa and Cry1Ie.  
conserved blocks of both proteins are underlined and in colour font as follows: conserved block 1 in red, conserved block 2 in orange, 
conserved block 3 in green, conserved block 4 in pink, conserved block 5 in blue. For Cry41Aa, domain II of Cry41Aa are highlighted 
as follows: Loop1 in red, loop 2 in yellow, loop 3 in navy and extra loop in pink. The ricin domain is highlighted in teal.  
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The wildtype pGEM Cry1Ie (figure 41)   and wildtype BS41Aa (figure 21) plasmids were 
used as templates to amplify fragments of each Cry toxin to construct 
pGEMCry1Ie_Cry41Aa plasmid (figure 43). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43 Schematic representation of hybrid plasmid. 
Construct plasmid pGemCry1Ie_Cry41Aa with hybrid ORF that is made up of Cry41Aa and Cry1Ie shown in dark and light blue. 
Ampicillin resistance gene shown in red. Bacterial origin of replication shown in yellow. No Restriction sites shown for this plasmid.  
 
 
The linear PCR products were run on agarose gel, cut out and gel purified and allowed 
to ligate overnight. The ligation mixture was introduced into E. coli GM2163 and plated 
onto ampicillin (100 µg/mL) LB agar plates. The plates were incubated overnight at 37˚C. 
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Six colonies were picked and incubated in ampicillin LB broth for 2-3 h. A Hae III digest 
was carried out on the recovered plasmids from the six colonies and visualised on 
agarose gel as shown in figure 44.  NEB web cutter software predicted the Hae III digest 
profiles for both the wildtype and construct as listed in table 17. 
 
 
Hae III digest profile by NEB web  cutter 
Table 17 Hae III digest profile by NEB web  cutter 
 lists the key fragements of the Hae III  digest profile for wiltype pGEMCry1Ie  and the construct pGEMCry1Ie_Cry41Aa  
 
 
The construct pGEM Cry1Ie_Cry41Aa plasmid had the distinctive 2192bp and 500bp 
bands which are absent in wildtype pGEMCry1Ie. Figure 39 is the picture of agarose gel 
analysis of the Hae III digested plasmids extracted from E. coli cells.  Colony 1 shows 
distinctive 2192 bp and 500 bp bands.   
 
Hae III  
fragments  
Wildtype pGEMCry1Ie (bp) pGEMCry1Ie_Cry41Aa Construct 
(bp) 
1 2238 2192 
2 654 654 
3 485 500 
4 458 458 
5 434 434 
6 289 289 
7 279 279 
8 267 267 
9 174 174 
10 142 142 
11 102 102 
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Figure 44 Banding profie of construct in agrose gel 
Agarose gel showing Hae III digest profile for plasmids extracted from six bacterial colonies respectively loaded onto lanes 2,3,4,6, 
7 and 8. Lane 5 contained wildtype Cry1Ie.  All lanes labelled with contents.   
 
The construct was grown in antibiotic LB broth overnight and harvested for the hybrid 
crystal. The hybrid was subjected to various sodium carbonate and protease conditions 
in an attempt to obtain a soluble protein. Microscopic observations confirmed the 
presence of crystal and crude (also referred to as total sample) samples were analysed 
in SDS-PAGE as shown in figure 45.  
 
Previous Cry1Ie investigations by George et al. (2011) indicated that Cry1Ie partially 
solubilised and resulted in a ˜55 KDa core post protease treatment. George et al. (2011) 
carried out the solubilisation and activation of Cry1Ie in one step. In brief, a volume of 
crude Cry1Ie was centrifuged and superannuant discarded, the pellet was dispersed in 
  1       2         3          4       5       6          7        8 
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a volume of carbonate, trypsin in carbonate was added and the sample allowed to 
incubate for 1 h. Contrary to this Cry41Aa is solubilised and activated in two separate 
steps to get the best yield of activated toxin. Crude Cry41Aa was solubilised in carbonate 
for 1 h. The sample was centrifuged, and supernatant retained. The solubilised sample 
was then activated with trypsin and incubated for a further hour.  
 
To address both methods Cry1Ie_41Aa hybrid was processed using both. The one step 
solubilisation and activation of crude total hybrid samples are shown in lanes 2 to 5. The 
two-step solubilisation and activation of hybrid Cry1Ie are shown in lane 6 to 10. Crude, 
samples in lanes 2, 3, and 4 exhibit the major band with a molecular weight of ˜81 KDa 
and are indicated with a yellow arrow. There is no evidence of 55 KDa activated core in 
trypsin treated crude samples in lanes 4 and 5.  
 
In comparison, lanes 6 was loaded with solubilised only supernatant hybrid and lane 10 
was loaded with   solubilised and trypsin treated supernatant hybrid, and both did not 
show any protein bands. Previous observations by George et al., (2011) of poor Cry1Ie 
solubilisation, suggested that this may also be the case for the hybrid.  Additionally, it is 
likely that the hybrid was not stable in trypsin. Despite altering the carbonate pH and 
trypsin concentration, a solubilised hybrid capable of resulting in a trypsin resistant core 
was not obtained.    
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Figure 45 SDS-PAGE gel of hybrid pGEMCry1Ie_Cry41Aa.  
All lanes labelled with content.  Lane 1 contained protein marker. Lane2 was loaded with 5µL of crude hybrid in 50mM 
carbonate buffer at 11pH. Lane 3 was loaded with 5µL crude hybrid in 50mM carbonate buffer at 10.5pH and 0.01mM 
DTT. Lane 4 was loaded with 5µL of crude hybrid in 0.1 µg/mL trypsin in 50mM carbonate buffer at 11pH and 0.01mM 
DTT. Lane 5 was loaded with 5µL of crude hybrid in 1 µg/mL trypsin in 50mM carbonate buffer at 11pH and 0.01mM 
DTT. Lane 6 was loaded with 5µL of supernatant hybrid in 50mM carbonate buffer at 11pH. Lane 7was loaded with 
5µL supernatant hybrid in 50mM carbonate buffer at 10.5pH and 0.01mM DTT. Lane 8 was loaded with 5µL of 
supernatant hybrid in 0.1 µg/mL trypsin in 50mM carbonate buffer at 11pH and 0.01mM DTT. Lane 9 was loaded with 
5µL of supernatant hybrid in 0.1 µg/mL trypsin in 50mM carbonate buffer at 11pH and 0.01mM DTT. Lane 10 was 
loaded with 5µL of supernatant hybrid in 10 µg/mL trypsin in 50mM carbonate buffer at 11pH and 0.01mM DTT. 
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5.4 Discussion  
The application and creation of Cry hybrids has been used to enhance toxicity, create 
new specificity and elucidate modes of action (Abdullah and Dean, 2004; Abdullah et al., 
2003; Pardo-López et al., 2009; Dean. H and Sylvis L, 2006; Dean et al., 1996). Currently 
there is more than one model to explain the mode of action of Cry toxins (Vachon et al., 
2012, Pardo-Lopez et al., 2013) However, all theories on the mode of action agree that 
specific binding must take place before toxicity can commence (Likitvivatanavong et al., 
2009).  
 
Mutagenesis has been applied to investigate the role that specific regions of a given 
protein play in its mode of action. For insecticidal 3-domain toxins, the assembly of 
hybrids has mainly centred on domain swapping. This led to the creation of novel toxins 
with a wider target spectrum or a significant increase in toxicity to the target cell 
compared to that of the wildtype (Pardo-López et al., 2009). 
 
Initially the research plan was to carry out a Cry41Aa loop 3 exchange that would result 
in the removal of the wildtype loop 3 and the introduction of the insecticidal loop 3.  It 
was thought that this exchange may result firstly in a loss of specificity towards HepG2 
by Cry41Aa and or secondly a gain of specificity towards another insect cell.  Abdulla et 
al.  (2004) employed a similar experimental design when loops 1 and 2 of Cry4Ba (toxic 
to Anopheles and Aedes) were deleted and replaced with loops 1 and 2 of Cry4Aa (toxic 
to Culex). Despite the production of proteotically stable hybrids proteins, they did not 
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exhibit any toxicity towards susceptible insects (Abdullah and Dean, 2004). Mutagenesis 
of Cry4Ba involved the introduction of loop 3 of Cry4Aa; this resulted in a hybrid that 
not only gained toxicity to Culex but exhibited greater toxicity than wildtype Cry4Ba to 
Ades ageypti. It has been suggested that the natural evolutionary mechanism can act on 
Cry toxins and subsequently  generate new specificities (Bravo, 1997; de Maagd et al., 
2001; Wu et al., 2007).  
 
The synthetic creation of hybrids via mutagenesis  can be seen as mirroring natural 
selection in Cry proteins (Caramori et al., 1991). For example, Cry1Ab, Cry1Ac, Cry1Ba 
and Cry1Ea have little or no toxicity towards Spodopetera exigua, but they gained 
toxicity after swapping native domain III with domain III of Cry1Ca which targets this 
insect. Furthermore, the Cry1Ab hybrid has a significantly higher toxicity towards S. 
exigua compared to Cry1Ca (de Maagd et al., 2000).  
 
In another study by Abdullah et al. (2003) the loops of domain II Cry1Aa (toxic to 
lepidopteran) were designed to resemble mutants of Cry4Ba and the resulting Cry1Aa 
hybrid gained toxicity towards Culex pipiens larvae. Such findings suggest that the 
domain II loop can alter the specificity of a given toxin (Dean and Sylvis ., 2006).  
 
Unfortunately, attempts to make hybrids with Cry41Aa did not result in the generation 
of trypsin resistant protein cores, the hybrids were often unable to solubilise well and 
or were not stable in trypsin. Previous studies have highlighted the possibility that 
hybrids are susceptible to additional cleavage by host bacterial proteases (Abdullah and 
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Dean, 2004). This may explain the sudden absence of the hybrid protein when analysed 
in SDS PAGE gels. This finding suggests that Cry41Aa is sensitive to the slightest of 
structural changes. It seems that any subtle changes on the DNA of Cry41Aa appear to 
translate into significant structural changes. 
 
It is not known if Cry41Aa is toxic to other vertebrate or insecticidal cell lines. Without a 
protease resistant protein, it is difficult to shed further light on Cry41Aa specificity. At 
this stage. The findings suggest that mutagenesis on Cry41Aa by loop exchange or 
creation of hybrids was too drastic change and its structure too compromised. In a study 
carried out to investigate the effects of loop exchange between native domain II loops 
of Cry4Aa, it was revealed that exchange between loop 1 and 3 decreased toxicity to 
Culex but did not abolish toxicity in bioassay trails. However, a loop 2 exchanges 
eradicated toxicity completely and led to the proposal that it is loop 2 of Cry4Aa that is 
essential for mosquitocidal activity (Howlader et al., 2009).  
 
A study by Masson et al. (1994) proposed that N terminal regions do not affect 
specificity, after it was observed that N terminal exchange between Cry1Ac and Cry1Ea 
did not introduced novel specificity. The Cry41Aa_Cry1Ie hybrid did introduce an N 
terminal region of Cry1Ie to Cry41Aa. Unfortunately, the resulting hybrid was unstable 
in both sodium carbonate and protease conditions. Indeed, the only successful hybrid 
made was the solubilised trypsin treated pGEM1Acloop3 hybrid. Indeed, the only 
successful hybrid made was the solubilised trypsin treated pGEM1Acloop3 hybrid. This 
hybrid was made up of insecticidal Cry1Ac with loop 3 of Cry41Aa.  Once solubilised and 
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activated it resulted in a protein resistant core of ~ 65 KDa. Preliminary cell assay analysis 
was carried out on HepG2 cells with pGEM1Acloop3 hybrid to determine if it gained 
cytocidal activity. Observations indicated that the hybrid was not toxic to HepG2 cells. 
However, a study conducted both in vivo and in vitro cultured insect cell lines and 
dissociated midgut epithelial cells has concluded that hybrids can exhibit different 
toxicity which is dependent on bioassay systems in place (Masson et al., 1994). To shed 
light on the specificity of Cry41Aa a different mutagenesis approach was required in 
order to obtain a stable recombinant protein.   
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6.0. Production, purification, and 
characterisation of Cry41Aa loop 
mutants 
6.1 Introduction  
Amino acid substitutions were used to probe the mechanism of action of Cry insecticidal 
toxins (Dean et al., 1996). The theory that domain I is attracted to negatively charged 
membrane surfaces was researched in the early nineties.  The surface residues of 
exposed loops of Cry1Ab in domain I were substituted and the study concluded that a 
positively charged residue such as arginine or a neutral residue such as alanine had a 
stronger membrane insertion than the negatively charged aspartic acid wildtype residue 
(Dean et al., 1996).  
 
Alanine substitutions were made in domain II loops, in a study by Wu et al. (1996) which 
explored the toxicity of Cry3Aa and its ability to bind to receptor gut epithelia receptors 
of Tenebrio molitor beetle larvae. Alanine substitutions in loop I and loop 3 of domain II 
indicated a reduced binding affinity and toxin stability. However, a block of alanine 
substitution made in loop 3 despite having a lower binding affinity resulted in a higher 
toxicity compared to wildtype Cry3Aa. This was noted to be due to the mutants ability 
to have an increased membrane insertion compared to that of the wildtype (Wu and 
Dean, 1996).  
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A study by Garcia-Robles et al. (2012) explored the specificity and binding of insecticidal 
Cry3Aa towards the Colorado potato beetle.  Site directed mutagenesis was carried out 
in loop 1 of Cry3Aa.  The mutagenesis carried out corresponds to a previously identified 
ADAM metalloprotease recognition motif thought to take part in membrane associated 
proteolysis and toxicity in the Colorado potato beetle.  The study concluded that 
interactions with ADAM through the Cry3Aa recognition motif led to Cry3Aa proteolysis, 
and that this is vital for Cry3Aa toxic action in target insect. 
 
Further studies were carried out in nCry3Aa that investigated the receptor recognition 
and binding of Cry3Aa by T. molitor. One study introduced an alanine substitution in 
loop1 and 2 where a loss of toxicity was observed potentially due to reduced receptor 
binding. However, a loop 3 block alanine substitution resulted in an increase in toxicity 
due irreversible binding where the toxin is thought to insert itself in the membrane of 
target cells (Wu and Dean, 1996, Nachimuthu and Polumetla Ananda, 2004).  
 
Rajamohan et al. (1996) explored the effects of alanine substitutions on loop 2 and 3 of 
Cry1Ab, which resulted in the loss of toxicity to Manduca sexta and H. virescens as 
consequence of reduced binding affinity to BBMV (Rajamohan et al., 1996a; Rajamohan 
et al., 1996c; Nachimuthu and Polumetla Ananda, 2004). This was later supported by 
findings that suggested that loops 8 and 2 of Cry1Ab interact with M. Sexta Bt-R1 
receptor. (Gomez et al., 2003).  
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In this study, domain II loops 1, 3, and the extra loop from Cry41Aa underwent residue 
substitutions in the quest to understand its specificity towards mammalian HepG2 cell 
line. This mutagenesis approach involved the substitution of specific residues (i.e. amino 
acid substitutions) in domain II loops of Cry41Aa. The residue substitutions on domain II 
loops of Cry41Aa took place in residues of the loop sequences as identified in chapter 4. 
 
 Substitutions on the three loops of Cry41Aa were carried out in concurrence with one 
another so that each mutagenesis could provide information that would go on to build 
a picture of which residues and possibly how Cry41Aa is able to target HepG2 cell.   
 
Bioinformatics has predicted with confidence the sequences that make up loop1 and 
loop 3 of Cry41Aa. It had highlighted the uniqueness of the extra loop in category of 3-
domain Cry toxins and predicted it to have a secondary structure that is mostly made up 
of strands. Previous attempts to delete all or some of the extra loop have resulted in 
unstable recombinant proteins (Krishnan et al., 2017). 
 
 Studies that explore insecticidal 3-domain Cry toxins have typically investigated the 
exposed loops of domain II. The literature has highlighted the importance of these loops 
in the toxin’s ability to bind to and interact with target cells. The sequences of loop1 and 
loop 3 of Cry41Aa have been predicted as follows.  
 
Loop1 is a short four-residue sequence: 384SITS387. As it is the shortest loop being 
investigated it allows for several residue substitutions in attempt to collate as much 
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information possible on the specificity of Cry41Aa. Loop 3 of insecticidal 3-domain Cry 
proteins has been directly implicated in the mode of action of 3-domain toxins (Pacheco 
et al., 2009). Loop 3 of Cry41Aa is predicted to be 15 residues long sequence: 
503VRDNCPFAWPGYKQL517. Previous attempts to exploit loop 3 to create hybrids did not 
result in protease resistant protein (chapter 5.2), substitutions here can aid to narrow 
down sequences or residues that play a key role in Cry41Aa ability to target HepG2 cells.   
The three loops selected for investigation are shown in figure 46. The side chains of the 
residues chosen for substitution are shown for each loop of domain II in Cry41Aa.  
Since little is known about Cry41Aa it is difficult to hypothesise the effect of mutagenesis 
on toxicity which may improve, reduce or get completely knocked out.  
 
This section details how domain II loop constructs were designed and made. These were 
made using the general steps as outlined in introductory figure 20, chapter 5.1. All 
constructs have a PCR design that is specific to the mutation made. A small plasmid such 
as the wildtype pBS41Aa was commonly used as a DNA template for the PCR reaction. 
The wildtype plasmid contains ORF2 of Cry41Aa that is flanked by restriction sites 
(BamHI and XhoI) as well as an ampicillin resistance gene (figure 21).  
 
The PCR design is shown and details each construct’s design. From then on, all construct 
proceeded through similar lab procedures and check points. All linear PCR products are 
excised from agarose gels, purified and allowed to ligate overnight. The ligation mixture 
was introduced into an E. coli strain (usually JM109). The transformation mixture was 
poured onto ampicillin LB agar plates for overnight incubation at 37 ⁰C. Surviving 
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colonies were picked and grown either in antibiotic LB for 2-3 h or by re-streaking onto 
antibiotic LB agar plates for overnight incubation. Mini preps were carried out to extract 
potential constructs from bacterial cells. These underwent Hae III digests and gel images 
of the banding profile were compared to predicted NEB web software Hae III profiles. 
 
 Once the constructs were confirmed by Hae III digest profiles and sequencing, the 
mutant ORF2 was subcloned into a Bt expression vector. This step involved a double 
digest by BamH and XhoI enzymes on both the construct and the Bt shuttle vector 
(pSVP2741Aa figure 28). The fragments were allowed to ligate overnight to form the 
final Bt expression construct. A series of mini preps, Hae III digests and sequencing took 
place to confirm the constructs and their integrity, as they undergo a number of various 
strains E. coli and Bt4D7 bacterial transformations.   
 
This section shows in detail one or two constructs as examples of the processes and 
checkpoints that all Cry41Aa domain II loops constructs were subject to it also shows 
evidence of the recombinant proteins produced as a result of the mutagenesis carried 
out in loops of Cry41Aa, and their preparation for cell assays. The chapter begins with 
mutagenesis carried out on loop 1 of Cry41Aa. Followed by mutagenesis in the extra 
loop of Cry41Aa, and finally in loop 3 of Cry41Aa.
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Figure 46 UCF chimeria visualised putative loops of Cry41Aa on which mutagenesis was carried out. 
 Loop1 shown in red and has the sequence 384SITS387 , all four residues underwent substitutions. Loop 3 shown in green and has the sequence 503VRDNCPFAWPGYKQL517   the three hydrophobic residues which were 
substituted are shown in loop 3 F509 (red), W511 (blue), and Y514 (purple). extra loop is shown in pink and has the sequence 261NVSDYSRYPWTQYNQSGGFSYREAKGEYRGT291. Substitutions in 280SYRE283 were carried out 
on the extra loop.  
Loop1 
Extra Loop 
Loop3 
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6.2.1 Establishing optimum solubilisation and activation conditions  
The optimum solubilisation and activation conditions for wildtype Cry41Aa were 
investigated and later set as testing standard for all loop recombinants. Bt cells were 
harvested, crystals were analysed and visualised on SDS PAGE gel. In this study, 
bioinformatic analysis of Cry41Aa has revealed that it has a similar structure to 
insecticidal 3-domain Cry toxins known to have separate ORF or more than one ORF for 
crystallisation. These split genes encode products that resemble the C-terminal half and 
the N-terminal half of 135  KDa or larger than 60  KDa toxins (Adalat et al., 2017, Bietlot 
et al., 1990). Cry41Aa is known to have ORF2 and ORF3 thought to be responsible for an 
˜80   KDa and ˜120  KDa protoxin respectively. Yamashita et al. (2005) has argued that 
both ORF2 and ORF3 are necessary to encode and crystallise the cytotoxic crystal and 
that previous attempts to produce Cry41Aa crystals without ORF3 did not result in 
crystal formation (Yamashita et al., 2005, Krishnan, 2013). 
 
All 3-domain Cry toxins have distinct  globular domains, domain I, II and III  are  known 
to produce protoxins of ˜65 or ˜135  KDa where the highly conserved C-terminal aids to 
crystallise the protoxin by forming intermolecular disulfide bonds and non-covalent 
interactions which stabilise the crystal structure (Adalat et al., 2017). Once ingested the 
alkaline insect gut provides the reducing environment to dissociate the cross-links bonds 
effectively solubilising the crystal. The soluble protoxin is  subsequently processed by 
insect gut proteases (Bravo et al., 2007). An in vitro setup was established to mimic the 
pH and protease conditions present in an insect gut in order to solubilise and activate 
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Cry41Aa and its mutants. Previous studies have observed proteolysis of endotoxins as a 
result of native bacterial proteasese released during the in vitro solubisation stage , the 
Cry41Aa crystals and its mutants were thus washed with 1M sodium chloride to remove 
absorbed bactrial proteases (Zalunin et al., 2004).  
 
The harvested Cry41Aa crystals and its crystal mutants were solubilised in sodium 
carbonate pH 10.5. The reducing agent 2-mercaptoethanol and dithiothreitol (DTT) was 
also added to disrupt the disulfide bonds. Crude total sample of Cry41Aa crystals were 
exposed to different carbonate and trypsin conditions and incubated for 1h in a 37˚C 
water bath.  
 
The samples were then analysed on an SDS PAGE gel as shown in figure 47. Initially both 
solubilisation and activation were carried out in a single 1 h incubation step. The gel 
indicates that there was no significant difference between the Cry41Aa crude control 
(crystals) sample and the Cry41Aa crystals that have been incubated with 50mM sodium 
carbonate pH 11, trypsin (2 mg/mL), and DTT (2.5mM). Both protoxins ORF3 (˜120 KDa 
protein) and ORF2 (˜80-88 KDa protein) are present in these conditions and indicated 
by yellow arrows in the gel.  It indicated that on this instant Cry41Aa crystals did not 
solubilise well and activation was also inadequate.  
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Yamashita et al, (2005) proposed that the proteinase K activated 64 KDa toxic protein is 
derived from the 88 KDa protoxin, and it is this 64  KDa peptide which is responsible for 
the cytocidal activity to HepG2 cell lines. The gel did not clearly show the activated ˜60 
KDa toxin. 
 
The characterisation protocol of Cry41Aa was adjusted to improve solubilisation and 
activation of the toxin. These were carried out in separate steps independent of one 
another in order to obtain first the solubilised protoxin and then to activate it with 
trypsin. This is the 2-step method. A number of conditions were tested. The pH levels, 
DTT and trypsin concentration were optimised.  Figure 48 is the SDS PAGE gel picture of 
solubilised activated Cry41Aa in various trypsin concentrations.  
 
Crude Cry41Aa was incubated for an hour in 50 mM sodium carbonate pH 10.5 with DTT 
in a water bath at 37˚C. The sample was then centrifuged, and the supernatant was 
retained. The solubilised Cry41Aa was activated by different concentrations of trypsin 
to establish the optimum concentration of trypsin for activation. The 1 mg/mL trypsin 
activated sample gave a clear ˜80 KDa or less major protein and an ˜60 KDa minor 
protein both indicated by yellow arrows in gel. These two proteins are thought to 
originate from the solubilised and activated ORF2 encoded crystal.  The 120 KDa protein 
(ORF3) is no longer detected in the trypsin activated gel lanes but is clearly noted in the 
carbonate-DTT solubilised sample prior to trypsin activation. Background proteins were 
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noticeably reduced compared to single step solubilisation activation gel picture (figure 
47).  
 
Therefore, all crystals including wildtype were solubilised and activated in a 2-step 
process that took 2 h. First the crude samples were incubated for an hour in 50mM 
sodium carbonate pH 10.5 and DTT (2.5mM) in a 37 ⁰C water bath. The samples were 
centrifuged, and supernatant retained.  Followed by the activation step followed where 
trypsin (1 mg/mL) was added and the samples were incubated for 1 h in a 37 ⁰C water 
bath.  This procedure was applied as standard to all mutant crystals as well as wildtype 
Cry41Aa crystal.  The activated form of the toxins was ready for further analysis.   
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Figure 47 7.5% SDS PAGE gel of crude total (crystal) Cry41Aa  
Cry41Aa was incubated for I h in a 37⁰C water bath in varying different pH, trypsin and DTT conditions. Lane 1 
contained protein marker. Lane 2 contained wildtype crude Cry41Aa in water. Lane 3 contained crude Cry41Aa 
treated with 2 mg/mL trypsin in carbonate. Lane 4 contained crude Cry41Aa incubated with carbonate pH 11. Lane 5 
contained crude Cry41Aa incubated with carbonate pH 11 and DTT. lane 6 contained crude Cry41Aa incubated with 
trypsin 2 mg/mL in carbonate and DTT.  All lanes labelled with content.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48 7.5% SDS PAGE gel of a solubilised Cry41Aa supernatant treated with different concentrations of trypsin 
in carbonate pH 10.5 and DTT (2.5mM). 
 lane 1 contained protein marker. Cry41Aa was activated by different trypsin in carbonate concentrations, 1 mg/mL 
(lane 2), 0.1 mg/mL (lane3, 0.01 (lane 4, 0.001 (lane5). Lane 6 contained solubilised Cry41Aa in carbonate pH 10.5 and 
DTT. 
1                  2                 3                         4                 5                6               
ORF2 protease 
resistant 
peptides  
ORF3 
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6.2.2 Assessment of Cry41Aa mutants and their effect on cell lines  
In an effort to investigate the specificity and toxicity of Cry41Aa towards HepG2 cells, a 
number of recombinants mutants from loop1, 3 and extra loop were created, and their 
cytotoxicity to a number of different human cell lines were investigated.  
 
Cell assay analysis carried out on HepG2 cells incubated with Cry41Aa and its 
recombinant toxins to establish the cytotoxicity of the activated proteins. Cell viability 
assay that measure metabolic activity of viable cells was applied to establish toxicity.  
Membrane permeability assay was applied to confirm nuclear membrane breakdown.  
Western blots analysis was applied to depicts the activation of p38 MAP kinase in toxin 
treated cells. This particular pathway is activated as a consequence of membrane 
damage by pores (Zhang et al., 2005,  Ratner et al., 2006). Finally, the presence and type 
of potential pores as a consequence of the effect of Cry41Aa and its loop recombinant 
was also addressed. All Cry41Aa  recombinant toxins were  characterised against 
Cry41Aa, these recombinants formed crystals which were harvested, solubilised and 
activated with trypsin in the same manner as Cry41Aa. Table 18 below summarises the 
constructs made to investigate the specificity of Cry41Aa to HepG2 cells. 
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Table 18  A  summary of  the constructs made to invetigate the specificty of Cry41Aa toxin. 
List of Contructs name along with details of ORFs, host bacterial cell, mutagensis, and whether they expressed proteins. The progression of expressed proteins from each constrcut through the 
stages of solublisation, trypsin activatiation, and toxicity on HepG2 cell lines.  
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6.3 Residue substitutions in loop 1 of Cry41Aa. 
Bioinformatics was used to predict loop1 of Cry41Aa. The native sequence 384SITS387 
underwent site directed mutagenesis with the aim of creating various mutants in an 
effort to understand Cry41Aa specificity towards HepG2 cells.  
 
 Four degenerate nucleotides were included in the forward primer to make three 
possible substitutions, making the number of possible mutant outcomes 34=81 as 
detailed in table 19. The pBS41Aa plasmid acted as template DNA. Once PCR products 
were purified and allowed to self-ligate, E. coli transformations were carried out.   
 
Table 20 lists the PCR primers for loop1 substitutions. Colonies with potential 
degenerate constructs were first identified by RSS. Bacterial colonies were picked and 
lysed 2% NaOH solution. The intact plasmids were separated on an agarose gel, large 
plasmids with insert travel slower than smaller plasmids no insert control (Law and 
Crickmore, 1997). In this instant loop1 mutant plasmids were the same size as wildtype 
BS41Aa and appeared to run equally when loaded in an agarose gel. Constructs that 
appeared similar to BS41Aa on RSS agarose gel were incubated overnight, centrifuged, 
pellet resuspended and mini prepped for further analysis. The extracted plasmids were 
subject to Hae III digests and were indistinguishable from wildtype Cry41Aa Hae III digest 
profile on an agarose gel. Constructs were confirmed by sequencing.  
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The mutant plasmids were introduced into Bt where the recombinant proteins were 
expressed. The resulting loop1 mutants’ proteins were CVSC, CLAC, and GLAC, their 
toxicity towards HepG2 was investigated.  
 
 
 
Table 19 PCR primer list to create constructs 
 primer design for the substitutions for each residue in loop1 of Cry41Aa following the introduction of degenerate 
codons. Native residues and codons are highlighted in red.  
 
primer list to create constructs 
 
Table 20 PCR primer list to create constructs 
 lists PCR primers used to create loop1 substitution construct 
 
 
6.3.1. Establishment of the cytotoxicity of loop1 Cry41Aa recombinants 
The predicted loop1 of Cry41Aa is a relatively short surface loop with the sequence 
384SITS387. Substitutes were made using degenerate nucleotides and successful 
Native residues OF CRY41AA LOOP1 
 
                                                                         5’     T        G        S       I      T      S      Y     T   3’ 
Codons      5’  ACG    GGT    AGC   ATT  ACT  AGC  TAT ACT  3’ 
Degenerate codons                                   BGC    BTT BCT BGC 
Outcomes  384 Serine:  AGC to BGC: Glycine, Cysteine, Arginine 
385Isoleucine ATT to BTT: Phenylalanine, Valine, 
Leucine 
386Threonine ACT to BCT: Alanine, Serine, Proline 
387Serine AGC to BGC: Glycine, Cysteine, Arginine 
 
Template DNA Primer name Oligonucleotide/ Primer sequence 5’-
PHO 
pBS41Aa JTLoop1F  5’ GGTBGCBTTBCTBGCTATACTCACGGTC 3’ Yes 
JTLoop1R  5’ GGTATTCCTTATATAAAATTTCATTTCTG 3’ Yes 
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recombinants were recovered. These recombinants were characterised against the 
wildtype Cry41Aa. Recombinants formed crystals that were harvested, solubilised and 
activated with trypsin in the same manner as Cry41Aa. The recombinants behaved 
similar to Cry41Aa and were indistinguishable on an SDS PAGE gel. Initial cell assay data 
indicated that all loop1 substitutes retained toxicity towards HepG2 cells. Since the 
mutant protein’s concentrations were not standardised, it was not possible to establish 
whether some mutants were significantly more or less toxic than Cry41Aa. It was clear 
that the loop1 substitutions did not knock out toxicity suggesting that this putative loop 
may not play a key role in the specificity or toxicity of Cry41Aa as shown in figure 49.   
 
 
Figure 49 CellTiter blue HepG2 cell assay of loop 1 mutants  
Figure shows % cell viability of HepG2 after a 24h incubation period with dialysed substitution mutants’ of loop1 
Cry41Aa. Protein concentrations were not standardised.  HepG2 cells seeded at density 25x104 cells/mL.  
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Loop1 recombinants did not reveal many details on the specificity of Cry41Aa, the 
distinctive extra loop was explored next  
 
 
6.4 Residue substitutions in extra loop of Cry41Aa. 
Homology protein structure prediction software highlighted the distinctive extra loop 
which is unique to Cry41Aa. Structurally, the loop appears to extend away from the main 
Cry41Aa structure according to SWISS-MODEL software predication; or it is tucked 
towards the main structure according to Phyre software (figure 46). It has the sequence 
261NVSDYSRYPWTQYNQSGGFSYREAKGEYRGT291.  
 
Previous work has shown that complete or  partial deletions on the loop did not result 
in a protease resistant core (Banani, 2013). A study by Howlader et al. (2009) created 
alanine substitutions in domain II loops 1, 2, and 3 of Cry4Aa. These mutants exhibited 
significant reduced toxicity to the susceptible Culex pipinen mosquito as well as 
highlighting loop 2 as a key loop in the role of receptor recognition (Howlader et al., 
2009).  Further investigation in loop 2 of Cry4Aa led to the creation of additional mutants 
in which multiple residues in loop 2 were replaced with alanine resulting in significant 
reduction in the level of mosquitocidal activity. The findings led to the speculation that   
the receptor binding site (S) of Cry4Aa is different from loops 1, 2, and 3 or that there 
may be multiple binding sites that work cooperatively for receptor binding. (Howlader 
et al., 2010). The role of the extra loop in Cry41Aa was investigated for specificity.  
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The sequence for the extra loop was analysed independently from the rest of the 
Cry41Aa sequence by PSIRED. The software data suggests that the extra loop has a 
secondary structure where residues 271TQY273 and 279FSYRE283 are sheets. An alanine 
substitution of residues 280SYRE283 was carried out. This substitution created an alanine 
cassette changing the native secondary structure of the extra loop from sheets to 
helixes. The PCR primers used are listed in table 21. The mutagenesis design is illustrated 
in figure 50.  
 
 PCR primer list to create construct 
 
Table 21 PCR primer list to create construct 
 Table lists PCR primers used to create extra loop substituation. 
 
 
The PCR product was purified and allowed to self-ligate overnight followed by a 
transformation into E. coli. The construct was processed in much the same way as that 
employed for all loop constructs.   Schematic diagram in figure 13 in methods 3.2 details 
the steps and process taken to obtain extra loop mutant protein.  
 
 
Template DNA Primer name Oligonucleotide/ Primer sequence 5’-
PHO 
pBS41Aa extra Loop JMF  5’ GCTGCAGCCAAAGGAGAGTACCG 3’ Yes 
extra Loop JMR  5’ GGCGGCAAAACCACCCGATTGATTATAC 3’ Yes 
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Figure 50 Schematic diagram of Primer design for Alanine substitution in extra loop of Cry41Aa. Substitution Residues and codon are highlighted in red in the native, primers and mutant sequence. 
Mutant extra loop: alanine substitutions 
N  V  S   D   Y    S   R   Y   P  W  T   Q   Y   N  Q   S  G   G   F   A  A   A   A   A   K   G    E    Y  R  G   T 
5’AAC  GTA  TCC  GAC  TAT  AGT  CGT  TAT  CCA  TGG  ACA  CAG  TAT  AAT  CAA  TCG  GGT  GGT  TTT  GCC  GCC  GCT  GCA  GCC   AAA  GGA  GAG  TAC  CGA  GGT  ACA 3’ 
Native extra loop sequence 
    N  V   S   D   Y   S   R   Y   P  W   T  Q   Y   N   Q   S   G   G   F   S   Y   R   E   A   K   G    E    Y  R  G   T  
5’AAC  GTA  TCC  GAC  TAT  AGT  CGT  TAT  CCA  TGG  ACA  CAG  TAT  AAT  CAA  TCG  GGT  GGT  TTT  AGC  TAC  CGT  GAA  GCC   AAA  GGA  GAG  TAC  CGA  GGT  ACA 3’ 
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Colonies with potential constructs were picked and grown in ampicillin LB broth for 2-3 
h. The suspensions were centrifuged, and pellet were mini prepped and to extract 
potential constructs. The potential constructs were profiled by Hae III digests. NEB web 
cutter software predicted the Hae III digest profiles of wildtype pBS41Aa as well as the 
extra loop construct.  
 
In preparation for subcloning into a Bt expression vector, the constructs in blue script 
plasmid and the Bt expression vector pSVP2741Aa underwent a double digest by BamHI 
and Xhol. In the constructs the mutant ORF2 2.5Kb fragments was isolated. In 
pSVP2741Aa the backbone 7.8Kb fragment with ORF3 was isolated. Once excised, and 
gel purified the linear fragments were allowed to ligate overnight before an E. coli JM109 
transformation.  
 
The transformation mixtures were plated on LB agar plates prepared with 5 µg/mL 
chloramphenicol and 100 µg/mL ampicillin for overnight incubation at 37 ⁰C. The 
pSVP2741Aa backbone fragment encodes ampicillin and chloramphenicol genes, 
correctly ligated constructs ensure bacterial cell survival.  The JM109 colonies were 
picked and incubated for 2-3 h in antibiotic LB broth. The suspension was centrifuged, 
and pellets resuspended for plasmid(s) extraction. 
 
 Hae III digests were performed on recovered mini preps. Table 22 lists the NEB web 
cutter predicted fragment sizes (bp) for the extra loop wildtype pSVP2741Aa.  
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Figure 51 is the gel picture of Hae III digest profile of wildtype pSVP2741Aa and the extra 
loop construct in Bt expression vector. The extra loop construct Hae III digest profile is 
indistinguishable from pSVP2741Aa.  
 
 Once confirmed by sequencing, the construct was introduced into E. coli strain GM2163 
in preparation for transformation with Bt4D7. This removed any methylated DNA. The 
integrity of the construct was checked as it proceeded through various bacterial 
transformations via Hae III digests profiles and sequencing.  
 
The construct was introduced into Bt4D7 to express recombinant crystals. The 
transformation mixture was incubated overnight on 5 µg/mL chloramphenicol LB agar 
plates at 30 ⁰C. Bt colonies were picked and incubated in 3mLs of antibiotic LB broth for 
2-3 h. The solution was centrifuged, and pellets were resuspended in order to extract 
the construct plasmids.  Mini preps from Bt cells would also include native Bt plasmids, 
therefore a Hae III digest to check the correct sequence of the construct cannot be 
carried directly on mini preps from Bt cells. The Bt mini preps were first introduced into 
E. coli and plated onto antibiotics LB agar plates. The lawn(s) of cells were scraped, 
resuspended and mini prepped for the construct. A Hae III digest was performed on the 
recovered plasmids.  
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After a 3-day incubation, Bt cells with extra loop construct were observed for crystals 
under a light microscope and thereafter harvested and characterised.   
 
Hae III digest profile by NEB web cutter 
 
Table 22  Hae III digest profile by NEB web cutter 
Table lists the key fragments of the Hae III  digest profile for wiltype pSVP2741Aa  and the extra loop construct in Bt 
expression vector   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51 Agarose 1% gel of Hae III digest profile of extra loop construct  
Lane was loaded with DNA 1kb marker. Lane 2 was loaded with wildtype Cry41Aa. Lane 3 and 4 were loaded with 
extra loop construct.  
Hae III  
fragments  
Wildtype pSVP2741Aa (bp) extra loop in Bt expression vector 
Construct (bp) 
1 2469 2469 
2 1895 1895 
3 1007 1007 
4 879 879 
5 629 629 
6 598 598 
7 587 587 
8 558 458 
9 458 434 
10 434 306 
11 306 267 
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The extra loop mutant was solubilised in carbonate buffer pH 10.5 and activated in 1 
mg/mL of carbonate trypsin. Two protease resistant proteins were observed. An ˜80   
KDa or slightly less as indicated with yellow arrows. A ˜60   KDa proteins was also 
observed but it was very faint. it is indicated in with a yellow arrow in the Cry41Aa 
control sample.  The extra loop recombinant was processed in both the 1 and 2 step 
method discussed in chapter 6.2.1. as indicated in the SDS PAGE gel the 2-step method 
was more efficient and a clear protease resistant protein in seen for recombinant in lane 
3 of figure 52. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52 SDS PAGE gel analysis of the extra loop recombinant protein against wildtype Cry41Aa protein. 
Lane 1 was loaded with protein marker. Lane 2 was loaded with 5µL of crude extra loop recombinant protein. Lane 3 
was loaded with 5µL of extra loop recombinant which was processed in the 2-step method. Lane 4 was loaded with 
5µL of extra loop recombinant protein processed in the 1 step method. Lane 5 was loaded with 5µL of wildtype 
Cry41Aa protein control.   
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The recombinant protein was gel purified and its concentration optimised against 
Cry41Aa and loop 3 recombinant proteins (chapter 6.4). A concentration range was 
made, and the extra loop recombinant was analysed for its effect on HepG2 cell lines. 
The final concentration of the extra loop recombinant in the well with HepG2 cells was 
0.197, 0.131, 0.0657, 0.0263, 0,013, 0.006, 0.002 µM/ml.   A gel picture of the protein 
concentration optimised activated extra loop recombinant protein (0.197 µM/mL) is 
shown in chapter 6.5.1. figure 73. HepG2 cell assay demonstrated that this mutant lost 
its toxicity towards HepG2 cells as indicated in figure 74 where the graph details a dose 
response of HepG2 treated with all recombinant proteins whose protein concentrations 
were optimised.  
 
6.5 Residue substitutions in loop 3 of Cry41Aa 
A combination of bioinformatic tools predicted loop 3 of Cry41Aa (chapter 4). 
Mutagenesis took place on three hydrophobic residues of loop 3 at positions F509, 
W511, and Y514 shown in figure 53.   
 
A number of studies have noted the likeness between the receptor binding loops of 
domain II and other known protein to protein epitopes. Protein to protein epitopes 
involve interactions between hydrophobic residues that able to bind tightly to receptors 
that are surrounded by hydrophobic or charged residues (Schnepf et al., 1998). In a 
study that examined the role of domain II, a number of alanine substitutions were made 
in loop 2 residues of 3-domain insecticidal CryIAb. The recombinant protein 
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demonstrated loss of toxicity to susceptible Manduca sexta and Heliothis virescens. The 
loss of toxicity directly correlated to reduced binding affinity for brush-border 
membrane vesicles (BBMV) prepared from susceptible insect midguts. The study 
proposed that 368RRP370 residues play a key role in toxin-receptor interactions and may 
even direct the toxin to receptor molecule. Further investigation in the same loop 
analysed the role of single hydrophobic aromatic Phenylalanine residue at position 371 
in the loop. A number of substitutions with hydrophilic, aliphatic residues with a small 
side chain were made. Observations indicated that irreversible binding and the toxicity 
of Cry1Ab to BBMV of M. sexta was significantly affect and the study concluded that a 
hydrophobic aromatic side-chain residue at position 371 was crucial for irreversible 
binding of Cry1Ab toxin to susceptible insect BBMV.   
 
Further investigations on the effect of residue substitution in loop of Cry1Ab revealed 
that alanine substitutions not only affected toxicity but also binding affinity to toxin to 
BBMV prepared from susceptible H. virescens midguts (Rajamohan et al., 1996b). 
Domain II loops of Cry1Aa toxins demonstrated that hydrophobic residues are critical 
for binding to BBMV of Bombyx mori midgut (Lu et al., 1994).   
 
Wu and Dean studied the effect of alanine substitutions in loop 1 and 3 of insecticidal 
Cry3Aa.  The recombinants were analysed for their toxicity to the susceptible Tenebrio 
molitor. Substitutions of tyrosine residues in loop1 resulted in a reduction in receptor 
binding. Unexpectedly, a block substitution in loop 3 residues to alanine resulted in a 
reduction in receptor binding while concurrently the recombinant toxin demonstrated 
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an increase in toxicity by 2.4-fold when compared to wildtype Cry3Aa. Comparative 
analysis of the loop 3 alanine substitution block mutant and wildtype Cry3Aa conclude 
that mutant demonstrated increased membrane insertion into the BBMV of T. mori and 
proposed that there is a direct correlation between toxicity and irreversible binding of 
this mutant to susceptible BBMV. The study concluded that loop1 and 3 of Cry3Aa are 
involved in receptor binding and loop 3 playing a key role in membrane insertion (Wu 
and Dean, 1996). 
 
Such studies have highlighted the importance of a hydrophobic residues in receptor 
recognition and irreversible binding to susceptible cells. In this study initial mutagenesis 
involved native hydrophobic, aromatic residues substitution with alanine at positions 
509, 511, and 514 to create three different mutants.   
 
 
 
6.3. Primer design for alanine substitutions at positions 509, 511, and 514 of loop 3 in 
Cry41Aa. 
 Initial mutagenesis aimed to create alanine substitution in position 509, 511, 514 of loop 
3 in domain II of Cry41Aa.  The three-loop 3 alanine substitution mutants F509A, W511A, 
and Y514A were made according to the primer design illustrated in figure 20 chapter 
5.1. The wildtype pBS41Aa plasmid (figure 21) acted as a template DNA to amplify loop 
3 of Cry41Aa. All three-substitution mutants F509A, W511A, and Y514A were made 
using pBS41Aa plasmid as a template as listed in table 23 and illustrated in figure 53.  
206 
 
 
 
 
 
 
The primers were designed so that each DNA fragment forms one half of loop 3. Once 
these linear PCR products were excised, gel purified and allowed to ligate, they formed 
a construct ready for introduction into E. coli. Correct ligation results in an MfeI 
restriction site introduced when codon change was introduced in the reverse primers.  
This silent mutation did not change native residue, a digest with MfeI was never carried 
out as Hae III digests and sequencing were sufficient in identifying constructs. The 
primer design is illustrated in figure 53 The constructs were introduced into E. coli   
JM109, and the mixture plated on 100 µg/mL ampicillin agar plates.  
 
 
PCR primer list used to create constructs 
 
Table 23 PCR primer list used to create constructs 
Table of primers used to introduce amino acid substitution into loop 3 of Cry41Aa. Substitution amino acids are 
highlighted in green. A codon change allowed the introduction of an MfeI restriction site in the PCR product.   
 
Substitution Forward Primer PCR product sequence 
F509 to  A 5’GCCCTGCCGCGTGGCCTG
G3’ 
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTGCCGCGTGGCCTGG3’ 
W511 to  A 5’GCCCTTTCGCGGCGCCTG
GTTATAAA3’ 
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGGCGCCTGGTTATAAAC3’ 
W511 to Y 5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGTATCCTGGTTATAAAC3’ 
W511 to F 5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGTTTCCTGGTTATAAAC3’ 
Y513 to A 5’GCCCTTTCGCGGCGCCTG
GTGCTAAACAATTAAGT3’ 
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGTGGCCTGGTGCTAAACAATTAAGT3’ 
F509 to 
Degenerate  
 5’ 
GCCCTTNBGCGTGGCCTGG
3’  
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTNBGCGTGGCCTGGTTATAAA3’ 
Reverse 
Primer 
5’ATTGTCCCGTACAGGTTCAAATTTAATC3’ 
MfeI Restriction 
site    
5’ CATTG3’ 
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Figure 53 Schematic representation of primer design for alanine substitutions on loop 3 of Cry41Aa. 
Wildtype pBS41A acted as template DNA to create construct. The position of each amino acid destined for substitution 
is numbered and highlighted in red in the native sequence of the plasmid. A codon change at ‘T’ allows the 
introduction of an MfeI restriction site in the PCR products.  
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Colonies with potential constructs were picked and grown in ampicillin LB broth for 2-3 
h. The suspensions were centrifuged, and pellet were mini prepped and to extract 
potential constructs. The potential constructs were profiled by Hae III digests. NEB web 
cutter software predicted the Hae III digest profiles of wildtype pBS41Aa as well as the 
constructs. The Hae III profile of each mutant loop 3 varied dependents on the type of 
substitution made.  
 
The construct W511A is used here as an example to illustrate the steps and check points 
that all constructs undertook. Table 24 lists some the predicted Hae III fragments of 
construct W511 and wildtype pBS41Aa as calculated by NEB web cutter. 
 
Hae III digest profile by NEB web  cutter 
 
Table 24 Hae III digest profile by NEB web cutter 
 lists the key fragements of the Hae III  digest profile for wiltype pBS41Aa  and the construct W511A in blue script 
Hae III fragments  Wildtype pBS41Aa (bp) pBS41Aaloop3 Construct (bp) 
1 767 767 
2 629 705 
3 558 629 
4 549 549 
5 458 458 
6 434 434 
7 340 340 
8 306 306 
9 267 267 
10 254 254 
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Figure 54 is the gel picture of mutant W511A which had a distinctive 705bp band the 
wildtype pBS41Aa band 558bp was noticeably missing. The W511A as well as other loop 
3 constructs were first identified by Hae III digests performed on mini preps of plasmids 
extracted from E. coli   JM109 cells. The constructs were subsequently confirmed by 
sequencing before preparation for subcloning into a Bt shuttle vector.  
 
 
Figure 54 Banding profie of construct in agrose gel 
 Agarose 1.5% gel of Hae III digest of plasmids extracted from JM109 colonies a lane 1, colony b in lane 2 , and colony c in lane 5 . 
lane 3 contained wildtype pBS41AA. Lane 4 contained DNA marker.   All lanes labelled with content.   
 
 
In preparation for subcloning into a Bt expression vector, the constructs and the Bt 
expression vector pSVP2741Aa underwent a double digest by BamHI and Xhol. In the 
constructs the mutant ORF2 2.5Kb fragments was isolated. In pSVP2741Aa the backbone 
1                  2                 3                 4                 5 
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7.8Kb fragment with ORF3 was isolated. Once excised, and gel purified the linear 
fragments were allowed to ligate overnight before a transformation into E. coli   JM109. 
The transformation mixtures were plated on LB agar plates prepared with 5 µg/mL 
chloramphenicol and 100 µg/mL ampicillin for overnight incubation at 37⁰C.   
 
The pSVP2741Aa backbone fragment encodes ampicillin and chloramphenicol genes, 
correctly ligated constructs ensure bacterial cell survival.  The JM109 colonies were 
picked and incubated for 2-3 h in antibiotic LB broth. The suspension was centrifuged, 
and pellets resuspended for plasmid(s) extraction. Hae III digests were performed on 
recovered mini preps.  
 
Table 25 lists the NEB web cutter predicted fragment sizes (bp) for the construct W511A 
and wildtype pSVP2741Aa. Figure 55 is the gel picture of Hae III digest profile of wildtype 
pSVP2741Aa and the W511A construct in Bt expression vector. Colony 1 and 5 both 
show the distinct 705bp band of a Hae III digest profile on construct W511A. Once 
confirmed by sequencing, all constructs were introduced into E. coli   strain GM2163 in 
preparation for Bt4D7. Transformation.   
 
The integrity of all constructs was checked as they proceeded through various 
transformations. Figure 55 confirmed that the construct W511A of colony 1 and 5 were 
indeed the same construct that was recovered after GM2613 transformations.  All loop 
3 constructs were processed and checked in the same manner as construct W511A.  
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Hae III digest profile by NEB web  cutter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 25 Hae III digest profile by NEB web cutter 
lists the key fragements of the Hae III  digest profile for wiltype pSVP2741Aa  and the construct W511A in Bt expression vector   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55 Banding profie of construct in agrose gel 
 Agarose 1.5%  gel of Hae III  digest performed on plasmids recoverd from  E. coli  strains JM109 and GM2163 colonies. Lane 1 
containe wildtype pSVP2741AA. Lane 2 DNA marker. Lane 3 conatined colony 1 extracted from JM109. Lane 4 conatined colony 1 
extracted from GM2163. Lane 5 conayined colony 5extracted from JM109. Lane 6 conatined coloy 5 extracted from GM2163.  
 All lanes labelled with contents  
 
Hae III  
fragments  
Wildtype pSVP2741Aa (bp) W511A in Bt expression vector 
Construct (bp) 
1 2469 2469 
2 1895 1895 
3 1007 1007 
4 879 879 
5 629 705 
6 598 629 
7 587 598 
8 558 587 
9 458 458 
10 434 434 
11 306 306 
1                2            3            4            5              
6 
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Sequencing confirmed all constructs were recovered from GM2163 cells. The constructs 
were introduced into Bt4D7 to express recombinant crystals. The transformation 
mixtures were incubated overnight on 5 µg/mL chloramphenicol LB agar plates at 30⁰C.   
Bt colonies were picked and incubated in 3mLs of antibiotic LB broth for 2-3 h.   
 
The 2mL solution were evenly distributed on 5 µg/mL chloramphenicol LB agar plates at 
30⁰C for a 3-day incubation. The remaining solution was centrifuged, and pellets were 
resuspended in order to extract the construct plasmids. The Bt mini preps were first 
introduced into E. coli and plated onto antibiotics LB agar plates. The lawn of cells was 
scraped, resuspended and mini prepped for the constructs. Hae III digest were 
performed on the recovered plasmids to check for the correct constructs.  
 
Figure 56 is the gel picture of various Hae III digests performed on construct W511A 
from where it was first created in JM109 cells to its GM2163 transformation to remove 
methylated DNA in order to introduce it with Bt cell where the recombinant crystal was 
expressed, to finally out of Bt cells and JM109 transform to confirm the integrity of 
construct W511A.  
 
All constructs were subject to Hae III digests and sequencing checks. After a 3-day 
incubation, samples were observed for crystals under a light microscope and thereafter 
harvested and characterised. 
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Figure 56 Banding profie of construct in agrose gel 
 1.5%agarose gel of various Hae III  digests performed on construct W511A as it journed to and out various  E. coli  and Bt cells.  Lane 
1 contanined DNA marker. Lane 2 conatined W511A extracted from JM109. Lane 3 conatined wiltype pSVP2741Aa. Lane  4 conatine 
W511A extraced from GM2163. Lane 5 conatined W511A extracted from JM109  post tranfromation with Bt4D7.    All lanes labelled 
with content.  
 
 
 
6.5.1 Characterisation and purification of alanine substitutes F509A, W511A, and 
Y514A 
Bt bacterial cells undergo a stationary phase during their cycle that is thought to be 
triggered by a shortage in nutrients. It is during this phase that protein molecules 
accumulate in the mother cell as crystal inclusions constitute 25% of the dry weight of 
the sporulated cells. Studies have indicated that much of the Bt cell’s energy is used for 
1             2             3           4          5 
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crystal and spore production which are physiological changes indicative of the stationary 
phase in the bacterium’s life cycle (Agaisse and Lereclus, 1995; Palma et al ., 2014). 
 
 Once the constructs were introduced into Bt4D7 and plated onto 5 µg/mL 
chloramphenicol agar, they were incubated for 3days at 30˚C.  Samples were observed 
under the light microscope to confirm the presence of crystals.  Electron microscopy 
images were taken of some mutant crystal and compared to wildtype Cry41Aa crystal 
made Bt4D7 strain.  It shows typical bipyramidal Bt crystals mixed with spores (figure 
57). The mutant crystals are indistinguishable from wildtype. 
 
 
 
 
 
 
 
 
 
 
 
Figure 57 Electron microscope images of Bt crystals taken after three days of incubation during the sporulation 
stage of Bacillus thuringiensis 4D7.  
Crystals and spore labelled accordingly indicated in green. Picture A=Cry41Aa (wildtype), B= F509A, C= W511A, D= 
Y514.  
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Cry41Aa wildtype and its recombinant were subjected to the two-step procedure. Figure 
58   is the SDS PAGE gel picture of crude wildtype Cry41Aa and F509A and W511A loop 
3 substitution recombinant crude samples. The blue box highlights the ˜120 KDa protein 
expressed by ORF3 gene. The yellow box highlights the ˜80-88 KDa recombinant protein 
expressed by ORF2 gene. All crystals made by the loop substitution mutants were 
observed under light microscope and then visualised in an SDS PAGE gel. All 
recombinant crude samples are comparatively indistinguishable from Cry41Aa crude 
crystals.  The loop substitute recombinants were solubilised and activated in the 
established 2 step process.  
 
 
Figure 58 7.5% SDS PAGE gel showing total crude sample of recombinant F509A and W511A of different volumes 
against crude wildtype Cry41Aa.   
The blue box highlights the 120  KDa recombinant protein expressed by ORF3 gene. The yellow box highlights the 80  
KDa recombinant protein expressed by ORF2 gene. All lanes labelled with content and volume (µL) 
 
1             2           3          4            5           6           7           8           
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Figure 59 shows the SDS PAGE gel analysis of the solubilised and activated F509A mutant 
and Cry41Aa.  The F509A mutant exhibited a faint band that represented ORF3 (˜120 
KDa) and an ORF2 (˜80-88 KDa ) in only the carbonate lane 3. Its equivalent wildtype 
Cry41Aa carbonate sample was quite faint but an ORF3 protein was apparent.  
 
Both Cry41Aa and F509A proteins showed better yield of activated toxins when 
solubilisation in carbonate and DTT as indicated by prominent bands that represented 
˜80-88  KDa protoxin protein 5 and 6. With the exception of sample in lane 3 there was 
an absence of the ˜120  KDa protein encoded by ORF3 in other samples in the gel.  
According to Yamashita et al. (2005) the ORF2 gene encodes the active toxin, thus the 
88 KDa proteins is activated by proteinase K to produce a protease resistant core of ˜64 
KDa. Here, Cry41Aa was activated by 1 mg/mL trypsin in carbonate and produced a 
prominent major protein of ˜80  KDa (or slightly less) as observed in lanes 2, 7, 8, 9, and 
10. The minor ˜60  KDa protein appeared fainter and although it was observed in gel it 
does not show well in picture.  
 
The smaller protein˜60 KDa is less concentrated than the bigger 80 KDa protein. The 
activated F509A mutant resulted in a major ˜80 KDa band as seen in lanes 8 and 10 of 
the gel picture.  The minor ˜60 KDa band was also present but very faint and clear in 
image. In Cry41Aa activated protein sample (lane 7 and 9) and of a similar concentration 
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to that of mutant F509A the minor protein is also very faint. Both F509A samples are 
shown in the lanes 9 and 10 of the gel picture.  Protease inhibitors were added post 
activation to reduce degradation of protein by native proteases.  
 
 
 
Figure 59 7.5% SDS PAGE gel of Cry41Aa and recombinant F509A in different conditions. 
Lane 1 is loaded with protein marker. Lane 2 is loaded with supernatant Cry41Aa after it was solubilised in carbonate 
pH 10.5and DTT (2.5mM).  Lane 3 was loaded with supernatant F509A after incubation in carbonate pH 10.5. Lane 4 
was loaded with supernatant Cry41Aa after incubation in carbonate pH 10.5. Lane 5 was loaded with supernatant 
Cry41Aa after it was solubilised in carbonate pH 10.5and DTT (2.5mM). Lane 6 was loaded with supernatant F509A 
after it was solubilised in carbonate pH 10.5and DTT (2.5mM). Lane 7 was loaded with activated Cry41Aa which was 
solubilised in carbonate pH 10.5. Lane 8 was loaded with activated F509A which was solubilised in carbonate pH 10.5. 
Lane 9 was loaded with activated Cry41Aa after it was solubilised in carbonate pH 10.5and DTT (2.5mM). Lane 10 was 
loaded with F509A after it was solubilised in carbonate pH 10.5and DTT (2.5mM).  
 
 
1                  2                 3               4                5            6                 7            8            
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6.5.3.  Purification of Cry41Aa loop substitute F509A, W511A and Y514A 
The activated forms of the recombinant toxins required purification. This step aimed to 
isolate the two peptides thought to be responsible for toxicity. The findings from this 
study have identified a major protein of ~ 80 KDa (or slightly less) and a minor protein 
of ~60 KDa.  
 
Anion exchange chromatography was employed to isolate each protein separately, so 
that each could be analysed for its toxicity towards HepG2 cell lines. The pI of Cry41Aa 
was calculated as 6.18 by compute pI/Mw Expasy tool.  Yamashita, et al. (2005) 
successfully separated individual peptides via anion exchange. Cry41Aa and its 
recombinants F509A, W511A, and Y514A were dialysed overnight against 10mM CAPS 
buffer at pH 10.4 in order to remove DTT and other low molecular weight contaminants. 
They were then eluted by increasing sodium chloride gradient from 0 to 1 M. The 
fractions were collected and visualised on SDS PAGE gels.  
 
Activated Cry41Aa was purified using AKTA to separate the two peptides (˜80 KDa and 
˜60 KDa) and visualised in SDS PAGE gels as shown in figure 60a. The toxin was eluted 
as a single peak (figure 60b), and the collected fractions always show traces of the minor 
60 KDa protein particularly once the fractions were concentrated in preparation for cell 
assays of toxins. In this study, it was not possible to individually isolate each of the 
protein in the wildtype toxin. However, Domanska, 2016 did manage to separate the ˜80  
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KDa protein and the ˜60  KDa peptides from each other by activating with proteinase K 
and concluded that both proteins were subject to  proteolytic activation and exhibit 
cytotoxicity to HepG2 cells (Domanska, 2016, Souissi, 2018).  
 
The recombinant toxins F509A, W511A, and Y514A were also AKTA purified and 
fractions collected as shown in figure 60-63. Similarly, to Cry41Aa gel images, the minor 
60 KDa protein band is not obvious in some SDS PAGE gels of the collected AKTA purified 
loop recombinants fractions, but they were quite evident once the sample were 
concentrated in preparation for cell assay investigations.  
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(a) 
Peak 
Concentration of eluted peptide 
 Low High 
(b) 
Figure 60 of AKTA purified fractions of activated Cry41Aa. 
 (a) SDS PAGE 7.5% gel of AKTA purified fractions of activated 
Cry41Aa. (b) AKTA elution profile of trypsin activated 
Cry41Aa.  Toxin was eluted in 10mM CAPS, pH 10.4 buffer as 
a single peak at  
~750mM sodium chloride 
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(a) 
Peak 
(b) 
Figure 61 AKTA purified fractions of 
activated recombinant F509A 
(a) SDS PAGE 7.5% gel of AKTA purified 
fractions of activated recombinant F509A. 
(b) AKTA elution profile of trypsin activated 
recombinant F509A. Toxin was eluted in 
10mM CAPS, pH 10.4 buffer as a single peak 
at ~750mM sodium chloride. 
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Conductivity 
(b) 
Figure 62 AKTA purified fractions of 
activated recombinant W511A 
(a) SDS PAGE 7.5% gel of AKTA purified 
fractions of activated recombinant W511A. 
(b) AKTA elution profile of trypsin activated 
recombinant W511A. Toxin was eluted in 
10mM CAPS, pH 10.4 buffer as a single peak 
at ~750mM sodium chloride. 
 
(b) 
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(a) 
Peak 
Figure 63 AKTA purified fractions of activated 
recombinant Y514A 
(a) SDS PAGE 7.5% gel of AKTA purified fractions of 
activated recombinant Y514A. (b) AKTA elution 
profile of trypsin activated recombinant Y415A. 
Toxin was eluted in 10mM CAPS, pH 10.4 buffer as a 
single peak at ~750mM sodium chloride 
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6.5.4. Establishing cytotoxicity of F509A, W511A, and Y514A recombinants proteins 
Preliminary experiments were carried to establish the cytotoxicity status of Cry41Aa 
toxin and its mutants towards HepG2 cell line.  Cell assays of HepG2 cell incubated with 
AKTA purified recombinant proteins were carried out. Figure 64 is the gel image of AKTA 
purified Cry41Aa, F509A, W511A, and Y514A. showing activted protein of ˜80  KDa of 
similar concentration Table 26 lists the spectroscopic analysis from  Braford protein 
assay carried out on preliminary AKTA purified Cry41Aa, F509A, W511a, and Y514A.    
 
 
 
 
 
 
 
 
Figure 64 SDS PAGE gel of purified recombinant samples used on HepG2 cell assay 
The protein concentration is optimised to approximately 100µg/mL. lane 1 was loaded with 5µL of Cry41Aa. lane 2 
loaded was loaded with 5µL of recombinant protein F509A. Lane 3 was loaded with 5µL of recombinant W511A. lane 
4 was loaded with 5µL of recombinant Y514A. the samples were used in HepG2 cell assay.  
 
 
 
 
 
225 
 
 
 
 
 
Protein concentration assay 
 
Toxin name  protein concentration  
(mg/mL)  
Cry41Aa 0.487 
F509A 0.463 
W511A 0.481 
Y514A 0.484 
 
Table 26 Protein concentration assay  
Table lists the spectroscopic analysis from  Braford protein assay carried out on preliminary AKTA purified Cry41Aa, 
F509A, W511A, and Y514A  
 
 
The toxins were incubated with HepG2 cell lines for 24 h, thereafter the cell viability was 
measured using CellTiter-Blue assay.  The assay estimates metabolic activity of cells 
using a fluorometric method. The resazurin dye is nontoxic but permeable to cells, once 
it enters viable cells it is reduced  to high fluorescent resorufin, the signal is measured 
to give an estimate of viable cells (O’Brien et al., 2000).  
 
CellTiter-Blue assay was added as an end point reagent of toxin-cell experiments and 
incubated for two hours.  Hela and HepG2 cells were seeded at different densities in a 
96 well plate at 22500 cells/well and 5000. Hela is a cancerous cell line that is not 
susceptible to  Cry41Aa and thus acted as  negative control to Cry41Aa susceptible 
HepG2 cell line (Yamashita., 2005). The Crickmore lab had previously carried out cell 
assays investigations on Cry41Aa and had used the 5000 cell/well density as a standard 
(Krishnan, 2013).  The higher cell density of 2x104 was used by Yamashita et al. (2005) 
and was used here to check the consistency of the toxicity of Cry41Aa. 
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 Cry1Ca is well characterised insecticidal 3-domain toxin which was expressed in Bt4D7 
strain in the same manner as Cry41Aa. HepG2 cells are not susceptible to Cry1Ca toxin 
and it therefore acts a negative control for 3-domain toxins made in the lab in Bt4D7. 
The HepG2 cell lines were incubated with buffer used to dialyse the recombinants as 
well as TX-100 (detergent that disrupts cell membrane) and etoposide (cytotoxin).  TX-
100 caused cell death by necrosis and etoposide by apoptosis.  These were used as 
positive controls for toxicity i.e. cell death.  
 
Figure 65 is the graphical presentation of a preliminary investigation on different cell 
densities of both HepG2 and Hela cells incubation with Cry41Aa (wildtype), the 
recombinant toxins F509A, W511A, and Y514A, as well as the positive cell death controls 
TX-100 and etoposide. At this stage the toxins were of similar concentration.  
 
The data indicated that Cry41Aa and its three loop 3 recombinant mutants F509A, 
W511A, and Y514A do not have any effect on cancerous HeLa cell at 22,500 cells per 
well. Unfortunately, a cell assay with HeLa cells at a lower density was not carried out. 
It cannot be stated that the loop 3 recombinant proteins or Cry41Aa are not toxic to 
Hela cells at a lower cell density. Cell assay studies have demonstrated that toxins can 
exert a different toxicity depending on cell densities used (Soberón et al., 2018).    
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The cell assay registered almost 0 % cell viability with TX-100 and a 75 % cell viability 
after etoposide incubation. This observation has highlighted the specificity of the 
Cry41Aa toxin and to an extent the specificity of its recombinants to HepG2 cells. 
 
The Y514A mutant has retained toxicity to HepG2 cells with a 20% cell viability in higher 
cell density compared to 40% in lower cell density.  Wildtype Cry41Aa toxins was also 
toxic to HepG2 cell lines but not as fatal as recombinant toxin Y514A with 38 % cell 
viability (higher cell density) and a 60 % cell viability in lower cell density. Microscopic 
observations of HepG2 cell lines in incubation separately with Cry41Aa and Y514A toxins 
indicated that Y514A induced immediate cellular swelling and appeared to be more 
potent than wildtype Cry41Aa. It was too soon at this stage to recognise Y514A as more 
potent compare to the wildtype Cry41Aa. The protein concentrations required 
optimisation and visualisation on an SDS PAGE gel first. A dose response experiment 
would also confirm if Y514A was indeed more toxic than wildtype Cry41Aa.  
 
Both F509A and W511A toxins were not toxic to HepG2 cell line, along with insecticidal 
Cry1Ca both these recombinants had no effect on the viability of HepG2 cells. Under the 
microscope, HepG2 cells appeared intact and viable. This loss of toxicity was evident. 
Thus, substitution in both recombinant toxins may have affected how they interact with 
HepG2 cells which resulted in the disrupted specificity or reducing cell-toxin(s) 
interactions. Alternatively, it is also possible that interactions did still occur but no longer 
led to cell death.  
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Figure 65 CellTiter-Blue 24h assay of loop 3 substitutions, F509A, W511A, and Y514A at 1.3 µM/ml on Hela (seeded at 22x104) and HepG2 (seeded at 5,000 and 22x104) cell lines at different cell 
densities. Cry1Ca act as negative controls. TX-100 and Etopside act as positive controls. 
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The effects of Cry41Aa and its loop 3 recombinant F509A were investigated for their 
effects on cell membrane damage with the use of cytotoxic markers such as CellTox-
Green cell assay kit. Cell membrane permeability can be determined when a small 
fluorescent DNA binding molecule permeates the damaged membrane and binds to the 
cell’s DNA. The fluorescent signal correlates to membrane damage and increases in a 
time-dependent manner.  
 
HepG2 cells were incubated for a period of 28 hrs and cytotoxicity was measured every 
half an hour for the first 3hrs and then every hour for the following 3hrs with reading at 
26hrs of incubation and a final reading at 28hrs of incubation. Figure 66 is the graphical 
representation of HepG2 cell membrane damage as a result of incubation with 
recombinant toxin F509A and wildtype Cry41Aa.   
 
CellTox green fluorescent signal increased proportionally as Cry41Aa incubation time 
with HepG2 cell line also increased. The fluorescent signal from HepG2 cells incubated 
with F509A remained very low even after 28hrs of incubation and is not different to 
readings from negative controls buffer and insecticidal Cry1Ca.  Low CellTox green 
fluorescent signals suggest that F509A did not induce HepG2 cell membrane damage 
and can be interpreted as lack of toxicity by F509A toxin. The echo findings from 
CellTiter-Blue analysis on F509A confirm that the single amino acid substitute mutant as 
nontoxic to HepG2 cell lines.  
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Figure 66 CellTox green assay 
Membrane damage assessments by CellTox green in HepG2 cells incubated over a 28hrs period. HepG2 cells were seeded at 25x104 cell/mL with CellTox-Green dye in a black 96-well plate. The 
next day the cells were incubated with Cry41Aa, F509A, Cry1Ca at 1.3 µM/ml concentration, lysis, or buffer. The fluorescent signal was measure at various time points post toxin addition. 
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HL-60 was reported as a susceptible cell line to Cry41Aa (Yamashita et al., 2005). In this 
study cell viability analysis has concluded that Cry41Aa as well as its loop mutant F509A, 
W511A, and Y514A, did not exhibit toxicity towards HL-60 cell lines (data not shown). 
The cytotoxicity of these mutants and Cry41Aa towards other human cell lines was 
investigated and the findings are presented in figure 67.    
 
Therapeutic drugs can readily induce apoptosis in both Burkitt’s lymphoma and non-
cancerous lymphoblastoid cells lines. Thus, investigating how Cry41Aa and its loop 3 
recombinants affect these cells lines can shed light on its specificity, particularly when 
compared to the susceptible HepG2 cell line. Cell viability was calculated in percentages 
relative to buffer values and determined by metabolic activity of viable cells. Table 27 
lists the cell lines tested.   
 
Figure 67 is a graphical representation of CellTiter Blue assay analysis of the cell lines 
listed in table 27 after a 24 h incubation with Cry41Aa F509A, W511A, and Y514A toxins. 
For statistical comparison of treatments in experiments, a Post-Hoc analysis applying a 
Bonferroni adjustment was carried out in SPSS. The cell line MUTU1 was not susceptible 
to any of the toxins tested. In the Y514A treatment of MUTU1 a high percentage of cell 
viability was recorded. It is likely that is due to human error during in the experimental 
procedure.  The Post-Hoc analysis did not find any significance to this value when 
compared with buffer only treatments.  
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BL31 cell line treatments with toxins and buffers indicated a decrease in the percentage 
of cell viability.  It is possible that the cell line was being affected by other factors such 
as contaminants or unfavourable buffer conditions. When a Post-Hoc statistical analysis 
was carried out there was no significant difference found between toxin treated BL31 
and buffer only treated cells. Microscope observations confirmed presence of detached 
and ruptured cells in buffer and toxin treated BL31 wells. The cell lines GM12878 and 
IB4 had a 100% cell viability relative to buffer after a 24 h period of incubation with the 
said toxins.  HepG2 cell lines were treated with toxins, only two toxins had a significant 
effect on percentage cell viability when compared to buffer only treated cells. Cry41Aa 
recorded 45 % cell viability and Y514A a 38 % cell viability after a 24h incubation period.  
 
List of mammalian cell lines 
 
 
 
 
 
 
Table 27 List of mammalian cell lines 
Table lists the cell lines used to investigate the cytotoxicity of Cry41Aa, F509A, W511A, and Y514A.  
Cell line Origin 
HepG2 Hepatocyte cancer 
Hela  Uterus cervix cancer 
Mutu1 Burkitt’s lymphoma (EBV positive) 
BL31 Burkitt’s lymphoma (EBV negative) 
IB4 Lymphoblastoid (B cells transfected with EBV 
GM12878 Lymphoblastoid (B cells transfected with EBV) 
HL-60 Acute myeloid leukaemia 
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Figure 67 CellTiter-Blue Assay of various cultured cell lines. 
The cells were seeded 24 h before the day of experiment at 25x104 cells/mL. Cells were treated with activated Cry41Aa and loop 3 recombinant at 1.3 µM/ml. Viability was measured as 
a metabolic activity of viable cells 24h h post-treatment. Bars with asterisks are significantly different from buffer only control cells (* p < 0.005, Post-Hoc comparison with Bonferroni 
correction).  
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The lack of toxicity by F509A and W511A highlighted the need to further investigate the 
type of residue and the position of these residues. Based on these findings the study 
carried out mutagenesis on residue substitutions in positions F509 and W511.  A number 
of degenerate substitutions were made in position F509, as well as two aromatic residue 
substitutions at position W511. 
 
6.6 Degenerate amino acid substitutions at positions 509 and 511 
The degenerate substitution at position 509 of Cry41Aa loop 3 was created using BS41Aa 
plasmid and the primers listed in table 28 below.  The PCR design for the degenerate 
substitution is detailed in figure 68 and could generate a number of substitution 
combinations. 
 
Mutagenesis carried out in loop 3 
Table 28 Mutagenesis carried out in loop 3 
Table of amino acid substitutions carried out in loop 3 of Cry41Aa. Amino acids changes are highlighted in green. 
 
Substituti
on 
Forward Primer PCR product sequence 
F509 to 
Degenerat
e  
 5’ GCCCTTNBGCGTGGCCTGG3’  5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTNBGCGTGGCCTGGTTATAAA3’ 
W511 to F 
 
 
5’GCCCTTTCGCGTTTCCTGGTTATA
AAC3’                                                               
                                                 
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGTTTCCTGGTTATAAAC3’ 
 
W511 to 
Y 
5’GCCCTTTCGCTATCCTGGATTATA
AAC3’ 
5’GGATTAAATTTGAACCTATTAAATTTGAACCTGTACGGGAC
AATTGCCCTTTCGCGTATCCTGGTTATAAAC3’ 
Reverse 
Primer 
5’ATTGTCCCGTACAGGTTCAAATTTAATC3’ 
MfeI 
Restriction 
site    
5’ CATTG3’ 
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 Figure 68 Schematic diagram of primer design for degenerate substitutions on loop 3 of Cry41Aa at position 509.  
 Wildtype pBS41A acted as template DNA to create construct. The position amino acid F509 destined for substitution 
is numbered and highlighted in red in the native sequence of the plasmid. A codon change at ‘T’ allows the 
introduction of an MfeI restriction site in the PCR products.  
 
The PCR product was gel purified and allowed to self-ligate overnight, before the first of 
many E. coli   transformations took place. The transformation mixture was placed on 
two 100 µg/mL ampicillin agar plates.  
 
Two strategies were applied to maximise the number of degenerate constructs. In the 
first strategy, individual colonies were picked from one ampicillin agar plate. A number 
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of Rapid Size Screens (RSS) of colonies as well as wildtype pBS41Aa were carried out, 
this gave a quick assessment of which colonies may have potential degenerate construct 
when compared on an agarose gel to wildtype pBS41Aa. Once the numbers of potential 
colonies were narrowed down, the colonies underwent a Hae III digest. 
 
 The Hae III digest profiles of some constructs were similar to that of wildtype pBS41Aa 
and were indistinguishable on gel from wildtype.  Thus, individual degenerate 
substitutions were confirmed by sequencing. Once identified a double digest with 
BamHI and Xhol was carried out to isolate the mutant OR2(s). These were ligated 
overnight with pSVP2741Aa back bone fragment 7.8kb that encode ORF3 to create 
constructs that can be expressed in Bt cells.  
 
The second strategy involved a mass scrape of colonies from the remaining plate. 1.5mL 
of distilled water was added to scrape any colonies, the solution was centrifuged, and 
the pellet was resuspended in distilled water followed by a double BamHI-XhoI digest to 
isolate the 2.5Kb fragments that encode the mutant ORF2(s). These were ligated over 
night with the 7.8kb backbone fragments of pSVP2741Aa plasmid to create a Bt 
expression vector before an E. coli transformation. At this stage the constructs undergo 
a process of selection by RSS. A construct with an RSS size that is identical on an agarose 
to wildtype pSVP2741Aa was selected for further analysis.  
 
237 
 
 
 
 
 
Figure 69 is the picture of agarose gel of RSS carried out in colonies with potential 
degenerate construct. Constructs are in Bt expression vector and were extracted from 
colonies 8 to 21. Of those colonies 10, 11, 12, 13, 14, 15, 16, 17, 20 and 21 showed an 
RSS size similar to wildtype pSVP2741Aa. 
 
 These were subject to Hae III digests and later confirmed by sequencing. Confirmed 
degenerate constructs in Bt expression vectors were introduced into E. coli GM2163 to 
remove methylated DNA, before a transformation with Bt4D7 where they incubate for 
3 days at 30˚C to allow for sporulation and production of crystals.  Constructs were 
extracted from Bt cells for a final transformation into E. coli cells. This final step involved 
further Hae III digests to confirm the integrity of constructs.  
 
Figure 70 is the gel picture of construct F509S and shows the Hae III digest profile of 
F509S where it was first identified and extracted from colony 4. The construct shares 
the same digest profile as wildtype pSVP2741Aa plasmid was hence it was in disguisable 
on gel. The construct was confirmed via sequencing.  The gel pictures confirmed the 
construct as it journeys through different bacterial host cells.   
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Figure 69 RSS analysis of colonies with potential construct 
Double deck 1% agarose gel showing RSS on colonies 8 to 21 harbouring degenerate substitution construct after mass 
scale ligation of 2.5kb fragments with 7.8kb backbone of pSVP2741Aa. Upper deck was loaded with colonies 8 to 14 
with Wildtype pSVP2741Aa labelled accordingly in the gel.  Lower deck was loaded with colonies 15 to 21 with 
pSVP2741Aa labelled in lane. Colonies with potential degenerate construct and similar sizes to wildtype are circled. 
 
 
 
 
 
 
 
 
 
Figure 70 Banding profie of construct in agrose gel 
Agarose 1.5% gel of Hae III digest profiles of construct F509S as the constructs are hosted by different E. coli   strains 
lane 1 contained control pSVP2741Aa. Lane 2 contained colony 4 extracted from JM109. Lane 3 contained construct 
F509S extracted from GM2163 prior to transformation with Bt4D7. Lane 4 contained construct F509Sa extracted from 
JM109 after extraction from Bt4D7. All lanes labelled with content. 
1               2                 3            4               5 
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The following loop 3 mutants were created F509A, F509Y, F509S, F509C, F509, W511A, 
W511Y, W511F, Y513A and their crystals were observed under light microscope. Figure 
71 is the electron microscope image of some recombinant crystals.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 71 Electron microscope images of Bt crystals taken after three days of incubation during the sporulation 
stage of Bacillus thuringiensis 4D7.  
Crystals and spore labelled accordingly; some spores are circled in green. Picture A=F509L, B= F509W, C= F509S.  
 
Spore 
Crystal 
Crystal 
Crystal 
Crystal 
Spore  
A 
B 
C 
C 
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A mass production of all loop recombinant proteins was carried out. A total of 10 mLs of 
crude protein of each recombinant was made and solubilised in 50mM sodium 
carbonate pH 10.5 and DTT (2.5mM) in two 5mLs batches. After an hour in a 37˚C water 
bath and occasional vortex, the samples were centrifuged, and the supernatants were 
recovered. Figure 72 illustrates the SDS PAGE gel analysis of the efficacy of the mass 
production of loop recombinants protein. Once solubilised the samples were 
centrifuged to separate the protoxins in the supernatant from the pellet.   The absence 
of proteins in lanes 2 and 3 was suggestive of the efficacy of the mass solubilisation 
event. The solubilised recombinant F509L and F509Y proteins in lane 4 and 5 are 
indistinguishable from solubilised Cry41Aa in lane 1 and 4. All recombinant proteins 
were subject the same solubilisation, activation and purification procedure as wildtype 
Cry41Aa. Due to the large volume of proteins for purification the samples were purified 
by column gel filtration.  
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Figure 72 7.5% SDS PAGE of mass scale solubilisation of Cry41Aa, F509L and F509Y. 
 10mLs of crude protein of each recombinant was made and solubilised in 50mM sodium carbonate pH 10.5 and DTT 
(2.5mM) in two 5mLs batches in incubated in a 37˚C water bath for 1 h. Centrifugation separated pellets from 
supernatants, and both were analysed in SDS PAGE gel. Lane 1 was loaded with solubilised Cry41Aa in carbonate pH 
10.5and DTT (2.5mM). lane 2 was loaded with F509L pellet sample after supernatant was removed. Lane 3 was loaded 
with F509Y F509L pellet sample after supernatant was removed. Lane 4 was loaded with solubilised Cry41Aa in 
carbonate pH 10.5and DTT (2.5mM). lane 5 was loaded with was loaded with solubilised F509L in carbonate pH 
10.5and DTT (2.5mM). lane 6 was loaded with solubilised F509Y in carbonate pH 10.5and DTT (2.5mM). lane 7 was 
loaded with protein marker. 
 
A stock of 10 mg/mL of trypsin in 50mM sodium carbonate pH 10.5 was made and added 
to the supernatant samples to activate the recombinant toxins. This resulted in a final 
trypsin concentration of 1 mg/mL.  Activated recombinant toxins were removed from 
the 37˚C water bath and prepared for dialysis, purification and optimisation of the 
protein(s) concentration relative to each other. After activation by trypsin, protease 
inhibitors were added at end as it was confirmed that protease inhibitors significantly 
slow the rate of Cry41Aa  degradation at temperature above room temperature 
(Domanska, 2016).  Table 29 summarise the mutagenesis carried out in loop 3 of 
Cry41Aa.  
 
 
1                  2                 3               4                     5              6                 7          
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Mutagenesis carried out in loop 3 
 
Table 29 Mutagenesis carried out in loop 3 
Table of amino acid substitutions carried out in loop 3 of Cry41Aa. Native codons of amino acids target for 
mutagenesis are highlighted in green. 
 
 
 
6.6.1. Optimisation of recombinant proteins concentration 
In preparation for cell assay analysis, protease inhibitors were added to activate the 
toxins. The activated recombinant toxins were concentrated with viva spin tubes.  
 
A stock of each was made with a concentration of 150 µg/mL according to Braford 
protein assay. This is equivalent to 0.197 µM/ml. The stock samples were visualised on 
                                  
Type of substitutions 
Native residues of Cry41Aa loop 3 
   503V     R     D   N   C     P   F    A    W    P   G   Y    K    
Q   L 517 
5’GTA CGG GAT AAT TGC CCT  TTC GCG TGG CCT GGT TAT AAA 
CAA TTA 3’ 
1st 
mutagenesis  
Alanine                                               GCC        GCG              GCT 
 
2nd 
mutagenesis 
Degenerate at 
position 509 
                                               TNB 
                                               TAG 
                                               TTT 
                                               TGC 
                                               TCC 
                                           TCT 
                                               TAT 
                                               TAC 
                                               TTG 
                                               TGG 
                                               TGT 
 
3rd 
mutagenesis 
Phenylalanine/ 
Tryrosine at 
position 511  
                                                                  
                                                               TTT 
                                                               TAT 
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three SDS PAGE gels and analysed by Image Lab software. Figure 73 is the picture of one 
of the three SDS PAGE gels. All recombinants displayed both the major ˜80 KDa protein 
and the minor ˜60 KDa protein. The gel showed that the ˜80 KDa (slightly less) bands 
were of identical intensity across all recombinant mutants and wildtype Cry41Aa toxin. 
The 60 KDa bands have more variation in their intensity and hence it was not possible 
to separate the two proteins and optimise the minor band intensity across all 
recombinants. The recombinants were similar to Cry41Aa and were  indistinguishable 
on an SDS PAGE gel (figure 64), which suggest that they likely have a similar protein 
folding pattern (Krishnan et al., 2017).  
 
Image lab software was employed to analyse the band intensities and was able to 
calculate and quantify a band relative to a reference or a control band. The reference 
band was given a value of 1, other bands compared to it were given a value that was 
either higher or lower than 1. In this case the two reference bands are the major (~80 
KDa) and minor (~60 KDa) of Cry41Aa with a concentration of 150 µg/mL or 0.197 µM/ml 
as determined by Braford protein assay.    
 
Table 30 lists the values for band(s) densities for all activated recombinant toxins with a 
concentration of 150 µg/mL (or 0.197 µM/ml) relative to Cry41Aa bands of the same 
concentration.  The average values of the major bands were consistent and close to the 
Cry41Aa control band values.  The minor band(s) values showed slight variation 
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compared to its Cry41Aa minor control band. Hence, in this study it was not possible to 
separate the major and minor bands to calibrate the bands independently. The software 
also calculated the molecular weight of proteins based on information gathered against 
the protein marker of the same gel.  
 
Table 31 shows the average molecular weights of each activated recombinant toxin and 
Cry41Aa toxin. The results were consistent with the control activated Cry41Aa. In 
addition to the following 150 µg/mL ((or 0.197 µM/ml) concentration optimised 
recombinant toxins F509L, F509Y, F509A, Y514A, F509W, F509S, W511A, and extra loop.  
The recombinant toxin W511F was also made. The concentration of this recombinant 
was also optimised to a concentration of 150 µg/mL according to Bradford protein assay. 
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Figure 73 calibrated concentrations of activated recombinant toxins. 
SDS PAGE 7.5% gel of stock samples of 150 µg/mL (or 0.197 µM/ml) of activated recombinant toxins are labelled on the gel. Cry41Aa acts as the control sample.  All lanes labelled with content. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Marker          F509L       F509Y      F509A       Y514A          F509W       F509S      W511A   Cry41Aa     Extra loop 
80KDa 
60 
1                            2                        3                       4                        5                      6                       7                     8                      9                    10 
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Protein concentration analysis of SDS PAGE gel with recombinant toxins 
 
 
 
 
 
 
 
 
 
Table 30 Protein concentration analysis of SDS PAGE gel with recombinant toxins  
Image Lab quantification of band density of 150 µg/mL of activated recombinant toxins relative to Cry41Aa. 
 
 
Relative qualification of recombinant toxin concentration from SDS PAGE gel bands density against Cry41Aa (150µg/mL or 0.197 µM/ml) 
 
 
Recombinant toxin 
 
Upper major band density 
 
Lower minor band density 
Cry41Aa control reference 
(150µg/mL or 0.197 µM/ml) 
Gel 1 Gel2 Gel3 Average Gel 1 Gel2 Gel3 Average 
1 1 1 1 1 1 1 1 
F509A 0.627491 0.799602 1.005402 0.810831667 1.169772 0.786371 0.864311 0.940151333 
F509W 0.840239 1.335881 0.666376 0.947498667 0.660156 0.881126 0.724691 0.755324333 
F509L 0.946215 0.811198 0.811224 0.856212333 1.123384 0.934124 0.925462 0.994323333 
F509S 0.893227 0.665652 1.021243 0.860040667 1.341398 0.764116 0.844891 0.983468333 
F509Y 0.736255 1.420251 0.733981 0.963495667 1.272967 0.736255 1.123241 1.044154333 
W511A 1.272112 0.767586 0.772999 0.937565667 0.983826 1.180234 0.867586 1.010548667 
Y514A 0.636653 0.837145 1.121344 0.865047333 0.710095 0.725442 0.813021 0.649519333 
extra loop 0.992829 1.118322 0.404306 0.838485667 1.348998 0.803918 0.901101 1.018005667 
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Molecular weight analysis of SDS PAGE gel with recombinant toxins. 
 
 
Table 31 Molecular weight analysis of SDS PAGE gel with recombinant toxins. 
Image Lab quantification of molecular weight of 150 µg/mL (or 0.197 µM/ml) of activated Cry41Aa and recombinant toxins 
 
 
Relative qualification of recombinant toxin molecular weight (KDa) from SDS PAGE gel bands      
 
Recombinant toxin 
 
Upper major band KDa  
 
Lower minor band KDa  
 
Cry41Aa  
Gel 1 Gel2 Gel3 Average Gel 1 Gel2 Gel3 Average 
89.44272 82.50056 83.89433 85.2792 68.36135 63.29883 66.34767 66.0026 
F509A 86.3987 83.78 83.28477 84.4878 69.05066 65.01564 65.36828 66.4782 
F509W 86.06694 89.69982 83.58999 86.4523 67.67858 70.03068 66.17343 67.9609 
F509L 86.3987 88.21282 83.89633 86.1693 67.67858 68.82748 66.98848 67.8315 
F509S 85.40723 88.30491 85.44495 86.3857 66.33375 70.07084 67.39977 67.9348 
F509Y 86.3987 87.68822 85.82213 86.6364 65.22731 65.67911 68.64884 66.5184 
W511A 86.3987 84.46567 85.75809 85.5408 64.67858 65.32076 66.54944 65.5163 
Y514A 85.73645 82.51252 86.07237 84.7738 67.31151 65.67707 66.78228 66.5903 
extra loop 84.75258 81.02807 87.34107 84.3739 65.89144 63.48475 66.42312 65.2664 
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6.6.2. Dose response of HepG2 cells treated with Cry41Aa recombinant toxins   
A dose response analysis was carried out to assess the effects on cell viability after 
incubation with Cry41Aa and its recombinant mutants. The protein concentration of 
Cry41Aa and its mutants was optimised and visualised on SDS PAGE gel (figure 73) The 
concentration of the toxins in the medium of the 96 well plate was as follows 0.197, 
0.131, 0.0657, 0.0263, 0,013, 0.006, 0.002 µM/ml.   
 
Figure 74 is the graphical representation of the dose response CellTiter-Blue assay of 
HepG2 cell line incubated for 24 h with Cry41Aa as well as loop recombinant toxins. The 
following recombinant toxins F509A, F509L, F509S, F509W, F509Y, W511A, and the 
extra loop did not exhibit any cytotoxicity to HepG2 cells. This is based on CellTiter-Blue 
fluorescent assay where percentage cell viability is 100% relative to buffer regardless of 
toxin concentration.  For statistical comparison of treatments in dose response 
experiments a Post-Hoc analysis applying a Bonferroni adjustment was carried out in 
SPSS. 
 
Only Cry41Aa and the recombinant Y514A appear to be cytotoxic to HepG2 cell line.  
Here the fluorescent signal, indicative of the percentage of viable cells compared to 
that of buffer, was significantly less. In cells treated with the highest Y514A and 
Cry41Aa toxin concentrations (0.197 µM/ml) a significant reduction was noted in 
percentage of viable cells. Treatments with toxin concentration 0.197, 0.131, 0.0657, 
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0.0263 µM/ml of Cry41Aa and Y514A were statistically significantly when compared to 
treatments with buffer only cells.  Furthermore, microscope observations confirmed 
that swelling of cells was observed within the first 10 min of incubation with Cry41Aa 
and Y514A.   
 
Figure 75 illustrated a dose response curve for HepG2 cells treated with Cry41Aa and 
Y514A with the same concentration range (0.197 to 0.00263 µM/ml) for 24 h in order to 
estimate the half maximal lethal concentration (LC50) of both toxins. The LC50 values 
were determined by probit analysis using SPSS software. Cry41Aa had an LC50 value of 
0.061 µM/ml, and Y514A had an LC50 value of 0.048  µM/ml. Y514A appears to kill faster 
with clear indication of cell swelling within 10 min of exposure to toxin mutant. The Post-
Hoc analysis supports finding that the lower cell viability observed with recombinant 
Y514A treatment is significantly less when compared to treatments with Cry41Aa. This 
supports the theory that Y514A is likely more toxic than its wildtype Cry41Aa toxin. 
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Figure 74 Dose response effects of recombinant toxins on HepG2 cells using CellTiter-Blue assay.  
The cells were seeded 24 h before the day of experiment at 25x104 cells/mL. Cells were treated with activated Cry41Aa, loop 3 and extra loop recombinants of different concentrations. Viability 
was measured as a metabolic activity of viable cells. Reading was taken 24 h post treatment with recombinant proteins. Bars with asterisks are significantly different from buffer only control 
cells (* p < 0.005, Post-Hoc comparison with Bonferroni correction).  
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Figure 75 Dose response curve for HepG2 cells treated with Cry41Aa and recombinant Y514A. 
 HepG2 cells were seeded at the density of 25x104 cells/mL.  The following day cells were incubated with different concentrations of Cry41Aa and the recombinant toxin Y514A.  Fluorescence was measured after 24 h 
using CellTitre-Blue. LC50 was calculated using SPSS probit software Cry41Aa EL50= 0.061 µM/ml, Y514A LC50= 0.048 µM/ml. 
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The W511Y mutant did not produce a protease resistant core, however activated 
recombinant W511F did form a protease resistant core. The mutant W511F was 
engineered to investigate the effects of phenylalanine residue on toxicity. The protein 
concentration of this mutant was not optimised at the same time as the other 
degenerate residue substitution loop mutants, its concentration was calculated using 
Bradford protein assay.  The effects of W511F on HepG2cell viability percentage were 
presented in graph as histograms in figure 76 after a 24 h incubation with W511F and 
relative to cell viability percentage in buffer. Recombinant toxin W511F was toxic to 
HepG2 cells. However, it is the protein concentration was not optimised with the 
cytotoxic Y514A and Cry41Aa on the same protein SDS PAGE gel.  
 
 
 
 
Figure 76 CellTiter blue assay of loop 3 recombinants   
24hr CellTiter-blue assay of loop 3 substitutions W511F on HepG2 (seeded at 5,000 and 22x104). TX-100 act as positive control.  
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6.6.3. Western blot application to investigate p38 MAP kinase phosphorylation in 
HepG2 cell lines after incubation with mutant F509A  
The loop 3 recombinant F509A has not shown any cytotoxic characteristics towards 
HepG2 cells. The reason behind this lack of toxicity by this single alanine substitute is 
unknown. The substitution may have induced loss interactions with HepG2 cell. It also 
possible that interaction continues to take place, but it no longer exerts the same effect, 
and thus does not that result in cell death.  At the time of ligand blot experiments F509A 
was the only nontoxic mutant to have undergone two assays to assess its effects on 
HepG2 cells. CellTiter-Blue assay concluded that HepG2 cells were not affected after 
treatment with F509A. CellTox green assay indicated that nuclear membrane of HepG2 
cells remained intact after F509A treatment and there was no different to buffer only 
treated cells.   
 
HepG2 cellular response to F509A was investigated using ligand blotting and 
electrophysiology. It was carried out in an attempt to better understand the lack of 
toxicity of F509A and thus gaining a better understanding of the specificity of Cry41Aa. 
A cellular response by a target cell as a result of  pore formation toxin can vary but one 
the commonly employed mechanism is the phosphorylation of p38 mitogen- activated 
protein kinase (MAPK) (Ratner et al., 2006).  The MAPK protein family is made up of 
highly conserved serine-theronine kinases that are activated in response to extracellular 
stresses such as osmotic shock or DNA damage. One of the subgroups of the MAPK 
protein family is p38. When activated, p38 phosphorylates a number of proteins that 
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include cytokines, nuclear transcription factors and extra cellular receptors (Zarubin and 
Han, 2005).   
 
A number of Cry toxins have been found to activate p38 pathways. These include p38 
pathways induced by Cry5B toxin in C.elegans, as well as M. sexta and A.aegypti treated 
with Cry1Ab and Cry11Aa toxins (Cancino-Rodezno et al., 2010; Huffman et al., 2004; 
Porta et al., 2011). Domanska,  confirmed that Cry41Aa induces p38 MAP kinase 
phosphorylation in HepG2 cells  (Domanska, 2016). 
 
Western blotting was carried out to examine if non-cytotoxic loop 3 recombinant F509A 
induced phosphorylation of p38 in HepG2 cell.  Figure 77 shows a western blot prepared 
from HepG2 cell extract incubated with the different solutions. Sodium arsenite is a 
toxin known to induce p38 phosphorylation and is used here as a positive control, 
Cry1Ca an insecticidal 3-domain toxin is used as a negative control like the buffer. 
Cry41Aa is toxic to HepG2  (Krishnan et al., 2017), and loop 3 F509A mutant toxin which 
has so far not shown any signs of toxicity towards HepG2. CD59 is a loading control. It 
suggested that sodium arsenite, Cry41Aa and F509A all produced a signal for p38 MAP 
phosphorylation. 
 
 A positive signal for F509A is unexpected as cell viability from CellTiter-Blue assay and 
membrane damage by CellTox-Green cell assay concluded that F509A is not toxic to 
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HepG2 cell lines. It is possible that F509A interacts with HepG2 cells causing a signal, but 
it also possible that this interaction is insufficient or unstable and does not result in cell 
death. Krishnan et al. (2017)  had suggested that  Cry41Aa  has a similar mode of action 
to insecticidal 3 domain Cry toxins, and thus  may cause pore formation in the 
membranes of HepG2 cells causing a p38 signal activation (Krishnan et al., 2017). 
However, it is the stability, size, and the time period that these pores remain open that 
may dictate if the cells die or recover. Western blots of HeLa cells and HL60 incubated 
with the F509A and Cry41Aa were carried out. Western blots of Hela cells did not detect 
any p38 MAP kinase signal (data not shown). However western blots of HL60 cell 
extracts indicated that both Cry41Aa and its mutant F509A did induce p38 MAP kinase 
phosphorylation as shown in figure 78. This finding is not reflective of cell viability data 
which indicated that both Cry41Aa and its mutants were not toxic to HL60 cell lines.  
 
 
 
 
 
 
 
Figure 77 western blot analysis HepG2 cell extracts 
 Western blot of HepG2 cell extract treated with : Lane 1 sodium arsenite (0.5mM) lane 2 buffer, lane 3 Cry1Ac 
(15µg/mL),  lane 4 F509A (15µg/mL) , and lane 5 Cry41Aa (15µg/mL), cells were lysed in NP-40 15 min after toxin 
treartment. 10µg of protein were loaded in each lane and after SDS-PAGE proteins were subjected to western blot 
analysis fro the detection of phosophorlayted p38 and CD59 (loading control).  
1                2                 3             4                   5                              
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Figure 78 western blot analysis of HL60 cell extract 
western blot of HL60 cell extract treated with: Lane 1 sodium arsenite (0.5mM).  lane 2 Cry1Ac (15µg/mL).  lane 3  
buffer, lane 4 Cry41Aa (15µg/mL),  , and lane 5 F509A (15µg/mL),  cells were lysed in NP-40 15 min after toxin 
treartment. 10µg of protein were loaded in each lane and after SDS-PAGE proteins were subjected to western blot 
analysis fro the detection of phosophorlayted p38 and CD59 (loading control).  
 
 
 
 
6.6.4. Electrophysiology application to investigate the interactions between HepG2 
cell lines and the loop 3 recombinant F509A  
Electrophysiology was employed to study the formation and type and of pores in 
membranes. The following section explores the effects of Cry41Aa and F509A on whole 
cell patch clamping and on an artificial planar lipid bilayer (PLB) membrane. Whole cell 
patch clamping technique uses cells whilst PBL uses artificial membranes. The following 
cell assay work was carried out by Barbra Domanska under the supervision of Prof 
Michelle West, university of Sussex, UK. Electrophysiology work was carried out by 
Barbra Domanska and Eva Fortea under the supervision of Prof Jean-Louis Schwartz, 
university of Montreal,Canada. 
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6.6.5. Whole cell patch clamping  
Whole patch clamping is techniques discovered in 1976 used to study electrophysiology 
of membranes and ion channels (Neher and Sakmann, 1976).  The nature of the ion 
channel formed in excised membrane patches or intact membranes is discoverable 
when recordings of the current passing through the membrane are made. In essence, 
ion channels are pores defined by their ability to conduct a current. The easier a current 
pass through a pore the more efficient the pore or ion channel is.   In order to successful 
apply the patch clamp technique the membrane must first become electrically isolated 
from the external buffer by placing a glass pipette with electrolyte solution onto the 
membrane.  An electrode attached inside the pipette records current flow in the 
membrane, the signal is picked up by an amplifier and data recorded.  
 
Whole cell patch collects data on multiple channels on a given cell membrane. Here, the 
pipette sucks the intact cell membrane rapturing it but without disrupting contact 
between the outside of the cell membrane and rim of the pipette creating a seal. 
Eventually, the buffer in the pipette equilibrates with the cell cytoplasm.  Currents data 
on whole patch carried out on whole cells tend to be big due the abundant number of 
channels opening simultaneously. Although whole patch clamping can record 
macroscopic currents in whole cell membrane, it cannot give detail on the nature and 
type of pore present.   
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Whole cell patch clamping was used to study macroscopic currents in HepG2 cells during 
incubation with Cry41Aa and loop 3 recombinant F509A. Data was collected prior to 
toxin addition and every 5 min thereafter for 20 min post toxin addition. The resting 
membrane potential of hepatocytes ranges between -30 to -40mV as a consequence of 
high basal chloride conductance (Moule and McGivan, 1990). KCl buffer, which consisted 
of 140mM KCl, 1.1 mM MgCl2, 0.1mM EGTA, and 10mM HEPES, pH 7.4, was added to 
the pipette and a holding potential of -20mV was applied so it was close to the resting 
potential of HepG2 cell membrane. NaCl buffer was added to the bath as the 
extracellular solution. A set of 17 one second depolarising step potentials (from -20 to 
+140mV from a holding potential of -20mV) were applied to initiate currents.   
 
Figure 79 and 80 are graph representations of whole patch cell clamping on HepG2 cell 
membranes after exposure to cytotoxic Cry41Aa (figure 79) and its non-cytotoxic loop 3 
recombinant F509A respectively (figure 80). The experiment aimed to measure the 
current that is exerted as a result of ion channels or pores opening as a consequence of 
toxin activity inHepG2 membrane. Three whole cell patch experiments were carried out 
on each toxin in order to obtain a mean value as shown in figures 73 and 74.  It is clear 
that as the voltage increased current also increased in Cry41Aa treated HepG2 cells 
(figure 79). Significant current data is recorded for 15- and 20-min time points, however 
current increase as early as 10 min after toxin addition.  
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Figure 80 shows the effect of an electrical current on HepG2 cell membrane after 
exposure to F509A. It is clear that there is no elevated current recorded as a 
consequence of F509A toxin despite increased voltage and exposure time. The slight rise 
in current post a voltage of 70mV is due to the increase in voltage. This suggests that 
either F509A does not induce the significant opening of channels or that the effect is 
short lived rendering it unstable to have any significant effect on the membrane. This is 
consistent with permeability assay for F509A (cell Tox green, Figure 66 chapter 6.6.5) 
where results indicated that F509A had caused little damage to HepG2 cell membrane. 
This suggests inhibition of binding or ineffective pore formation by F509A. 
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Figure 79 whole cell patch recording from a time course experiment of HepG2 cell exposed to Cry41Aa.  
HepG2 cells were seeded at the density of 5x104 cells/mL on the glass coverslip inside the 35mm petri dish. The following day whole cell patch clamp data was recorded at 0, 5, 10, 15, and 20 
min after exposure with Cry41Aa (12µg/mL) as well as NaCl bath solution.  Currents were induced by 1 s lasting set of 17 depolarising potentials from -20 to 140mV form holding potential of -
20mV. Error bars indicate the standard error of the mean. The lines represent the mean currents from three different whole patch cell experiments 
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Figure 80 whole cell patch recording from a time course experiment of HepG2 cell exposed to F509A.  
HepG2 cells were seeded at the density of 5x104 cells/mL on the glass coverslip inside the 35mm petri dish. The following day whole cell patch clamp data was recorded at 0, 5, 10, 15, and 20 min after exposure with 
F509A (12µg/mL) as well as NaCl bath solution.  Currents were induced by 1 s set of 17 depolarising potentials from -20 to 140mV form holding potential of -20mV. Error bars indicate the standard error of the mean. 
The lines represent the mean currents from three different whole patch cell experiment
-1000
0
1000
2000
3000
4000
5000
-20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
C
u
rr
en
t 
(p
A
)
Voltage (mV)
whole cell patch clamping on HepG2 cell membrane  after exposure to F509A
0 min
5 min
10 min
15 min
20 min
262 
 
 
 
 
 
6.6.6. Single channel activity in planar lipid bilayers 
Single channel activity can be investigated using an artificial planar lipid bilayer (PLB).  
An artificial phospholipids bilayer is prepared by using two identical aqueous solutions 
which represent the inner (inside the cell) and outer (outside the cell) regions of a 
membrane. This technique allows investigations to take place where the  buffer and lipid 
arrangements can easily be manipulated due to the simplicity of this cell membrane 
model (Mueller et al., 1963). In vertebrate cells, the membrane is made up of 
phosphatidylcholine (PC) which is present in the external side of the membrane, 
phosphatidylethanolamine or PE which is present in the internal cytoplasmic side of the 
membrane and cholesterol adds to the fluidity of the membrane.  
 
The experiment was set up as follows, two chambers known as cis and trans were 
separated by a lipid membrane which was pre-painted onto a plastic divider placed 
between the chamber. 1mL of buffer (150mM KCl, 1mM CaCl2, 10mM HEPES, pH 7.5) 
was equally distributed between both cis and trans chambers. Traces of any current 
were checked for 30min before any of the toxins were added to ensure absence of 
channel activity. The toxins Cry41Aa or F509A were added to the cis chamber and 
activity was recorded at different applied voltages.   
 
Three different experiments were carried out on both Cry41Aa and F509A.  Electrical 
conductance is the measure of the ease at which a current pass through and this 
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measure was calculated to indicate the presence and effectiveness of pores.   Figure 81 
illustrates examples of traces recorded in planar lipid bilayer after application of Cry41Aa 
and F509A at a positive voltage. Any trace above zero indicated the opening of a 
channel. There is an obvious steady trace for Cry41Aa indicating that pores are 
structurally intact and functionally efficient. This is in contrast to F509A trace which 
remains close to zero and is not consistent suggesting that pores here were fragile and 
unstable.   
 
 
 
 
 
 
 
 
 
 
 
264 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 81 sample of a single channel trace recoding in planar lipid bilayer after toxin application at the positive voltage. 
 Single channel activity was recorded at +100mV (upper and lower traces) from PLB in KCl buffer after addition of Cry41Aa or F509A to the cis chamber. Records were filtered at 200Hz. The trace 
is representative of the three experiments   
 
 
 
 
Planar Lipid Bilayers Trace 
Cry41Aa (8µg/ml) at +100mV 
F509A (8µg/ml) at +100mV 
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 Approximately 20-25 current jumps were averaged for each experiment and analogous 
conductance values were grouped together. Data were plotted on a graph and a mean 
conductance within the group was read from a slope of linear regression.   
 
Figure 82 is a graphical representation of the three experiments for Cry41Aa and the 
calculated mean values deduced from the linear regression points on the graphs and 
were carried out to investigate single channel activity as a consequence of Cry41Aa 
toxin.  The data is consistent throughout the three experiments. A number of 
conductance values were recorded.  
 
There is an indication that the two lowest conductance values may relate to highest 
conductance value.  The two lowest conductance values roughly add up to the highest 
value.  For example, in experiment I, the two lowest conductance values are 91 and 
131pS which add up to the highest recorded conductance value of 220pS. It is possible 
that the lowest conductance values are due to two different channel populations that 
open and close independently, but when they are opened simultaneously, the highest 
conductance value is recorded. 
 
Figure 83 is a graphical representation of the results of three experiments and the 
calculated mean values deduced from the linear regression points on the graphs carried 
out to investigate single channel activity as a consequence of loop 3 recombinant F509A 
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toxin.  The conductance here is more diverse that for Cry41Aa. There are four different 
conductance values for each experiment suggesting the presence of more than one 
channel population.   
 
There are no obvious patterns linking low conductance values with high conductance 
values in the same experiment and experiment II has quite a high value of conductance 
of 470pS. This is almost double the conductance value of the experiment I and III and it 
is not clear whether the PLB in experiment II has twice as many pores. No rectification 
was observed for data collected on both Cry41Aa and F509A PLB experiments as 
conductance did not change with the application of different voltages.  
 
To investigate the type of ions that pass through the pore in i.e.  the selectivity of the 
pore, chemical conditions were changed in the cis chamber. The concentration of KCl 
was increased to 450mM to create a concentration gradient; current was measured 
after this change to calculate whether the pore is catatonic or ionic.  
 
The experiment was carried out thrice for each toxin. Figure 84 illustrates the selective 
conductance of the pores formed by Cry41Aa and F509A. Goldman-Hodgkin Katz 
potential equation was used to calculated the selectivity which states that ion 
permeability across a membrane is linked to reversal potential (Vr)(Goldman, 1943).  
The reversal potentials of Cry41Aa and F509A are calculated in table A and B of figure 
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84; Vr represents the potential at which there is no current passing through a pore.  Both 
Cry41Aa and F509A maintained similar pS range for channel conductance in 
asymmetrical in symmetrical chamber conditions. However, the reversal potential shifts 
to -10.97 mV (± 1 mV) for Cry41Aa and a similar shift of Vr is observed for F509A with -
11.5 mV (± 0.43 mV). This shift indicates that pores formed by Cry41Aa and F509A in the 
artificial PLB membrane tend to be more selective to cations.  A small PK+/PCl-   is also 
observed with both toxins where Cry41Aa has a PK+/PCl-    value of 2.47(± 0.23), and F509A 
has a PK+/PCl-    value of 2.86 (±1.92). The large standard of error calculated for F509A in 
its PK+/PCl-   value is due to the instability of the trace as a result of instability and fragility 
of pores formed by the loop 3 recombinant F509A. 
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Cry41Aa: PLB single channel current activity 
   
-40
-30
-20
-10
0
10
20
30
40
-100 -80 -60 -40 -20 0 20 40 60 80 100
C
u
rr
en
t 
(p
A
)
Voltage (mV)
Experiment II
193 ps
115 pS
75 pS
Figure 82 single channel –voltage relationship for Cry41Aa in planar lipid bilayer.  
Current-voltage characteristics of single channel activity in 150/150 mM KCl (cis/trans) buffer (n=20-25) at different voltage after Cry41Aa (8µg/ml) was added to the cis chamber. Conductance was calculated (G=I/V) and 
data points fitted by linear regression. Experiment I: mean conductance values were deduced at the slopes of the linear regression on the data points as 91, 131, and 220pS. Experiment II: mean conductance values were 
deduced at the slopes of the linear regression on the data points as75, 115, and 193pS. Experiment III: mean conductance values were deduced at the slopes of the linear regression on the data points as 79, 122, and 196 
pS.  Data curtesy of Domanska, 2016 
 
-40
-30
-20
-10
0
10
20
30
40
-100 -80 -60 -40 -20 0 20 40 60 80 100
C
u
rr
en
t 
(p
A
)
Voltage (mV)
Experiment III
196 pS
122 pS
79 pS
-40
-30
-20
-10
0
10
20
30
40
-100 -80 -60 -40 -20 0 20 40 60 80 100
C
u
rr
en
t 
(p
A
)
Voltage (mV)
Experiment  I
220 pS
131 pS
91 pS
269 
 
 
 
 
 
F509A: PLB single channel current activity 
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Figure 83 single channel –voltage relationship forF509A in planar lipid bilayer.  
Current-voltage characteristics of single channel activity in 150/150 mM KCl (cis/trans) buffer (n=20-25) at different voltage after F509A (8µg/ml) was added to the cis chamber. Conductance was calculated (G=I/V) and data points 
fitted by linear regression. Experiment I: mean conductance values were deduced at the slopes of the linear regression on the data points as 54, 96, 129, and 247pS. Experiment II: mean conductance values were deduced at the 
slopes of the linear regression on the data points as 114, 167, 272, and 470pS. Experiment III: mean conductance values were deduced at the slopes of the linear regression on the data points as 59, 105, 185, and 243pS. pS 
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Experiment for Cry41Aa 
 I II III Mean SEM 
Vr (mV) -10.5 -9.5 -12.9 10.97 1.0 
PK+/PCl- 2.53 2.25 2.93 2.48 0.23 
Experiment for F509A 
 I II III Mean SEM 
Vr (mV) -7.7 -14.0 -12.7 11.5 0.43 
PK+/PCl- 1.85 3.30 2.88 2.68 1.92 
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Figure 84 single channel current –voltage activity for Cry41Aa and F509A in planar bilayer asymmetric conditions for experiments I, II, and III.   
Selectivity (PK+/PCl-) and reversal potential (Vr) were calculated in PLB experiments I, II, and III for (A) Cry41Aa and F509A (B) in asymmetrical 450/150 mM KCl (cis/trans) conditions. Current-voltage 
characteristics of single channel activity in 450/150 mM KCl (cis/trans) buffer (n=20-25) at different voltage after toxin addition (F509A and Cry41Aa at 8µg/ml) was added to the cis chamber. Conductance 
was calculated (G=I/V) and data points fitted by linear regression.  (C) Mean conductance values for Cry41Aa were deduced at the slopes of the linear regression on the data points as 90, 113, and 206pS. (D) 
Mean conductance values for F509Awere deduced at the slopes of the linear regression on the data points as 55, 290, and 421pS. 
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6.7 Discussion 
Table 18 in chapter 6.2.2 summarises the constructs made via loop exchange, creation 
of hybrids with other Cry genes and loop residue substitution.  The following Cry41Aa 
mutants were successfully solubilised and activated. Loop 3 exchange mutant 
pGEM1Acloop3 (this is made up of the Cry1Ac gene with loop 3 of Cry41Aa). The 
following are all loop substitutions, in loop1 the mutants 384 CVSC 387, 384CLAC384, and 
384GLAC384 were made. In Loop 3 substitutions the following mutants were made F509A, 
F509W, F509L, F509S, F509Y, W511A, W511F, W511Y, Y514A; and finally, in the extra 
loop substitution mutant 280AAAA 283 was created.   
 
To explore the specificity of Cry41Aa and identify regions responsible a number of 
mutants were created as summarised in table 18.  Several studies have applied site 
directed mutagenesis to investigate Cry toxin specificity and have implicated domain II 
loop in receptor binding and toxin specificity.  In particular loops 8, loop1,2,and 3 of 
domain II are implicated in receptor binding and mutagenesis there can result in 
structural changes that affect the stability and susceptibility of the recombinant protein 
to protease such as trypsin  (Dean et al., 1996; Gómez et al., 2003; Lee et al., 1996, 
Schnepf et al., 1998; Tuntitippawan et al., 2005).   
 
Likitvivatanavong et al. (2009) investigated specific residues in loops 8, loop1, 2, and 3 
of Cry11Ba for binding.  The alanine residue substitutions in loops 8, loop1, and 3 
resulted in reduced toxicity by 80-100% towards Aedes aegypti and Culex fourth instar 
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larvae (Likitvivatanavong et al ., 2009). Specific residue in  8 of Cry1Ac were  substituted 
for alanine resulted in a  reduced binding affinity for BBMV and the purified receptor 
aminopeptidase N (APN) from both Lymantria dispar  and Manduca sexta and 
subsequent reduction in toxicity (Lee et al., 2001).  
 
Further studies on binding and toxicity were carried out which involved mutagenesis. 
The Cry1Ab residues of loop 3 (toxic to M. sexta and H. virescens) underwent alanine 
residue substitutions. The resulting mutants were stable in trypsin and insect gut juices 
and were thought to be structurally similar to wildtype. However, bioassay data 
revealed significant reduced toxicity and binding analysis of BBMV from both insect’s 
species. This loss and reduction of toxicity in some mutants may be due to the reduced 
initial binding.  
 
The study highlighted the role of hydrophobic residues where it was observed that 
alanine substitutions in loop 3 of Cry1Aa did exhibit reduce toxicity as a consequence of 
reduced initial binding of mutant toxins to Bombyx mori and M. sexta BBMV. The study 
implicated hydrophobic residues in loop 3 of both Cry1Ab and Cry1Aa in initial binding 
to receptor molecules that proceed to form hydrophobic interactions (Rajamohan et al., 
1996b).  
 
Mutants which successfully produced crystals were harvested and characterised against 
wildtype Cry41Aa. Schematic table 18 in lists all the mutants made from Cry41Aa 
including those which did not proceed to cell assay stages. The recombinants W511Y 
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and W511F were created and processed in the same manner as Cry41Aa and other loop 
recombinants. The recombinant W511Y was not stable in trypsin and no further action 
was taken. The W511F recombinant did result in two proteolytically stable proteins of 
~80 KDa and ~60 KDa ; however, its protein concentration was not optimised against the 
control Cry41Aa. Despite this, its toxicity and that of loop1 recombinants were assessed 
(see chapter 7) with the remaining loop mutants.  
 
Yamashita et al. (2005) solubilised the parasporal inclusions obtained from Bt strain 
A1462. A number of major peptides 180, 150, 120, and 100 KDa were observed; 
however, the most significant was the 88 KDa doublet. The study findings proposed that 
it was from this doublet that the 64 KDa cytotoxic peptide and the minor 80 KDa peptide 
were derived from protease treatment. They were able to successfully isolate each 
protein and observed that was indeed the 64 KDa peptide that is toxic to HepG2 cell line. 
In the present study Cry41Aa was solubilised in sodium carbonate and DTT. A protein of 
~ 80-88 KDa which is thought to be encoded by ORF2 was consistently observed with 
better dissociation when solubilised in the presence of DTT. A protein of ~ 120 KDa was 
thought to be encoded by ORF3. Upon treatment with trypsin, the solubilised Cry41Aa 
degrades to a protein of ~ 80  KDa (or slightly less as) well as protein of ~ 60  KDa 
(Krishnan et al., 2017).  ORF3 band was absent after trypsin activation. It is thought that 
this peptide lacks a protease resistant core and or is unstable in trypsin thus degrading 
completely upon toxin activation.  
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In this study, AKTA was applied in an attempt to isolate each activated protein after 
trypsin treatment. However, it was not possible to isolate the two peptides produced by 
each activated protein from Cry41Aa or any of its mutants. Thus, the main method of 
protein purification was through the use of gel resin filtration column which allowed 
purification of large volumes of activated protein.   
 
Previous attempts to express Cry41Aa without ORF3 resulted in an unstable protein  that 
did not solubilise well and could not be activated by proteases (Krishnan, 2013). The 
ORF3 of Cry41Aa has similarities with the C-terminal part of the larger 3-domain Cry 
toxins, a region known to be responsible for expression and crystallisation of toxins in 
Bt (de Maagd et al., 2003). This suggests that ORF3 gene may plays a role in the 
crystallisation and correct folding of the Cry41Aa crystals (Krishnan et al., 2017).  
 
All recombinants produced crystals which were indistinguishable from those made by 
Cry41Aa when observed under both light and electron microscopes.  In addition, the 
recombinants are indistinguishable from the wildtype Cry41Aa on an SDS PAGE gel. They 
were processed similarly to the wildtype and no observations were made about any 
differences in their response to conditions that would differentiate them from wildtype 
Cry41Aa. 
 
 F509C and W511Y were the only Cry41Aa loop 3 recombinant which produced crystals 
but failed to solubilise well and were degraded upon activation by trypsin. These 
recombinants may have a different folding conformation to Cry41Aa. The stability of 
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recombinant toxins may possibly be affected by the type of residue at a particular 
position with consequently could increase sensitivity to trypsin.  
 
The recombinant mutants of Cry41Aa had their concentration optimised in preparation 
for cell assay work.  This stage of the study was addressed by bringing together analysis 
data from different tools to combine and support findings. The Bradford protein assay 
was able to provide a numerical value of the protein concentrations. SDS PAGE gels 
revealed visually these numerical representations and showed how accurate the values 
were to their numerical representation. The image lab software allowed for the 
quantification of toxin concentration from SDS PAGE gel bands densities relative to a 
control bands density as well as quantifying the average molecular weight (KDa) of 
recombinants against a protein marker of the same SDS PAGE gels.   
 
From these data it was concluded that the recombinant toxins have a similar molecular 
weight to that of wildtype Cry41Aa. It has also confirmed that the stock 150 µg/mL 
concentration of each recombinant toxin was very close to the control band densities of 
Cry41Aa, where each of the reference bands have a value of 1 the recombinants show 
an average value of 0.9 to 0.8 when compared against the reference bands of three gels.  
This confirms that protein concentration of the stock samples for each recombinant 
were optimised and finalised as 150µg/mL, before proceeding to cell assay analysis.  
 
Initial mutagenesis of Cry41Aa loop 3 highlighted the residues at F509 and W511 and 
their potential to influence the specificity of Cry41Aa. Cell assays were carried out on 
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the three initial loop 3 recombinants F509A, W511A, and Y514A. CellTiter Blue assays 
indicated that both F509A and W511A did not exhibit toxicity towards HepG2 cell lines.  
However, Y514A retained toxicity and showed signs that it killed faster and more cells 
within the same given time compared to wildtype Cry41Aa. A dose response on HepG2 
cells treated with Cry41Aa and Y514A confirmed an EL50 for both toxins. Cry41Aa had an 
EL50 value of 0.061 µM/ml, and the recombinant Y514A had an EL50 value of 0.048 
µM/ml. This confirmed that Y514A is indeed a more potent toxin than wildtype Cry41Aa.  
 
The lack of toxicity by F509A was confirmed by cell assay with cytotoxic markers (Cell 
Tox Green) which binds nuclear material once the cell membrane has been damaged. 
Here, no significant cell membrane damage to HepG2 cells was recorded for mutant 
F509A. It was clear that alanine substitutions at position 509 had knocked out the 
toxicity, however it did not explain whether this loss of toxicity was due to loss of the 
wildtype residue as a result of the substitution or if the position of the residue formed 
an integral part of Cry41Aa’s specificity. Furthermore, it was not known whether the 
interaction between F509A and HepG2 cell membrane did occur but that this interaction 
no longer produced a toxic effect on the cell.  In the quest to better understand the 
specificity of Cry41Aa further amino acid substitutions were made at position 509 and 
511 of loop 3.  
 
None of the mutants created in position 509 were observed to have any toxicity to 
HepG2 cell lines. The mutant W511F was toxic to HepG2 cell lines. 
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The cytotoxicity of the initial three mutants F509A, W511A, and Y514a as well as 
wildtype Cry41Aa were tested on additional cell lines. BL31 showed only slight sensitivity 
to Y514A and Cry41Aa. Other cell lines did not show susceptibility to either Cry41Aa or 
Y514A.  
 
Assays on HL-60 indicated that trypsin activated Cry41Aa and its recombinants did not 
have a toxic effect on this cell line. This finding contradicts previous HL-60 toxicity data 
collected on proteinase K activated Cry41Aa by Yamashita et al. (2005). Therefore, 
experiments on Cry41Aa focused on the use of HepG2 cell lines instead of HL-60. 
Ongoing research on the toxicity of Cry41Aa confirmed its toxicity towards HL-60 cell 
lines only when activated by proteinase K (Souissi, 2018). These conflicting findings put 
forwards the argument that specificity may be influenced by how toxins are activated.  
 
Ongoing research on the toxicity of Cry41Aa confirmed its toxicity is observed towards 
HL-60 cell lines only when activated by proteinase K (Souissi, 2018). These conflicting 
findings put forwards the argument that specificity may be influenced by how toxins are 
activated. The cancerous Hela cell line was a negative control for Cry41Aa, however 
previous studies have shown that high dose of Cry41Aa can have a toxic effect on Hela 
cells (Yamashita et al., 2000). This postulation that Cry41Aa has the ability to from pores 
and may even bind non-specifically.  Low selectivity values for both Cry41Aa and F509A 
channels from electrophysiological analysis supports this notion and provides support 
to the theory that Cry toxins did not evolve with or alongside mammalian cells.   
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Electrophysiological technique and ligand blotting were used to study the effects of 
Cry41Aa and F509A on HepG2 cell membrane.  One of the responses by a target cell as 
a result of interactions with a pore forming toxin can be the phosphorylation of p38-
mitogen activated protein kinase (Zarubin, T. and Han, J. 2005).  
Western blots carried out on cell extracts after incubation with Cry41Aa and F509A 
indicated that both toxins induced a positive signal for p38 phosphorylation. 
Electrophysiological analysis indicated that Cry41Aa is a pore forming toxin which is 
potent at 0.5-1.05 µM/ml concentration for optimal pore formation effect. It forms  very 
stable membrane  pores with an opening probability of 1 (Domanska, 2016). 
Conductance of Cry41Aa range between 75-220 pS and the pore shows no rectification, 
but the pore seems to be voltage dependent and is slightly cationic selective (Rv: -10.96 
mV). 
 
Similarly, the loop 3 recombinant F509A is able to form pores in synthetic PLBs, however 
in contrast the pores are less stable and display different kinetics and opening 
probability. Conductance of F509A is in the range of 54- to 470. The selectivity of F509A 
is similar to Cry41Aa however standard error here is much larger (1.92) due to instability 
of the pore.  PLB pores formed by F509A are also slightly cationic, a characteristic 
observed in Cry1B, Cry1Ac, and Cry3A (Schwartz et al., 1997; Slatin et al., 1990; Walters 
et al., 1993) . 
 
In conclusion, F509A did not exhibit toxicity to HepG2 cell as evident by CellTiter blue 
data where cell viability percentage was no different to that of the buffer. In addition, 
279 
 
 
 
 
 
the membrane damage assays revealed that F509A did not cause significant cell 
membrane damage. These findings although supportive of F509A lack of toxicity to 
HepG2 cells did not explain the cause of this loss of toxicity.   
 
Western blots carried out on F509A indicated that it did induce phosphorylation of p38. 
From the results, it was evidence that F509A did indeed bind or interact with HepG2 
cells however the binding was ineffective or insufficient and did not result in cell death. 
Electrophysiological analysis supported this finding and confirmed that although F509A 
did form pores in the cell membrane these were unstable or were few in number.  
 
It is important to note that membrane damage by F509A was enough to induce a p38 
signal, similar to that observed with HL60 cells extract after incubated with F509A 
despite cell viability data indicating that F509A was not toxic to HL60 cell lines. 
Therefore, it is speculated that F509A binds to both HepG2 and HL60 cells. This binding 
leads to impaired pore formation in the cell membrane promoting phosphorylation of 
p38. It is possible that pores are repaired by cells or there are only few pores which do 
not induce toxicity, and thus not detectable in cell viability or membrane damage assays. 
F509A was one of loop 3 mutants created at position 509. All the mutants at this position 
did not exhibit toxicity to both HepG2 and HL60 cell lines. It is reasonable to suggest that 
like F509A, all the other mutants at this position may exhibit similar mode of action, by 
binding to cell in a manner that is ineffective and which results in unstable pore 
formation and thus lack of toxicity.  
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Phenylalanine was introduced at position W511 to explore whether the nature of the 
residue or its position could affect a toxin’s ability to be potent.   The recombinants 
W511F retained toxicity to HepG2 cells (figure 76 chapter 6.2.2). Further attempts to 
introduce more amino acid substitutions at position 511 resulted in mutant proteins that 
were proteolytically unstable.  Phenylalanine is an aromatic hydrophobic residue; these 
characteristics have been implicated in the toxicity of Cry toxins (Pardo-Lopez et al., 
2009; Vachon et al., 2012; Rajamohan et al., 1996b; Dean. and Sylvis, 2006). However, 
substitution with any aromatic hydrophobic residues does not guarantee a proteolytic 
resistant mutant protein as was seen with mutant W511Y which was unstable in trypsin.   
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7.0 General finding and Discussion 
7.1 Summary of findings 
This chapter will summarise the findings from the previous chapters and discuss 
their significance. It will conclude by evaluating the methods employed and the 
future work that can be done to continue exploring Cry41Aa and exploit its benefits .  
 
The 3-domain Cry toxins have been explored for their ability to kill certain insect 
orders.  Their narrow killing range emphasised their specificity to target cells and Bt 
based pesticides have been widely used. The 3-domain toxin specificity has been 
investigated in the quest to understand the mode of action of Cry toxins, create 
novel toxicities, and overcome resistance (Crickmore et al., 1998; de Maagd et al., 
2001; Bravo et al., 2011).  
 
Mizuki et al. (1999) investigated the parasporal inclusions from Bt cells that 
appeared to be non-insecticidal and did not display any biological activity, however 
they did display very specific cytotoxicity to some cancer lines (Mizuki et al., 1999; 
Mizuki et al., 2000). This unique category of Cry toxins was named parasporins and 
constitutes , parasporins 1,2,3,4,5, and 6 (Okumura et al., 2010).  Parasporin 3 or 
Cry41Aa was first reported by Yamashita et al. (2005) as a 3-domain Cry toxin with 
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cytotoxic properties that kills hepatic and cervical cancer cell lines (HepG2 and HL60). 
This very specific ability to identify and kill these two cancer cell lines raised the question 
about the mode of actin of Cry toxins.  
 
Cry41Aa shares the five conserved blocks typically found in insecticidal 3-domain Cry 
toxins. Yamashita et al. (2005) demonstrated that it also required in vitro solubilisation 
and activation similarly to insecticidal 3-domain Cry toxins in order to obtain the 
protease resistant cores known to be toxic to the cancer cell lines. It has a ricin domain 
which resembles the β-trefoil domain found in putative carbohydrate binding epitopes, 
however Krishnan, (2013) confirmed the ricin domain was not responsible for Cry41Aa’s 
specificity to HepG2 cell lines, as when it was removed, Cry41Aa retained cytotoxicity 
(Krishnan, 2013).  
 
Many studies on the specificity of Cry toxins have highlighted the exposed loops of 
domain II (de Maagd et al., 2001). Research findings show that it is domain II which is 
primarily responsible for receptor recognition and target cell specificity in 3-domain Cry 
toxins (Bravo et al., 2007; Crickmore et al., 1998; de Maagd et al., 2001; de Maagd et al., 
2003).  
 
Yamashita et al. (2005) argued that Cry41Aa may have a similar mode of action to a pore 
forming 3-domain insecticidal Cry toxin (Krishnan et al., 2017; Yamashita et al., 2005). 
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This comparison can be extended to question the extent of the similarity of Cry41Aa to 
insecticidal Cry toxins and how research on insecticidal 3-domain Cry toxins sheds light 
on the specificity of Cry41Aa. 
 
This thesis aimed to investigate the specificity of Cry41Aa to HepG2 cells through 
mutagenesis in domain II loops. It employed bioinformatic tools to narrow down and 
identify regions in Cry41Aa that were potentially associated with binding and receptor 
recognition.  Bioinformatic tools collated and compared data from insecticidal Cry 
proteins to predict sequences in domain II loops and model the secondary of Cry41Aa. 
The predicted domain II loops of Cry41Aa were then subjected to a number of 
mutagenesis approaches.  
 
First, a loop 3 exchange loop was created with loop 3 of insecticidal Cry1Ac. The resulting 
recombinant protein was unstable and did not result in a protease resistant protein. The 
Cry1Ac insecticidal recombinant with loop 3 of Cry41Aa did result in a stable protease 
protein. Cell assay analysis indicated that this mutant did not gain toxicity to HepG2 cell. 
Second, a number of hybrids of Cry41Aa OFR 2 were created with insecticidal 3 domain 
Cry toxins.  
 
Cry41Aa is a split toxin made up of ORF2 and ORF3.  The five conserved blocks that make 
up domain I, II, and III and are typically found in 3-domain insecticidal. Cry were 
identified in ORF2 of Cry41Aa.  A number of domain hybrids of Cry41Aa with insecticidal 
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Cry domains were created.  Unfortunately, none of the domain hybrids resulted in 
protease resistant proteins.  
 
Third, a number of substitutions in loop 1 and 3, the extra loop of Cry41Aa were created. 
In loop 1 a number of degenerate substitutions were created. This resulted in three 
protease resistant proteins which were assessed for their toxicity to HepG2 cells. The 
three mutants retained toxicity to HepG2 cells and were indistinguishable from wildtype 
Cry41Aa on an SDS PAGE gel.  
 
In loop 3 of Cry41Aa three initial substitutions were made in position F509, W511, and 
Y514. These aromatic residues were substituted with an alanine residue. All three 
mutants resulted in protease resistant proteins and their toxicity to HepG2 was 
analysed. The Y514A retained toxicity and HepG2 cell assays suggested that is more 
potent than wildtype Cry41Aa. The remaining F509A and W511A lost toxicity to HepG2 
cells. In an attempt to shed light on the specificity of Cry41Aa, the position of residues 
and type of residues were investigated further.  
 
A number of degenerate residue substitutions were made at position 509. All 
degenerate substitution mutants resulted in a protease resistant protein with the 
exception of F509C.  Two aromatic residue substitutions were created in position 511, 
W511F and W511Y. The W511Y mutant did not result in a protease resistant protein.  
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Substitutions in loop 3 resulted in 11 recombinant protease resistant proteins.  A 
multiple alanine substitution mutant was created in the extra loop of Cry41Aa.   
 
12 recombinant protease resistant proteins, including the extra loop mutant, were 
analysed and compared to wildtype Cry41Aa. Transmission electron microscopy 
revealed that 12 mutants produced crystals which were undisguisable from those made 
by Cry41Aa. SDS PAGE gels of solubilised, and trypsin activated recombinants confirmed 
that each of the 12 mutants resulted in two protease resistant proteins of ˜60 and ˜80 
KDa. These proteins were indistinguishable from those produced by activated wildtype 
Cry41Aa. Along with activated Cry41Aa, the 12 mutants were purified, and 
concentrations optimised in preparation for HepG2 cell assays.  
 
All mutants did not exhibit cytotoxicity to HepG2 cell lines with the exception of W511F 
and Y514A.  Membrane assay of the effect of F509A on HepG2 cells indicated that it did 
not damage cell membrane, however, western blots of the effects of F509A on HepG2 
cell lines indicated the activation of p38 MAPK signalling pathway. This is known to be 
activated in response to pore formation (Huffman et al., 2004).  
 
Electrophysiology analysis revealed that both F509A and Cry41Aa form pores in an 
artificial lipid bilayer. However, F509A formed unstable pores and did not result in 
significant membrane disruption. This was in contrast to Cry41Aa which produced stable 
pores which resulted in permanent damage to cell membrane and eventual cell lysis. 
The findings conclude that Cry41Aa is likely to have a 3-domain structure similar to that 
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of insecticidal is 3-domain Cry toxins. Residue substitutions have indicated that domain 
II loops of Cry41Aa, like domain II insecticidal toxins, play a role its specificity and ability 
to exert toxicity on susceptible cells.  
 
 Similar to insecticidal Cry toxin domain II loops of Cry41Aa can be explored to enhance 
toxicity as shown by the more potent mutant Y514A. Cry41Aa is thought to have a mode 
of action similar to insecticidal 3-domain toxins where it forms pores in the membrane 
of susceptible cells causing osmotic shock and the eventual lysis of cell (Krishnan et al., 
2017) .  
 
 
7.2 Discussion  
The research question in this study aimed to investigate the specificity of the Cry41Aa 
toxin by exploring its domain II loops.  The study began by collating literature on the 
domain II loops which had been identified from revealed crystal structures (Adang et al., 
2014; Xu et al., 2014). The study employed bioinformatic tools that used information 
from secondary and tertiary protein structures to propose a three-dimensional model 
of Cry41Aa. It predicted Cry41Aa to have a typical 3-domain globular structure (Krishnan 
et al., 2017). Furthermore, the exposed loops of domain II were predicted and aligned 
with loops from the revealed Cry crystal structures (Xu et al., 2014).   
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Previous studies on 3-domain Cry toxins have demonstrated toxin specificity by 
modifying identified specificity regions such as domain II loops to create novel toxins or 
increase effectiveness of a toxin.  (Pigott et al., 2008; Abdullah et al., 2003; Abdullah and 
Dean, 2004; Abdul-Rauf and Ellar, 1999).  
 
The first mutagenesis approach attempted to identify the loops responsible for the 
specificity of Cry41Aa by exchanging loop 3 of Cry41Aa with loop 3 from an insecticidal 
3-domain toxin and vice versa. Previous studies on loop exchange have introduced novel 
toxicities in known Cry toxins confirming that it is indeed these loop that are involved in 
the specificity of the toxin in question. A study by Abdulla et al, (2003) aimed to 
introduce Culex mosquito toxicity in Cry4Ba (toxic to Anopheles and Aedes) by 
exchanging loop regions with Cry4Aa into Cry4Ba. Loop 1 and 2 of Cry4Ba were deleted 
and replaced with loop 1 and 2 of Cry4Aa. These recombinants did not exhibit toxicity 
to susceptible insects. However, loop 3 insertion of Cry4Aa into Cry4Ba produced a 
recombinant that gained toxicity to Culex (Abdullah et al., 2003, Howlader et al., 2009).  
 
Further investigation by Abdulla and Dean, (2004) led to the creation of a Cry4Aa loop1 
exchange with loop1 of Cry19Aa. The mutant sustained toxicity to Culex (Cry4Aa) and 
gained toxicity to Anopheles and Aedes (susceptible to Cry19A). Collated observations 
of competition binding assay on this loop exchange mutant concluded that there was no 
difference in its ability to bind BBMV between less or more active recombinant toxins. 
The study proposed a model whereby nontoxic recombinants bind to BBMV surface 
receptors but do not induce toxicity. The model suggests that enhanced toxicity 
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recombinants are able to bind to unique and minor receptors that elicit toxicity 
(Abdullah and Dean, 2004).  
 
In a study by Zhou et al. (2017) the domain II loops of Cry1Ah (toxic to Helicoverpa 
armigera but not Bombyx mori larvae) were exchanged with domain II loops of Cry1Ai 
which is active against Bombyx mori larvae but not H. armigera.  This mutagenesis 
approach involved the introduction and exchange of domain II loops 2 and 3 between 
Cry1Ai and Cry1Ah.  
 
Zhou et al. (2017) intended to explore the extent that these loops are involved in the 
toxins’ specificity to their target insect cells. They observed that the Cry1Ai-h-loop 2-
exchange mutant, containing loop 2 from Cry1Ah, showed significant toxicity towards 
H. armigera, whilst the Cry1Ah-i-loop 2-exchange mutant containing loop 2 from Cry1Ai 
did not indicate any toxicity towards H. armigera. The loop 2 exchange in Cry1Ah caused 
loss of toxicity to its target insect H. armigera. Similarly, the introduction of loop 3 from 
Cry1Ai into Cry1Ah also induced the loss of toxicity to H. armigera but neither loop 2 or 
3 exchange allowed Cry1Ah to gain a new toxicity towards B. mori. Contrary to this, is 
that loop 2 exchange in Cry1Ai where the presence of both loops 2 and 3 of Cry1Ah 
allowed Cry1Ai to gain toxicity to H. armigera which was not exhibited earlier (Zhou et 
al., 2017).  
 
The recombinant Cry41Aa loop 3 of Cry1Ac and Cry41Ab loop 3 of Cry1Ac exchange 
mutants were not stable in trypsin and did not result in a proteolytic protease core.  The 
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insecticidal Cry1Ac loop 3 of Cry41Aa exchange did result in a proteolytic stable core, 
however, cell assays indicated that it did not gain toxicity to the HepG2 cell line. We did 
not assess whether this mutant lost its native toxicity to M. sexta or other known target 
lepidopteran insects as a result of replacing of its native loop 3 with that of Cry41Aa. 
However, the lack of proteolytic stable mutants of Cry41Aa led to the second 
mutagenesis approach. 
 
 Research has shown that domain swapping has led to new specificities and improved 
toxicities. In addition to the domain II loops, domain II and III have been implicated in 
specificity and receptor recognition (Lee et al., 1999; Bravo et al., 2007; de Maagd et al., 
1996; Dean et al., 1996; Gomez et al., 2006; Herrero et al., 2004). 
 
A study by de Maagd et al, (1996) carried out a study on domain I, II, and III of Cry1Ab 
and Cry1Ca, they created a number of hybrids by swapping domains from both toxins in 
an attempt to improve the toxicity towards Spodoptera exigua larvae. They observed 
that combinations of different domain I and II were unusually toxic when combined with 
domain III of Cry1Ca. This observation extended to domain I and II from other 3-domain 
Cry toxins Cry1Ac, Cry1Ba, Cry1Ea, or Cry1Fa as long as domain III came from Cry1Ca. It 
highlighted the role that domain III of Cry1Ca played on the toxicity and specificity that 
it has towards S. exigua (de Maagd et al., 1996).  
 
In the quest to understand its specificity towards HepG2 cell lines, hybrids of Cry1Ie and 
Cry42Aa were created with Cry41Aa. There is no record of domain swapping 
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mutagenesis being carried out in Cry41Aa. A similar study by Masson et al. (1994) 
created an exchange of non-homologous N terminal regions of Cry1Ac with Cry1Ea and 
determined that the N-terminal region of a toxin is not important in specificity. This 
study, conducted both in vivo and in vitro on cultured insect cells and dissociated midgut 
epithelial cells, concluded that hybrid toxins can exhibit different toxicity and that this is 
dependent on bioassay systems in place (Masson et al., 1994). Despite this, our current 
hybrid was designed to introduce a region of N terminus (domain I) of Cry41Aa into 
Cry1Ea. However, both Cry1Ie-Cry41Aa and Cry42Aa-Cry41Aa hybrids did not result in a 
protease resistant cores upon activation and thus could not be investigated for their 
toxicity on HepG2 cells.  
 
The third mutagenesis approach involved residue substitution and specifically alanine 
residue substitutions to probe the domain II exposed loops of Cry41Aa for specificity 
after failure to obtain protease resistant cores from previous mutagenesis approaches 
on Cry41Aa. Research has highlighted the role that hydrophobic residue substitutions of 
domain II loops play on the specificity and toxicity of 3-domain toxins. (Lee et al., 1999; 
Lee et al., 2001; Lu et al., 1994; Rajamohan et al., 1996c; Rajamohan et al., 1996b; Roh 
et al., 2009).  
 
In a recent review on the structure of Cry toxins, Xu et al. (2014) proposed an alternative 
classification system of Cry toxins based on toxin mode of action and structural 
relatedness. This study suggested that Bt toxins be categorised into 3-domain type α 
pore forming toxins, Cyt toxins type β-pore forming toxins and aerolysin type β pore 
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forming toxins (Xu et al., 2014). Its highlighted findings on the structurally diverse 
domain II Cry toxins and highlighted the presence of aromatic residues and their rich 
presence on the surface of domain II.  
  
The surface exposed aromatic rings have been implicated in binding to polysaccharides 
and are often found in carbohydrate-protein complexes.  Parasporin 2 (Cry46Aa1) has a 
number of aromatic residues on the surface and these may play a role binding. Although 
the effects of aromatic residues have been explored in insecticidal Cry toxins, parasporin 
have remained behind in this aspect. The presence of aromatic residues of the surface 
of toxins suggests that they may have specific interaction with susceptible cell 
membranes (Xu et al., 2014). 
 
 Studies suggest that hydrophobic residues may be responsible for interactions between 
the cell membranes of  target insect cells (Wu et al., 2000). Three hydrophobic residues 
were identified in loop 3 of Cry41Aa and were substituted with alanine F509A, W511A, 
and Y514A. All three resulted in protease resistant peptides that were purified and their 
toxicity to HepG2 was investigated.  
 
A 24 h CellTiter-Blue assay was applied to measure the percentage of HepG2 cell viability 
relative to the buffer. CellTox Green Cell Assay was used to assess HepG2 membrane 
damage caused by Cry41Aa and the nontoxic F509A. It was concluded that Cry41Aa 
caused pores in the membrane of HepG2 cells where the small green fluorescent 
molecule was able to bind to nuclear material. There was no record of any nuclear 
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binding of the dye molecule in cells incubated with F509A. These findings suggest that 
F509A did not cause any cell membrane damage even after 28 h of incubation with 
HepG2 cells.   
 
Cell assay data suggested that the Y514A mutant retained its toxicity to HepG2 cells.  
W511A was also not toxic to HepG2. These findings highlighted the need to clarify 
whether it was the type of residue or the position of the residue that lead to the loss of 
toxicity. This led to further mutagenesis at positions F509 and W511. 
 
A number of degenerate residues were introduced at position F509.and W511 The 
recombinants F509L, F509S, F50W, and F509Y were made, activated and purified.  An 
attempt to introduce W511Y and W511F residue substitutions were also made. Only the 
W511F mutant was proteolytically stable and initial cell assays indicated, that together 
with Y514A, they both retained the cytotoxic properties towards HepG2 cells. Apart 
from wildtype Cry41Aa, and mutants W511F and Y514A all other mutant did not exhibit 
cytotoxicity towards HepG2 cell lines.  
 
The loss of toxicity by F509A and W511A could be due to the loss of interaction with 
HepG2 cells or that interaction was insufficient or ineffective to cause cell death. Initially, 
western blots were carried out to assess phosphorylation of p38 and activation of the 
p38 MAP kinase pathway in Cry41Aa and nontoxic F509A. Brasseur et al. (2015) 
investigated the activation of apoptosis by Cry46Aa (Parasporin 2) and observed that 
Cry46Aa triggered this pathway by phosphorylation of p38  (Brasseur et al., 2015).  
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Western blots of Cry41Aa and mutant F509A revealed that both were found to induce 
p38 phosphorylation. These  finding suggest that the toxicity of Cry41Aa may be affected 
by the type of protease used to activate the toxin (Souissi, 2018). It is possible that pore 
formation by F509A is deficient or insufficient in number to cause cell death. Thus, the 
type of pore and its effectiveness was investigated by electrophysiology.   
 
Seven cell lines including HL60 were assayed for their viability after incubation with 
recombinant toxins. Cell assay data concluded that none of the mutants or wildtype 
Cry41Aa were toxic to cell lines. The HL60 cell line was previously reported by Yamashita 
et al. (2005) to be susceptible to Cry41Aa. In contrast, viability cell assay in this study did 
not support such a finding, however some studies has shown HL60 cell lines to be 
susceptible to Cry41Aa when activated by proteinase K as previously used by Yamashita 
(Souissi, 2018, Domanska, 2016).  
 
A dose response curve for the protein concentration optimised toxins was calculated 
and the EC50 values were determined by probit analysis using SPSS software. Cry41Aa 
had an EC50 value of 4.6 µg/mL, and the mutant Y514A had an EC50 value of 2.6 µg/mL. 
Y514A appeared to be a more potent toxin than Cry41Aa., killing HepG2 cells faster than 
wildtype Cry41Aa as indicated by microscope observations.  
 
A similar study by Wu et al. (2000) on residue substitutions in loop 1 of Cry31Aa also 
indicated mutants that showed higher toxicity in bioassays of three coleopteran Cry3Aa 
susceptible species. Here substitution of phenylalanine for tyrosine at positions 350 and 
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351 affected the dissociation of the toxin which gave rise to enhanced toxicity by 
mutants. This study proposed that hydrophobic side chains of loop1 residues interact 
with a target receptor.  It further speculated that increased toxicity in phenylalanine 
mutant substitutions with tyrosine was due to the presence of aromatic phenol rings 
and not the phenolic hydroxyl group of tyrosine.  The study suggested that aromatic 
residues are involved in hydrophobic interactions with receptors, implicating them in 
the binding affinity of the toxin to the target receptor. Y514A and W511F retained their 
toxicity towards HepG2. In mutant Y514A, the aromatic tyrosine residue was substituted 
with the small non-aromatic alanine residue, yet toxicity appeared higher. HepG2 cells 
were observed to swell and detach within 10 min of incubation with the mutant.  It is 
relevant to point out that the HepG2 receptors for Cry41Aa are as yet unknown.  
 
An attempt to visualise binding was carried using fluorescein isothiocyanate (FITC).  
Activated Cry41Aa and F509A were incubated with FITC and then washed with a buffer 
to remove excess FITC. HepG2 cells were briefly incubated with FITC labelled Cry41Aa 
and F509A and then washed to remove excess or unbound FITC labelled proteins. The 
cells were observed under a Zeiss Axiovert 200M microscope using FITC and bright-field 
channels in a wide-field configuration. Unfortunately, the fluorescence signal was very 
weak despite the obvious cytotoxic effects of Cry41Aa on Hep G2, there was an absence 
of fluorescence outlining the cell membrane. Attempts to visualise and measure binding 
include biotin labelling of Cry41Aa and tagging Cry41Aa with HA-tag. Both of these were 
unsuccessful in determining the binding of Cry41Aa to HepG2 cells (Domanska, 2016).  
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Electrophysiology was carried out to investigate if Cry41Aa and the nontoxic F509A form 
any pores.  Whole patch clamping carried out on HepG2 membranes indicated that 
Cry41Aa does cause pore formation. The pores open in sufficient numbers and are stable 
enough to cause toxicity and eventual cell death. It also concluded that if pores are 
formed as a result of HepG2 incubation with F509A, they are not stable enough or 
sufficient in number. It is possible that the cells are able to recover and a significant 
change in cell viability or membrane damage would not be observed. PLB single channel 
activity was applied to study the activity of Cry41Aa and F509A toxin on an artificial 
membrane.  It concluded that Cry41Aa forms stable pores that seem to be voltage 
dependent and are slightly cationic selective. Although F509A revealed similar findings, 
the standard error was much higher which indicated the pore type formed was unstable 
and had different kinetics and opening abilities.  Electrophysiology tests indicated that 
F509A causes pores which were not always stable or effective, hence their inability to 
induce toxicity.  
 
In this study, a more potent Y514A does not necessarily suggest higher binding affinity to 
HepG2. The mutant Y514A may induce more pores that are very stable and effective 
which may explain its higher toxicity when compared to the toxicity of wildtype Cry41Aa. 
However, without supportive electrophysiology evidence this stands as a speculation.  
These finding are supported by studies that have implicated aromatic residues in the 
domain II loop region in initial binding and specificity (Rajamohan et al., 1996c; Pacheco 
et al., 2009; Abdullah et al., 2003; Dean et al., 1996; Lu et al., 1994).  
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Howlader et al. (2010) probed the effect of alanine substitution in loop 3 of insecticidal 
Cry4Aa and observed a lower toxicity to fourth instar C. pipien mosquitoes in two 
mutants: T512A and Y513A. Cry41Aa loop 3 recombinant Y514A was more toxic than 
the wildtype. This may suggest that a particular residue position is not important to Cry 
toxins but rather the type of residue at that position. The W511F mutant was also toxic 
to HepG2 cells. It can be argued that the mutant has retained its toxicity due to the 
presence the aromatic ring of phenylalanine.   
 
A similar study by Wu et al. (2000) suggested that an increase in hydrophobic 
phenylalanine rings and or the  removal of the phenolic hydroxyl groups at some 
residues in loop binding regions can result in higher binding affinity and subsequently a 
higher toxicity (Wu et al., 2000).   
 
In addition to the loop 3 mutants, an extra loop alanine substitution was also created as 
well as degenerate residue substitutions in loop1 of Cry41Aa.  The protein concentration 
for all recombinant loop mutants was optimised with the exception of the following 
loop1 mutants and loop 3 W511F. Loop1 mutants retained cytotoxicity to HepG2 cells 
on initial cell assays. These degenerate residue mutants suggested that loop1 may not 
have a key role in the specificity of Cry41Aa was not probed further.  
 
The W511F was made after the protein optimisation of the loop 3 mutants and was not 
run on the same SDS PAGE gel at the same time as all investigated mutants. Despite this, 
measures were taken to apply the Bradford protein assay to measure its protein 
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concentration before cell assays with HepG2 cell lines. Observations revealed that 
W511F is toxic to HepG2 cell lines, but its toxicity level compared to wildtype Cry41Aa 
and the potent Y514A remain unknown. 
 
The extra loop is unique to Cry41Aa, previous attempts to obtain a protease resistant 
core of Cry41Aa,  where the extra loop was completely deleted or partially deleted, were 
unsuccessful (Banani, 2013; Krishnan, 2013; Krishnan et al., 2017). These findings have 
highlighted the key role that the extra loop may play in the structural integrity of the 
toxin.  All mutagenesis attempts so far have resulted in unstable recombinant proteins 
that degrade in the solubilisation or activation stage.   
 
An extra loop substitute was created, as a series of alanine substitutions were 
introduced to create an alanine cassette in the loop. It changed the native secondary 
structure of the extra loop from sheets to helices. The mutant was proteolytically stable 
and its concentration was optimised along with the other loop substitution mutants. Cell 
assays suggest that the extra loop mutant was not toxic to HepG2 cell lines. A clear and 
definite role for this distinctive loop is yet to be found, although its presence is critical 
for obtaining a protease resistant mutant.  
 
Studies on the type of protease used to activate Cry toxins can affect their specificity 
and toxicity. Studies on insecticidal Cry toxins revealed that specificity of a toxin is linked 
to the type of protease present in the insect gut. Haider et al. (1986) proposed that 
different proteases produce different protease resistant proteins depending of the 
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amino acid sequence of the toxin(s), and it is the different molecular weights of the 
activated toxins that can define their specificity. For example, Mizuki et al. (2000) 
demonstrated that Cry31Aa (parasporin 1) had a different specificity when activated by 
different proteases.  
 
The study demonstrated that Cry31Aa was toxic to cancer cell line MOLT-4 only when 
activated by Proteinase K or trypsin.  Activation by chymotrypsin resulted in proteolysis 
profiles which differ to those produced by Proteinase K and trypsin and the loss of 
toxicity towards MOLT-4 cell lines. (Mizuki et al, 2000).  
 
Other studies on the parasporins linking their cytotoxicity to their activation have 
emerged. Brasseur et al. (2015) demonstrated that Cry46Aa (parasporin 2) was cytocidal 
HepG2, MCF-7, KLE, Hec-1A, MDA-MB231 cell lines as well as PC-3 cells when activated 
with Proteinase K, but no cytotoxicity was observed when activated with trypsin. 
Yamashita et al. (2005) demonstrated that the toxic effect of Cry41Aa towards HepG2 
and HL-60 cell lines was dependent on activation by Proteinase K  (Yamashita et al, 
2005). Similar observations were made by Souissi (2018). Findings concluded that 
Cry41Aa, potentially a pore forming toxin, has a similar mode of action to insecticidal 3-
domain toxins (Krishnan et al., 2017).  
 
Recently, some studies emerged that question the safety and risk assessment of Cry 
toxin. The confirmed discovery of parasporins and their ability to interact with 
vertebrate cell lines is drawing attention to the risk assessment of Cry toxin. This 
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previously unreported ability to interact with mammalian cells has highlighted the need 
for better understanding of Cry toxin specificity and mode of action. Indeed Cry toxins 
were deemed safe due to their lack of persistence in the environment and narrow 
toxicity range (de Maagd et al., 2003).  
 
However, a report of transgenic plants expressing Cry toxin has concluded that non-
target herbivores and insect predators throughout the food chain can obtain plant Bt 
Cry toxin. These were traced as far as the third trophic level in some cases (Torres et al., 
2006). The study recognises that their findings are dependent on the amount of Bt 
transgenic plant eaten by a prey, and how much of this prey is available to and consumed 
by the predators. Torres et al. (2006) concluded that the persistence of plant Bt toxins 
in the food chain, is dependent on community structure and dynamics of crop pest 
insects and their predators, as well as the availability of alternative Bt free prey. 
Nevertheless, the study highlights the need for more field research and less reliance on 
laboratory research based on artificial conditions. 
 
Despite the number of studies dedicated to understanding Cry toxin mode of action and 
the driving factor for their evolutionary diversity, there is not t a consensus on either 
(Then, 2010). Cry toxins with preferential toxicity to cancer are already being 
investigated for their potential application as an alternative to the current cancer drugs.  
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In a study by Wong, et al. (2010) which studied the binding affinity of Bacillus 
thuringiensis 18 Toxin to CEM-SS cancer cell (leukaemia) line and whether it competes 
with commercially available anticancer drugs. The study concluded that there was no 
completion between Toxin 18 and other drugs tested, furthermore it suggested that 
Toxin 18 was likely to bind  to a different receptor on the surface of CEM-SS cell and thus 
is thought to have a different mode of action compared to the other drugs used in this 
study (Wong et al., 2010).  
 
There is a long history of the safe use of Bt and transgenic Bt crops to control agricultural 
and disease carrying pests. some studies have claimed that Bt can increase allergenic 
potential, or cause hematotoxic reactions, however upon closer investigation the claims 
did not stand up to scientific scrutiny (Koch et al., 2015).  
 
The supposed toxicity exhibited by Bt toxins in particular, to mammalian cells, is 
debatable and many have argued that the term ‘toxic’ is an unfitting definition for the 
effects observed when Bt interacts with mammalian cells. However, the interaction, and 
effects of interactions, are observed and thus require further investigation (Rubio-
Infante and Moreno-Fierros, 2016).   
 
There are still some avenues to explore from the Cry41Aa loop substitution mutants.  
Attempts to use fluorescent microscopy to visualise Cry41Aa or its mutants’ interactions 
with susceptible cancer cell lines proved futile. It is possible that only a small amount of 
Cry41Aa is needed to cause toxicity of that the receptor that it interacts with is present 
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in low concentrations in the cell membrane. It’s worth exploring the nature of the 
toxicity of mutants Y514A and W511F in a quest to better understand the specificity of 
Cry41Aa and to investigate its binding affinity compared to its mutants. A series of 
alanine substitutions, where substitution occurs in more than one position at the same 
time, was not created. For example, it is not known whether a mutant with alanine 
substitution in positions 509, 511, and 514 at the same time would still retain toxicity 
despite the presence of an alanine at position Y514. Furthermore, loop1 substitutes of 
only alanine would help to clarify the role that aromatic rings may play in the toxicity of 
Cry41Aa and whether it has hydrophobic interaction with HepG2 cell membranes.  
 
Future work should include activation of mutants by different proteases such as 
Proteinase K, and analysis whether these mutants demonstrate a different toxicity after 
activation with a different protease. Further work on electrophysiology analysis of 
Cry41Aa treated HL60 cell lines would reveal the characteristics of pores, if any are 
formed as was the case with F509A mutant. single channel electrophysiology can 
indicate the stability of pores, frequency, opening probability and duration of opening 
of pores formed by toxic mutant W511F, and Y514A. Future work should attempt to 
identify receptor(s) of Cry41Aa in susceptible cell lines in order to gain a better 
understanding its mode of action and how it can potentially contribute to the treatment 
of cancer.     
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